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Chapter 1:  This chapter gives a brief history of α-hydroxytropolones, how they were discovered and 
unique properties of these substrates. Included is a background on the bioactivity of these substrates in 
cellular targets such as bacteria, fungi, parasites, tumors and toxicity, as well as their ability to inhibit 
various metallo-based enzymes. Structure activity relationships studies are reviewed on important 
metalloenzymes HIV-Reverse Transcriptase (RT) and Inositol monophosphatase (IMPase). Finally the 
chapter finishes with a synthetic overview of α-hydroxytropolones including natural product targets such 
as puberulic acid, puberulonic acid, β-thujaplicinol, and α-hydroxytropolone.  
Chapter 2:  A brief review on β-hydroxy-γ-pyrone based oxidopyrylium cycloadditions will be presented as 
well as important oxidopyrylium cycloaddition/ring opening procedures to yield natural tropolone products. 
Research from the Murelli laboratory will be highlighted. This chapter will discuss a new synthetic route 
toward functionalized α-hydroxytropolones. A β-hydroxy-γ-pyrone intermolecular oxidopyrylium 
cycloaddition with a range of alkynes that was optimized to an efficient and high yielding process will be 
discussed. Next two ring catalyzed ring openings will be discussed; one that utilizes boron trichloride that 
attains α-hydroxytropolones and 7-methoxytropolones, and a triflic acid mediated sequence that yields 
exclusive 7-methoyxtropolones and furans. Finally, a new reaction with the oxidopyrylium species will be 
highlighted that shows the exchange of alcohols in these reactive species. 
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Chapter 3: Chapter three describes the background on three specific medicinal targets: ANT (2”)-Ia, HIV 
RT RNase H, and HBV RT RNaseH and preliminary structure activity relationship studies with α-
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CHAPTER 1: The Biology and Synthesis of α-Hydroxytropolones1 
1.1 Introduction: A Short History and Background on α-Hydroxytropolones 
α-Hydroxytropolones (a.k.a, 7-hydroxytropolones, α-
HTs) are troponoids having a basic tropone (1) structure, 
where the carbonyl group is flanked by two hydroxyl groups, 3 
(Figure 1.1).2  The history of tropolones date back to the 
isolation of two molecules containing the α-hydroxytropolone 
core structure that were extracted from Penicillium puberulum and Penicillium aurantio-virens in 1932 and 
named puberulic acid, 5, and puberulonic acid, 4, respectively; at the time the structures could not be 
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In the case of puberulonic acid, the chemical formula was originally miss-assigned with the 
chemical formula, C8H4O7, but this was later amended to the chemical formula C9H4O7.4 Due to Dewar’s 
work in the 1950’s, the chemical structure of puberulic acid could be established as well as related 
systems and the name came into being, tropolone, 2 (Figure 1.1).5,6 Dewar was able to explain a seven 
membered ring structure with potential aromatic qualities and hydrogen bonding.7 This new seven 
membered ring structure proposed by Dewar mystified scientists due to its unique aromatic properties.  
Later these aromatic properties were validated and the system was deduced to have a partial positive 
charge, a tropylium cation system, within the seven membered ring and a partial negative charge on the 
carbonyl.8  
 α-Hydroxytropolones are slightly acidic, with two pKa values, one at a pKa1 of 5.6 and the second 










tropolones that are known to bind to metals through the carboxyl and hydroxyl group, the structure of α-
hydroxytropolones, which contain an extra hydroxyl group, allow them to bind to divalent metal 
centers.10,11 At physiological pH, the hydroxyl groups can be deprotonated giving the oxygens a 
considerable negative charge.12 This is important due to the fact that many enzymatic targets use divalent 
metal ions as a critical component of their activity.13 These characteristics impart notable biological 
activity and have made them important targets of this troponoid family, but have created synthetic 
challenges as will be discussed in this chapter (Figure 1.2). 14,15,16,17,18  
1.2 Cytotoxicity of α-Hydroxytropolones 
1.2.1 Antifungal Activity 
β-Thujaplicinol as well as other tropolone derivatives was isolated from the western red cedar.19  
Due to the tree’s durability, it was thought that these compounds may contribute to its ability to fend off 
plant diseases.20 The antifungal activity of the 
prevalent extracts, β-thujaplicinol (6) and its 
tropolone counterpart γ-thujaplicin (8) were 
studied for their activity against wood rot 
(Figure 1.3).21 It was found that both these 
compounds had similar activity against brown 
rot fungi Poria monticola and Coniophora 
puteana at MIC (minimum growth inhibitory 
concentration) values of 10 µM. Activity toward 
the white rot fungi Polyporus versicolor, Stereum sanguinolentum, and Phellinus weirii. With MIC 
concentrations of 800 µM, 330 µM, and 100 µM, respectively, β-thujaplicinol was much less potent than γ-
thujaplicin. γ-Thujaplicin had MIC values of 70 µM, 50 µM, and 50 µM respectively. While γ-thujaplicin 
was a pure extract from the cedar, β-thujaplicinol was extracted from the copper screening after the kiln 
(75-95°C) processing of the lumber, and was found to be an oxidation product.19 This may indicate the 
higher potency values for γ-thujaplicin which was in extracts before the wood was processed. Another 
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Figure 1.3. Antifungal activity of β-thujaplicinol vs. γ-thujaplicin.
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cause disease in immuno-suppressed humans.22 Concentrations of 35 µM showed no growth of the 
fungus after 96 hours. If reactions were run at longer time points, a higher concentration of β-thujaplicinol 
was needed to impart growth inhibition.23 Studies from Bristol-Meyers researchers with α-
hydroxytropolone showed less potency activity against A.fumigatus strain IAM2530 at higher MIC 
concentrations of 730 µM.24  
1.2.2 Antibacterial Activity 
In the two separate studies on antifungal activity by Sanders and by researchers at Bristol-
Meyers, β-thujaplicinol and α-hydroxytropolone were also evaluated for their antibacterial effects.23, 24 
Sanders tested the activity of β-thujaplicinol against 40 strains of bacteria, and in general found that the 
gram-positive bacteria was more inclined to be inhibited than gram-negative bacteria.23 The most potent 
effects were seen in the gram-positive strains, Bacillus megaterium and Sarcina lutea, with inhibition 
values of 35 µM. Gram-negative strains P. aeruginosa, P. fluorescens, and P. pyocyaneus presented no 
inhibition at concentration of 280 µM. Bristol-Meyers researchers found similar results in their studies with 
α-hydroxytropolone.24 Gram- positive bacterial strains Staphylococcus aureus and Micrococcus luteus 
displayed MIC values of 90 µM. Gram-negative strains such as P. aeruginosa and Klebsiella pneumonia 
had values of 700 µM and 360 µM respectively. An outlier was the gram-negative strain Escherichia coli 
NIHJ that had MIC values of 45 µM. No explanation for the selective bacterial inhibition was explained by 









1.2.3 Antitumor Activity 
In their broad review of activity, 
Bristol-Meyers researchers also tested the 
antitumor quality of tropolones and 
α-hydroxytropolones.24 They found that 
α-hydroxytropolones, 3,7-dihydroxytropolone 
(9) (named BMY-28438) displayed IC50 
value of 250 nM in B16 melanoma cells, 
while 4,7-dihydroxytropolone (10) and 
α-hydroxytropolone (3) had values of 2.5 µM 
and 2.2 µM, respectively (Figure 1.4). The 
tropolone, 5-hydroxytropolone (11), was the least potent with an inhibitory concentration at 50% (IC50) 
value of 13 µM.  Animal studies that involved mice with B16 tumor cells revealed that at concentrations of 
1.3 mg/kg/day of 3,7-dihydroxytropolone mice survived 29 days as compared to untreated mice who 
survived 16 days. These results were notable as Mitomycin C, a currently used chemotherapeutic agent, 
showed similar survival rates and concentrations at 1 mg/kg/day over 27 days. Alternatively, higher 
concentrations of 3,7-dihydroxytropolone was found to have a negative effect where concentrations of 5 
mg/kg/day were found to be toxic, and half that concentration (2.5 mg/kg/day) reduced the survival rate to 
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1.2.4 Antimalarial Activity 
 Shiomi, Omura, and co-workers isolated puberulic acid (5) and stipitatic acid (12) as well as other 
new tropolone compounds, viticolins A (13), B (14), C (15), from the Pencillium species FK-4410 and 
tested their ability to target malaria in vitro and in vivo (Figure 1.5) .16  
 
The in vitro activity of the substrates against two chloroquine resistant Plasmodium falciparum strains, K1 
and FCR3 were studied. Puberulic acid had activity against malaria to the same order of magnitude (Both 
strains IC50=50 nM) as the well known antimalarial agents artesunate (16), (K1 strain IC50=10 nM, FCR3 
strain IC50=2.5 nM) and artemisinin (17) (Both strains IC50=21 nM) in cell based assays (Figure 1.5). 
Comparison of tropone (1) with no hydroxyl groups and, tropolone (2) with one hydroxyl group, showed 
decreased inhibition with IC50 values for the K1 strain in the range of 89 µM and 100 µM respectively.  α-
Hydroxytropolone (3) which has two hydroxyl groups flanking the carbonyl had increased activity 
compared to these two at an IC50 value of 6.4 µM for the K1 strain. Similarly stipitatic acid (12) (IC50=39 
µM) showed reduced activity compared with puberulic acid (5). It would appear that the extra hydroxyl 
group may play a role in the antimalarial activity, but viticolin B (14) had similar activity to α-
hydroxytropolone (3) suggesting that two free hydroxyl groups may not be necessary for activity. All the 
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compounds showed low cytotoxicity, in fact puberulic acid (5) (IC50=287 µM) was comparable with both 
artesunate (16) (IC50=36 µM) and artemisinin (17) (IC50=160 µM). α-Hydroxytropolone (3) was the most 
cytotoxic of the compounds tested at a value of 1.7 µM, which could be due to the compound’s small size 
and ability to intercept important bimetallic enzymes in healthy cells. Excitingly, an in vivo antimalarial 
study in a mouse model using the rodent strain P. berghei, a chloroquine sensitive malaria strain, showed 
that puberulic acid had similar antimalarial activity as chloroquine and artesunate. Puberulic acid 
suppressed 69% of the parasite at 2 mg/kg, whereas artesunate and chloroquine had ED50 values at 1.7 
mg/kg and 1.5 mg/kg, respectively.  
1.2.5 Toxicology Studies 
Animal studies by Sanders revealed preliminary toxicology information on β-thujaplicinol.23 At 
concentrations of 50-100 mg kg-1 mice displayed depressant effects (such as not eating or drinking) that 
lasted between 4-7 hours. Positively they maintained muscle control and no deaths were reported. At 
concentrations of 150-200 mg kg-1 mice presented stimulant effects as well as occasional convulsions at 
doses of 163 mg kg -1. Also mice died within 48 hours. The lethal dose was uncovered at 175 ± 4.2 mg 
kg-1 for 48 hours and 155 ± 4.5 mg kg -1 at 72 hours. In combination with other drugs, β-thujaplicinol’s 
toxicity was studied. When barbiturates, sodium thiopental and hexobarbital, were administered in 
combination with β-thujaplicinol, sleeping periods increased while convulsive episodes decreased. The 
hexobarbital combination prevented the lethal outcomes of β-thujaplicinol. The combination of β-









1.3 Metalloenzyme Inhibition 
1.3.1 Inositol Monophosphatase 
 Inositol Monophosphatase (IMPase) is an enzyme that catalyzes the cleavage of phosphate from 
myo-inositol monophosphate and allows for hydrolysis of the compound by water, hence forming a fully 
protonated myo-inositol (Figure 1.6).25  
 
IMPase needs at least two Mg2+ ions for activation.  Magnesium may be needed to act as an activator of 
a nucleophile, stabilize or allow for cleavage of a leaving group, or stabilize the enzymes geometry, or a 
combination of these events in the enzyme.26 It has been implicated as a target in bipolar disorder 
therapy when it was discovered that lithium inhibits this enzyme. Lithium is the current treatment for 
bipolar disorder and is involved in inhibiting this enzyme-substrate complex.26a Current lithium treatment 
involves a near toxic amount of the drug, so a new drug is of a high interest.26b 
 Puberulonic acid, 4, a α-hydroxytropolone, was found to inhibit the enzyme in the low micromolar 
range (Figure 1.7).15 Initially it was thought that the 
anhydride moiety of puberulonic acid chelated to two Mg2+ 
molecules in the enzyme. However, modeling studies 
based on crystallographic data of the inhibitor-substrate 
complex suggested the carbonyl and dihydroxyl moieties 
bind to the two Mg2+ ions within the enzyme, displacing a phosphate that would otherwise bind there 
(Figure 1.7). They found that the distance between the two metal centers were about 3.73 Å.12  













 Piettre and co-workers were intrigued by this activity, so they tested different α-hydroxytropolone 
derivates for their inhibition of IMPase.15 They also investigated other bimetallic enzymes such as Alkaline 
Phosphatase (APase) which contains two zinc ions and Dopamine β-monoxygenase (DBM) which 
contains two copper ions. The results in relation to IMPase indicated that an additional hydroxyl group 
was needed for inhibition. Substrates without 
the extra or masked hydroxyl groups such as 
tropolone (2) and 3,7-dihydroxytropolones 
flanked by a methoxy and acetyl group 
instead of a hydroxyl group were inactive at 
concentrations less than 1 mM (Figure 1.8).  
Puberulonic acid (4) and 3,7-dihydroxytropolone (9) revealed the best profiles at 10 µM and 8 µM 
respectively. These results indicated that the placement of an extra hydroxyl at the C3 position of the 
tropolone ring may play a role in increased binding ability due to secondary interactions with amino acid 
residues within the enzyme. Structures without that C3 hydroxy group, such as α-hydroxytropolone (3) 
showed a bit lower activity at a value of 75 µM. Further, the efficiency and rate of deprotonation was 
believed to be a factor in the chelation of α-hydroxytropolones.  Pyrogallol, whose structure contains three 
contiguous oxygens on a benzyne ring and is super imposable with α-hydroxytropolone showed low 
inhibition of >1 µM. The authors stated that α-hydroxytropolone, which is much more acidic then 
pyrogallol with pKa of 6.7 versus 9.3, can be deprotonated much better at a neutral pH which increases its 
anionic character and thus its binding ability. 
The other enzyme targets tested, APase and DBM, revealed a bit more about the activity. APase 
which has a smaller pocket then IMPase was affected by substitution on the ring. An extra hydroxyl group 
at the C3 position of the 3,7-hydroxytropolone (9) lowered inhibition to 60 µM, as compared to the 
unsubstituted α-hydroxytropolone (3) at 15 µM. Where the enzymes structural makeup may have had an 
impact on those enzymes, DBM illustrated that chelating ability may be the main path of inhibition. Both 
tropolones and α-hydroxytropolones inhibited DBM in the same range of 2-3 µM; the authors indicated 
that the possible mechanism of inhibition was chelation to the metals and they believed that no other 




















Figure 1.8. Activities of tropolones in relation to bimetallic enzymes




1.3.2 Aminoglycoside 2’’-O-adenylyltransferase [ANT(2’’)] 
Aminoglycoside-2”-O-Adenylyltransferase (ANT(2”)) is part of a class of enzymes that include 
acetyltransferases (AAC), and O-phosphotransferases (APH); they were developed by gram-negative 
bacteria to deactivate aminoglycoside based antibiotics.27 This creates a problem as it imparts resistance 
which leads to the need to discover new classes of antibiotics. Molecules that could inhibit this enzyme 
and allow the aminoglycosides to regain their powerful activity are essential to preserve this class of 
clinically important compounds. Allen and co-workers discovered that α-hydroxytropolones have the 
ability to inhibit this enzyme;14 to test this theory they used a strain of E coli, E. coli W677/JR76.2 that 
contained the enzymes 2’’-O-adenylyltransferase, and phosphotransferases: 3"-O-neomycin-kanamycin 
phosphotransferase and a 3'-O-streptomycin phosphotransferase. They monitored the growth of the 
strain with a series of aminoglycoside 
antibiotics: tobramycin, gentamicin, 
kanamycin A, dideoxykanamycin B 
(dibekacin), or butirosin and a 
combination of an antibiotic spiked 
with α-hydroxytropolone. They found 
that antibiotics used alone did not 
affect the bacteria, unless paired with 
α-hydroxytropolone. In addition, α-
hydroxytropolone had no inhibitory 
ability alone, indicating that they were 
interrupting the activity of the enzyme. 
Further, some aminoglycosides and α-hydroxytropolone mixtures showed greater inhibition than others; 
tobramycin was the most effective while kanamycin A was the least. They postulated that another 
enzyme interaction within the bacteria could be disrupting the antibiotic affect, and α-hydroxytropolone did 
not inhibit that particular enzyme; For example, the group indicated that α-hydroxytropolone did not touch 
the phosphotransferase enzymes.  Using the most effective aminoglycoside, tobramycin, they tested 


































Figure 1.9. Inhibitory concentrations of some α-hydroxytropolones against ANT(2'').
10 
 
tropolone (2) with one hydroxyl group as well as derivates where the 7-hydroxyl group of α-
hydroxytropolone was replaced with a carboxyl, bromo, nitro, and amino group. The tropolone was shown 
to be inactive, as well as the bromo, amino, and carboxyl derivatives. The nitro group showed very little 
activity. They concluded that the extra hydroxyl group had a substantial effect on inhibition.  Additionally, 
they tried other diversely substituted dihydroxylated structures to see if derivation upon the seven 
membered rings affected the inhibition activity. IC50 values were not recorded but percent inhibition was 
presented at 100, 10, 1 µg/mL concentrations (converted to µM concentrations in figure) (Figure 1.9).  β-
thujaplicinol (6) which contains an isopropyl group at the C4 position of the α-hydroxytropolone ring 
demonstrated similar activity as α-hydroxytropolone, 76% vs. 78% at 10 µg/ml (55 µM and 73 µM), 
respectively. Ring alkylation with a 4-dimethylallyl group (18) displayed reduced activity at 21% inhibition 
at 10 µg/ml concentration (48 µM). This result possibly indicates that different types of substitution, such 
as alkenes, may have unfavorable secondary interactions or be too bulky, hence interfering with the 
binding. If an extra hydroxyl group was placed at the C4 position as in 10 versus the C3 position as in 9 of 
the α-hydroxytropolone ring, this proved to have better activity, 50% vs. 0% at 10 µg/ml (65 µM), 
respectively. In addition, derivatives that had enzyme inhibition activity allowed tobramycin to gain back 
its activity. 
Finally they concluded that α-hydroxytropolone hinders adenylation by competing with adenosine 
triphosphate (ATP) for the enzyme, with a Ki value of 10 µM. α-hydroxytropolone was not competitive with 
the aminoglycoside. A kinetics study showed that an increase of an antibiotic such as tobramycin did not 
affect the inhibitory ability of α-hydroxytropolone, but concentration of ATP did affect the inhibition 









 1.3.3 HIV (Human Immunodeficiency Virus) Reverse Transcriptase [HIV RT]: The 
Ribonuclease H (RNase H) Active Site 
While reverse transcriptase (RT) polymerase inhibitors are well known HIV drugs on the market, 
drugs that target the alternative site of the enzyme, RNase H, are not currently used.  In 2005 Le Grice, 
Beutler, and co-workers tested the inhibition potential of some naturally derived tropolones and two α-
hydroxytropolones in four types of RNase H studies: retroviral, HIV-1 RT and HIV-2 RT, bacterial, E.coli., 
and human.17 The most active 
compounds against HIV-1 RT were 
the α-hydroxytropolones β-
thujaplicinol (6) and manicol (7) at 
values of 0.21 µM and 0.60 µM 
respectively (Figure 1.10).  Overall, 
most of the tropolones showed no 
inhibition, except with respect to Human RNase H. A slight exception was α-thujaplicin (19); it had minor 
inhibition in HIV-1 RT at 50 µM and HIV-2 RT at 33 µM.  Manicol and β-thujaplicinol were more selective 
towards HIV-1 RT than HIV-2 RT. Further, α-thujaplicin showed a better selectivity for HIV-2 RT; they 
suggested this data may indicate a difference between these two domains. Importantly, β-thujaplicinol 
was more selective for HIV-1 RT RNase H, at 0.21 µM than human RNase H; with a value of 5.7 µM. 
Bacterial RNase H inhibition was not as strong in β-thujaplicinol or manicol, at 40 µM and 50 µM 
respectively which showed evidence of selective inhibition of HIV RNase H. They also found that the 
hydroxytropolones had very little binding ability to DNA polymerase. The authors concluded that the 
binding ability to RNase H was not affected by an indirect effect of being bound to DNA polymerase. In 
addition, they found that the hydroxytropolones did not intercalate to the DNA/RNA hybrid. Both β-
thujaplicinol and manicol displayed a mixed type of inhibition instead of competitive modes. The authors 
suggested that the hydroxytropolones could bind to either the free enzyme or an enzyme-substrate 
complex. They believed that this further signified that perhaps the hydroxytropolones could occupy a 
pocket near the active site. Additionally, they combined β-thujaplicinol and a nucleoside, calanolide A, in a 
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Figure 1.10. Inhibition values of tropolone and α−hydroxytropolone based compounds
for HIV-RT, E.coli (E.C) and Human (Hu) RNase H.
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targeted the polymerase site, while β-thujaplicinol targeted the RNase H site, and they did this 
simultaneously. The authors’ further postulated the idea of a bimetallic chelating ability of the 
hydroxytropolone moiety to two metals at the RNase H active site.  
In 2009, a crystal structure of β-thujaplicinol in the HIV RT RNase H active site was isolated.28 It 
was revealed that β-thujaplicinol did indeed coordinate to two Mn2+ ions in the active site of RNase H, and 
formed ionic or hydrogen bond interactions with the amnio acid residues Glu478 (glutamic acid), Asp498 
(aspartic acid), His539 (histidine), and Asp549. They found that the divalent metals were essential for 
binding.   The data suggested that β-thujaplicinol and the RNA/DNA substrate can be bound at the same 
time to the enzyme. Kinetics studies showed that the presence of the DNA/RNA substrate in RT is 
needed for optimal binding; β-thujaplicinol had less binding ability for the free enzyme. Modeling of the 
human RNase H site superimposed over the β-thujaplicinol RNase H model revealed that the metal 
cations in both substrates align, and that β-thujaplicinol usurps the position of the scissile phosphate; 
hence the inhibitor could interfere with phosphate binding and the ability of water to hydrolyze it. 
Furthermore, β-thujaplicinol and manicol displayed HIV integrase inhibition activity. β-thujaplicinol 
had IC50 values of 24.6 µM for 3’ processing, and 4.8 µM for strand transfer activity. Manicol had IC50 
values 20.2 µM for 3’ processing, and 11.7 µM for strand transfer activity.29 α-Hydroxytropolones inhibited 
integrase activity by binding to the DNA-integrase substrate after the 3’ processing step, hence affecting 
the subsequent strand transfer step with greater inhibition. Similar to RNase H, tropolones did not inhibit 
this process, which again outlines the importance of a dihydroxyl unit. Currently the limitations of these 








1.3.4 XMRV (xenotropic murine leukemia virus related virus) RNase H and Herpes Simplex 
Virus (HSV) 
Xenotropic murine leukemia-virus related virus (XMRV) is a laboratory derived potential human 
retrovirus. It was initially thought to exist in patients with chronic fatigue syndrome and prostate cancer 
but these studies were later retracted and refuted.30,31,32 It was found that XMRV was generated in the 
laboratory by a recombination of two proviruses that produced XMRV with the passage of a human 
prostate tumor cell line CWR22 in nude mice.33 Original human tumor cells CWR22 were not infected with 
the virus. Since XMRV does show the passage into human cells lines there could be potential for this to 
become a human pathogen such as the path of viruses like HIV. Interestingly, Sarafianos34 and 
Wlodawer35 found that the HIV RNase H inhibitor β-thujaplicinol also inhibits RNase H of XMRV.  
Wlodawer uncovered that β-thujaplicinol binds in a similar way to XMRV RT RNase H as HIV RT RNase 
H and that at similar concentrations it has inhibitory activity. Sarafianos indicated competitive binding (as 
concentration increases, inhibition activity does not) at an IC50 value of 1.4 µM.  
The herpes simplex virus (HSV) is a serious human disease that effects 1 out of 6 people from 
ages 14 to 49 in the United States.36 Worldwide estimates found that about 536 million people are living 
with HSV-2, most of them being woman.37 This is a disturbing occurrence as HSV can be passed from the 
mother to fetus at birth and cause death or serious brain injury in infants. Interestingly, HSV involves DNA 
replication catalyzed by a protein called pUL29 (ICP8) that has a similar protein fold as the RNase H 
enzyme.38 Tavis, Morrison, and co-workers believed that inhibitors of RNase H and integrase may also be 
applicable to the HSV virus, so the tested inhibitors that fall in these classes against HSV.39 They tested 
α-hydroxytropolones such as β-thujaplicinol and manicol and an array of tropolones for inhibitory potential 
in HSV-1 and HSV-2 replication (in log10 units at 50 µM and 5 µM concentrations), viral replication in 50% 
effective concentration (EC50), and cytotoxicity (CC50) in vero cells and human foreskin fibroblast (HFF) 
cultures. Vero cells are laboratory primate host cells used for HSV analysis. HFF’s are a human cell type 
that was infected with HSV-1 and HSV-2. It was found that α-hydroxytropolones, β-thujaplicinol (6) and 
manicol (7), and tropolone, nootkatin (20) had some of the best inhibitory profiles of the 42 compounds 
tested (Figure 1.11). Manicol was the strongest inhibitor at 5 µM concentration and inhibited vero cells 
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HSV-1 by 5.14 log10 (138,000 fold) units and HSV-2 by 5.95 log10 units (189,000 fold). They compared 
these results with an anti-HSV drug, acyclovir (ACV), in their assays. At a similar concentration ACV saw 
a value of 3.61 log10 units (4,070 fold) for 
HSV-1 and HSV-2 by 2.88 log10 units (758 
fold). Both nootkatin and β-thujaplicinol had 
values around 5 log10 units at 5 µM 
concentrations for both HIV-1 and HIV-2 in 
vero cells. Similar values were seen in HFF 
cells infected with HSV-1 and HSV-2 with 
log10 values ≥5 at 5 µM concentrations. 
CC50 values in both cells showed low 
toxicity at values of >100 µM. EC50 values and Therapeutic index (TI) values were determined 
(TI=CC50/EC50) for both cell lines with HSV-1 and HSV-2. In vero cells manicol (7) showed EC50 values of 
0.35 µM and 0.58 µM, and TI’s of 286 and 172 in HSV-1 and HSV-2, respectively (Figure 1.11).  
Nootkatin (20) showed EC50 values of 0.24 µM and 0.22 µM, and TI’s of 417 and 454 in vero cells HSV-1 
and HSV-2, respectively. In addition manicol (7) had EC50 values of 0.24 µM and 0.55 µM in HFF cells 
lines with TI’s of 417 and 182 for HSV-1 and HSV-2 respectively. β-Thujaplicinol’s (6)  TI was >100 in 
these cells lines. For comparison the drug ACV had TI’s of 625 and 69 in vero cells HSV-1 and HSV-2 
respectively and 833 for HSV-1 and HSV-2 in the HFF cell line. In addition, they found that β-thujaplicinol 
suppressed replication in ACV resistant strains of HSV-1 and HSV-2 at 5 µM concentration.  
1.3.5 HBV-Hepatitis B Virus RNase H 
The Hepatitis B virus (HBV) causes an infectious disease of the liver. Despite the development of 
a viable vaccine, worldwide the availability of the vaccine in underdeveloped countries is slim and the 
disease is still prevalent with 780,000 deaths a year and more than 240 million chronically infected.40  
Tavis and co-workers developed a low throughput screening assay for HBV RNase H inhibitors and 
started with the HIV-1 RNase H inhibitor β-thujaplicinol to see if it inhibits HBV RNase H.41 They found 


































Figure 1.11. EC50 values and therapeutic indexes of β−thujaplicinol (6), manicol (7),
and nootkatin (20) for HSV.
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and 2.3 ± 1.7 for genotype H of the enzyme. β-Thujaplicinol inhibited HBV replication in human hepatoma 
Huh7 cells, with an EC50 value of 5 µM and did not affect viral protein secretion. Finally, they found β-
thujaplicinol was cytotoxic to Huh7 cells at values of 10 ± 1.7 µM, but found that the membrane integrity 
of the cells was not affected for CC50 values of > 150 µM. In addition they tested cytotoxicity in HepG2 
cells, a heptaocyte line of cells that can be infected by HBV reverse transcriptase and found a CC50 value 
of 16.7 ± 3.7 µM. In sum, the activity of α-hydroxytropolones with respect to RNase H in both HBV and 
HIV is important with viable assays for both substrates, directed SAR studies would be the key to 
discovering a potent therapeutic. 
1.3.6 Phosphotidylcholine-Preferring Phospholipase C 
Phospholipase C is a dimetallic zinc enzyme that cleaves phospholipids by hydrolysis. α-
Hydroxytropolone was shown to have inhibition activity against this compound at a Ki of 16 µM.9 Martin 
and co-workers designed molecules that they believed could mimic the chelating ability of α-
hydroxytropolone yet be easier to 
synthesize by being more stable.9 
They chose N,N’-dihydroxyureas (21-
23),  with a similar carbonyl and 
dihydroxyl unit as that in α-
hydroxytropolone 3 (Figure 1.12). 
Unfortunately, of all the molecules 
derived, none had to the ability to inhibit the zinc containing enzyme phosphotidylcholine-preferring 
phospholipase C as well as α-hydroxytropolone. At more basic pH values the dihydroxyureas became 
more active. Compound 21 showed no inhibition at a pH of 7.3, but at a pH of 9.5 had a Ki of 71 µM. 
Compound 22 showed inhibition at neutral and basic pH values with Ki values of 388 µM at a 7.3 pH and 
53 µM at a 9.5 pH. They believed at basic pH values the molecules would be more negatively ionized, 
hence making them more active towards positive metal centers. It appeared pKa’s played a role but steric 
interactions also dominated the ability of molecules to inhibit the enzyme. Molecule 23 had similar pKa 
profile as α-hydroxytropolone, but showed no inhibition. The authors believed this may be due to 
O
OHHO
Figure 1.12. N,N'-dihydroxyurea mimics' and α-hydroxytropolone's pKa and Ki values



















Ki at 7.3 pH
Ki at 9.5 pH
5.6, 7.0 9.4, 11.2 5.0, 8.7 5.6, 7.1
16 µM 388 µM






unfavorable steric interaction of the ring carbonyl with an aromatic ring of the phenylalanine residue (Phe) 
within the enzymatic pocket. This study showed that pH values as well as steric interactions may play an 
important role in the α-hydroxytropolones ability to inhibit various enzymes with various degrees of 
inhibition.  
1.4 Structure Activity Relationship (SAR) Studies 
1.4.1 SAR studies for IMPase Inhibitor Development 
Due to the ability of 3,7-dihydroxytropolone (9) to inhibit inositol monophophatase15 Piettre and 
coworkers sought out to increase potency of this substrate by constructing 37 new 3,7-dihydroxytropolone 
based substrates.42 They took 3,7-dihydroxytropolone and brominated it which resulted in 57% 
conversion to a 4.8:4.7  mixture of 9:24 (Scheme 1.1). Compound 24 was a mixture of the singly 
brominated A to the doubly brominated B. 
 
The separated compounds were then protected with 
diazomethane and various substituents were installed via a Suzuki 
cross coupling reaction followed by deprotection with trimethylsilyl 
iodide in acetonitrile and subsequent hydrolysis. Their synthesis was 
relatively successful with moderate yields, but they noted that the final 
3,7-dihydroxytropolone products were difficult to purify by any means. They developed a demethylation 
process with trimethylsilyl iodide  (TMSI) in acetonitrile (MeCN) that was an important part of the 
synthesis to gain access to these compounds. Of the 37 compounds only five showed activity similar to or 
better than the parent compound (9) at a concentration of 10 µM (Table 1.1).  
 The best inhibitory activity was seen with the meta-cyano-phenyl dihydroxytropolone (25) with an 
















Table 1.1. IMPase Inhibitory activity
of most potent 3,7-dihydroxytropolones.
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Compounds 27-29 showed similar activity to 3,7-dihydroxytropolone. Disubstituted 3,7-
dihydroxytropolones yielded from a double Suzuki via structure B of 24 tended to have lower activity over 
all the compounds constructed. Kinetics with the new derivatives indicated competitive inhibition modes 
similar to the parent compound.  
1.4.2 SAR studies for HIV RT RNase H and Polymerase, and HIV Integrase Inhibitor 
Development 
Due to 3,7-dihydroxytropolone’s ability to inhibit Inositol Monophosphatase, Piettre, Marquet, and 
co-workers extended their studies to other bimetallic enzymes such as HIV RT RNase H and integrase.12 
Nineteen monosubstituted and disubstituted derivatives of 3,7-hydroxytropolones were synthesized as 
previously reported and their ability to inhibit HIV RT RNase H, HIV RT polymerase, and HIV integrase 
activity was studied. Approximately eight of the compounds had RT polymerase activity better than the 
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The best inhibitor for RT polymerase activity was the benzaldehyde containing derivative 30 with an IC50 
value of 0.57 µM. RT RNase H inhibition activity of most of the compounds tended to be around the same 
value or had worse inhibition than the parent compound, except for the meta-nitro-aryl substituted 31 that 
showed the best profile at an IC50 value of 1.3 µM. For integrase 3’ processing activity, compounds 30, 
31, and 32 had IC50 values under 1 µM which represented an increase of 40-fold over 3,7-
dihydroxytropolone (IC50= 40 µM); additionally these three compounds showed good activity for integrase 
strand transfer. The best integrase 3’ processing compound with an IC50 of 0.15 µM was the disubstituted 
N-acyl-phenyl groups (32) and the best strand transfer inhibition activity was seen with the meta-nitro-
phenyl (31) at a value of 0.78 µM.  Compounds were the three hydroxyl groups were masked by a methyl 
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or acetyl for example, tended to show no activity in all sites. One exception was acetylated compound 33 
that showed activity for polymerase (IC50= 7.6 µM).  The authors felt this finding could infer a different 
mechanism rather than a metal chelating one for the polymerase activity. They continued the polymerase 
activity study by changing the Mg2+ concentration. Using 3,7-dihydroxytropolone and the acetylated 33, 
they lowered the magnesium concentration from 6 mM to 0.3 mM. The result was that inhibition of 3,7-
dihydroxytropolone decreased to 19 µM and 33 showed no inhibition. This study implies that chelating 
ability is a mechanism of inhibition by tropolones, but polymerase activity may not be simply described as 
such. Another interaction or mechanism could be at play such as secondary interactions at the binding 
pocket. Some of the compounds that were tested had antiviral properties in HIV-1 LAI/CEM-SS cells, 
although no protective effects were seen in another cell assay (HIV-1 IIIB/MT-4 cells).  
1.4.3 SAR studies for HIV RT RNase H Inhibitor Development 
As noted earlier, β-thujaplicinol (IC50=0.21 µM) has the best inhibitory activity against HIV RT 
RNase H followed by manicol (7) (IC50=0.60 µM); Unfortunately both substrates offer no viral protection 
and are cytotoxic with CC50 values of 2.3 µM and 13.6 µM respectively.17,18 To improve the activity, 
antiviral properties, and cytotoxicity profiles, Le Grice, Beutler, and co-workers synthesized 14 new 
compounds by derivatizing the 
core of manicol.18 They took 
manicol and by two routes were 
able to derivate it. In the first 
route, they acylated manicol (34) 
and via the alkene portion they 
performed dihydroxylation and 
oxidation reactions (Scheme 1.2).  In the second route they installed an epoxide at the alkene (35) and 
opened it with various thiol and amine nucleophiles. None of the derivates tested improved inhibition of 
RNase H compared to manicol and β-thujaplicinol, the best inhibitory activity (IC50 values) was found in 















Scheme 1.2. Brief synthetic scheme of manicol derivation.
7 34 35




All the compounds tested except 36 were less cytotoxic than manicol, while over half of the newly 
synthesized derivatives offered some viral protection. Compound 40 was an interesting prospect, its 
inhibitory activity was in the same range as manicol and this substrate offered some antiviral protection 
(EC50= 10.2 µM), and was much less cytotoxic (CC50= >50 µM). Substrates 37, 38, 39, which each 
contained sulfur but appended to different groups such as an ethane, benzene and benzyl moieties 
respectively, were a fascinating trio analyzed. 
As the size of the appendage increased from ethane, benzene, benzyl, the inhibition decreased 
and antiviral activity increased.  The substrates were tested for polymerase activity on RNase H deficient 
RT and wild type HIV-1 RT, but almost all compounds did not inhibit this site on either strain. The 
exceptions were compound 41 and 42 which inhibited DNA polymerase activity on both strains. Finally 43 
showed the lowest inhibition activity (IC50= 1.9 µM), no antiviral activity, but was less cytotoxic (CC50= >50 
µM).  It seems that as inhibitory activities increase/decreased the opposite effect was had on antiviral 






1.5 Syntheses of α-Hydroxytropolones 
1.5.1 Total Synthesis of α-Hydroxytropolone  
One of the first syntheses of the α-hydroxytropolone core structure was developed by Nozoe and 
co-workers in 1953. They discovered that when 1.2 molar equivalent of potassium persulfate was added 
to tropolone, 2, the resultant product contained a mixture of 15% α-hydroxytropolone (3) and 30% of 5-
hydroxytropolone (11) in addition to 
un-reacted starting material 
(Scheme 1.3).43  Additionally, they 
did chemistry on 3. They protected 
the two hydroxyls with methoxy groups with diazomethane (no yield given) and a diacetate in 80% yield 
with acetic anhydride; additionally benzoylation by the Schotten-Baumann method gave a dibenzoate in 
60% yield.  
 In 1986, Takeshita and Mori achieved the exclusive α-hydroxytropolone core structure through a 
high yielding synthesis.44 They took methoxytropolone 44 and brominated it with N-bromosuccinimide 
(NBS) (Scheme 1.4). The resultant 7-bromo-2-hydroxytropolone (45) was acetylated to compound 46 in 
100% yield with acetic anhydride and acetyl trifluoroacetic acid under heat.  
 
Under heat and acetic acid they were able to deacetylate 46 to afford α-hydroxytropolone in 100% yield, 
with an overall yield of 89% from the starting material. This synthesis demonstrated a high yielding, low 
step synthesis to the α-hydroxytropolone core structure.  
In 2004, Föhlisch and co-workers explored a concise synthesis of substituted α-
hydroxytropolones by means of a ring opening of 8-oxabicyclo[3.2.1]oct-6-en-3-ones constructed from a 
[4+3] cycloaddition that involved furans as starting components.45 They achieved substitution at two 












Scheme 1.3. Nozoe's synthesis of α- hydroxytropolone (3) and 5-hydroxytropolone (11).
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different places on the α-hydroxytropolone ring structure, as well as a synthesis of α-hydroxytropolone 
and β-thujaplicinol. The synthesis started with substituted furans 47a-d; furan, 2-methylfuran, 2-
isopropylfuran, and 2-benzyloxymethylfuran (Scheme 1.5).  
R1=H, 72% 48a only
R1=CH3, 65% 48b:49b (2.3:1)
R1=i-C3H7, 62% 48c:49c (3.4:1)
R1=BnOCH2, 78% 48d:49d (1.2:1)












































R2=CH3, Butan-2-one, or H
KOH








R1=H, 97% 50a only
R1=CH3, 95% 50b:51b (2:1)
R1=i-C3H7, 93% 50c:51c (>19:1)






The furans were each reacted with a 1,1,3,3-tetrachloroacetone generated oxyallyl intermediate 
in a  [4+3] cycloaddition reaction that produced two diastereoisomers with 48 being the favored structure 
in all compounds, with combined yields of both diastereoisomers ranging from 62%-78%. In the next step, 
the mixture of these compounds were subjected to sodium methoxide then zinc powder, which added 
dimethoxy groups and dehalogenated the substrates to yield  50 and 51. Strangely the opposite 
regioisomer of the favored starting compounds 48 was favored, compound 50. They envisioned this may 
have been due to steric constraints between R1 and the chloro groups in 48. They constructed the 
mixtures of compounds 50 and 51 in combined yields ranging from 75%-97%. They were able to further 
functionalize the core structure by installing a methyl or a 2-oxobutyl group alpha to the carbonyl. With 
these compounds in hand, they tried various ring opening procedures until they discovered that a 
methanolic potassium hydroxide solution followed by acidification produced methoxytropolones 52 in 
yields ranging from 58%-88%. The compound with the 2-oxobutyl moiety at R2 needed alternative ring 
opening procedures involving methanolic sodium methoxide at reflux. The potassium hydroxide 
conditions, even at room temperature, produced an aldol condensation product between the ring carbonyl 
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and the ketone at position R2. Even with the new conditions they got minor amounts (16% yield) of the 
aldol product. Interestingly, only the products with the structure of 50 reacted, the 51 products did not but 
could easily be separated from the mixtures via an alkaline aqueous phase workup. They took 
methoxytropolones 52 and submitted them to demethylation procedures involving hydrogen bromide and 
acetic acid (HBr/AcOH), and generated such compounds as the naturally occurring α-hydroxytropolone, 
3, in 94% yield and β-thujaplicinol, 6 in 96% yield in five steps. This synthesis proved that more than one 
point on the α-hydroxytropolone ring could be diversified and offered an alternative synthesis to the 
precursor structures, 7-methoxytropolones in four steps. The limitations, as outlined by the authors, was 
the unavailability of appropriate substituted furans, and the formation of the wrong oxabicyclic compounds 
51 that did not undergo the ring opening and diminished the yields; they indicated that selectivity of the 
initial [4+3] cycloaddition needed to be refined.  
Balci and co-workers utilized a photooxygenation to obtain a functionalized α-hydroxytropolone 
that is a derivative of stipitatic acid.46 They took 1,3-benzodioxole 55 and reacted it with ethyl 
diazoacetate under rhodium acetate (Rh2(OAc)4) catalyzed conditions to yield cycloheptatriene 56 in 40% 
yield (Scheme 1.6). Then a photooxygenation reaction with tetraphenylporphyrin yielded peroxide 57 in 
90% yield. To obtain the 
α-hydroxytropolone they 
utilized a Cobalt meso-
tetraphenylporphyrin 
(CoTPP) rearrangement 
process. They believed 
the intermediate 
compound was the di-epoxide 58 that could quickly rearrange to the α-hydroxytropolone 59 in 60% yield. 





























Scheme 1.6. Balci's synthesis of a functionalized α-hydroxytropolone.
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1.5.2 Total Synthesis Puberulonic Acid  
Nozoe and co-workers were leaders in the synthesis of compounds in the troponoid family of 
molecules, so it was only fitting they would pursue the synthesis of the natural product, puberulonic acid 
.47  In 1960, they attempted this synthesis using purpurogallin (60) as the starting material (Scheme 
1.7).48,49  They oxidized this compound to the anhydride containing tropolone 61 in low yield as indicated 
in the paper. The insertion of a bromine atom alpha to the carbonyl was assembled with the reaction of 
bromine in acetic acid to form 62 in 86% yield. To install the hydroxyl group, they used β-
naphthalenesulfonate in a basic solution with copper powder to yield 63 in 83% yield. Installing the 
bromine beta to the carbonyl was not as facile, and the previous conditions of bromine in acetic acid left 
only a decomposed product.  
 
The circumvented this by adapting a new method which involved bromine in sodium hydrogen sulfate to 
yield 64 in 50% yield. Again, the additional hydroxyl group was installed with the previous method to yield 
puberulonic acid (4) in 35% yield. They noted that the reactivity of the bromine in 62, was stronger than in 
64, due to yields gained of the hydroxylated products. The yields could also indicate a mass loss. This 
could be attributed to the α-hydroxytropolone 64 chelating to the copper stronger than the tropolone 62 or 
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the loss of 64 in the water extraction. They could further synthesize puberulic acid by decarboxylation of 
puberulonic acid (4) under reflux with water; they obtained puberulic acid in 64% yield.  This attempt 
offered the first synthetic approach towards puberulonic acid, informed on the relative reactivity at various 
places on the ring, as well as introduced a low step count sequence.  
1.5.3 Total Synthesis of Puberulic Acid 
Johnson and co-workers wanted to understand more about the structures of the first two 
discovered natural α-HTs, puberulic acid and puberulonic acid. They made some interesting observations 
that led to a synthetic strategy to puberulic acid.3,4  Initially, it was found that puberulonic acid could be 
converted to puberulic acid by decarboxylation upon heating to reflux in sulfuric acid or water.4 Moreover, 
observations about reactivity were uncovered, such as that the carbonyl group was inert to chemical 
reactions, and substitution products were favored over addition products when bromine was added to the 
tropolone structure.4 In addition, as most tropolones produced benzenoids upon heating with potassium 
hydroxide, puberulic acid showed stability under temperatures of 320°C.4 These observations lead the 
group to take a very early synthetic approach towards puberulic acid. They did this by first targeting 
puberulic acid’s precursor, stipitatic acid, 12 which is similar to puberulic acid except for the absence of 
an extra hydroxyl group alpha to the carbonyl (Scheme 1.8).50,51  
 
They were able to achieve stipitatic acid through a synthetic sequence that involved utilizing a 
rearrangement product derived from 1,2,4-trimethoxybenzene 65 and 2-propionyldiazenecarbaldehyde. In 
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situ, the reaction was thought to generate a cyclopropyl intermediate, 66, that could immediately expand 
to the cycloheptatriene ring structure 67. The ester was hydrolyzed with potassium hydroxide to install the 
carboxylic acid in compound 68. Hydrogen bromide in bromine demethylated and oxidized 68 to reveal 
stipitatic acid (12). To install that extra hydroxyl group alpha to the carbonyl, they brominated that position 
in 69 then immediately subjected it to potassium hydroxide under heating to reveal puberulic acid 5 in 
58% yield. This was the first synthetic strategy towards the natural product puberulic acid, and utilized 
some notable chemistry such as cyclopropyl ring expansion to gain the seven membered tropolone ring 
structure, as well as a low step count. The negative part of this synthetic approach was the low yields 
obtained.  
Banwell and co-workers creatively applied a dibromopropane ring opening to the synthesis of the 
natural product puberulic acid.52 First, diol 70 was protected with acetone and perchloric acid to produce 




The acetonide was brominated and the dibromopropane moiety was established in 72. It was then 
deprotected and methylated with methyl iodide to craft compound 74 in 97% yield. The authors 
mentioned that they tried to find a more direct route to the methylated 74 right from starting diol 70 but 
failed to produce the required product for the dibromocarbene addition step (71-72).54 The cis-diol 
product, 75, was generated in 75% yield with osmium tetraoxide. To obtain the diketone, they initially tried 
modified Swern conditions, but this did not produce the require diketone 77. The required ketone was 
garnered through an alternative oxidation process using 4-acetamido-TEMPO (2,2,6,6-Tetramethyl-
piperidin-1-yl)oxyl and p-toluenesulfonic acid.  Interestingly, when the diketone was acetylated, a 5:3 
mixture was obtained in 85% combined yield, the lesser ratio implicating the acetylated compound 76 as 
well as starting diketone 77. They found that only the acetylated compound achieved the desired base 
activated ring expanded tropolone core, 78, in 79% yield. Making use of the bromine handle, a carboxylic 
acid was installed through a metal catalyzed methoxycarbonylation to obtain product 79 in 71% yield, 
after hydrolysis. Finally through demethylation procedures that involved hydrobromic acid in acetic acid, 
puberulic acid (5) was achieved in 90% yield. Although the step count increased from the previous 
attempt at puberulic acid, yields were slightly improved. 
 In 2011, Omura and co-workers gathered the preliminary biological data on puberulic acid’s 
activity against malaria and recently they attempted a synthesis of this natural product.16,55 First they 
utilized the readily available and inexpensive carbohydrate D-(+)-Galactose (80) as their starting material 
(Scheme 1.10). They protected the alcohols with acetonide groups and installed an iodide via an Appel 
reaction to yield 81 in 97% yield. They installed an aldehyde at the iodide position through a Barbier 
addition with zinc in tetrahydrofuran and water (THF/H2O) and then immediately added diene 82 until they 
formed 83 in 96% yield in a (2.3:1) ratio of the diastereoisomers (6S:6R). This mixture was subjected to a 
ring closing metathesis with the Grubbs second generation catalyst (10 mol%) to yield 84 in 97% yield. 
After a deprotection with 2,3-dichloro-dicyano-1,4-benzoquinone (DDQ) that removed the para-
methoxybenzyl (PMB) group to yield a hydroxyl group, the group tried various oxidation conditions to 






They found that under a multi-tandem Parikh-Doering oxidation with SO3∙pyridine in dimethyl sulfoxide 
(DMSO) in triethylamine (NEt3) they successfully created compound 85. They believed the mechanism 
first went through an oxidation that converted the hydroxyl groups to carbonyls. Then aromatization 
followed through tautomerization of the protons within the structure. To install the carboxylic acid they 
utilized a Pinnick oxidation to construct 86. The final step to form puberulic acid was the removal of the 
acetonide which was accomplished with hydrogen bromide in acetic acid. They formed puberulic acid via 
eight steps in 54% overall yield. This method not only offered a low step, and high yielding sequence, it 






1.5.4 Total Synthesis of β-Thujaplicinol 
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Martin Banwell was a forerunner in tropolone synthesis and in his progress toward achieving a 
synthesis towards another natural product, β-thujaplicinol, he discovered a route to add substitution 
around the tropolone core, which was previously not achieved up to this point. He did this through an 
efficient five step synthesis that involved a dibromocyclopropane ring expansion. With the easily 
accessible, cyclohexa-1,4-diene, 87,  the dibrominated cyclopropane structure was installed to generate 
88 in 72% yield (Scheme 1.11).56 Compound 88 was then oxidized to the diol 89.57 The key reaction 
involved an in situ ring opening. First, through an oxidation procedure developed by the group using 
dimethyl sulfoxide activated with trifluoroacetic anhydride, a diketone was generated.58 Then under basic 
conditions, a ring expansion was promoted that generated the 7- methoxytropolone 90 in 85% yield, an 
important intermediate towards the synthesis of α-hydroxytropolones.  
 
The bromine at the four position of the ring on 90 offered a point to install diverse substitution, 
including an isopropyl group that would lead to the generation of the natural product, β-thujaplicinol. They 
completed the synthesis of β-thujaplicinol by attaching propene in place of the bromide through a Stille 
cross coupling and obtained 91 in 89% yield; then with hydrogenation they were able to reduce the 
propene to an isopropyl group.59 Finally an acetic acid hydrogen bromide demethylation reaction 
generated β-thujaplicinol (6) in 73% yield over two steps. They were able to use 7-methoxytropolones to 
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do various cross coupling reactions to switch out the R group on the ring (92). Demethylation afforded the 
α-hydroxytropolone products. This synthesis was the first to achieve substitution on the core ring structure 
of α-hydroxytropolones, but was limited to only one access point on the ring. Fortunately, ideal placement 
of the bromine on the ring allowed for the first complete synthesis of the natural product, β-thujaplicinol.  
1.5.5 Synthesis of 7-Methoxytropolones 
Banwell and co-workers designed an alternative synthesis to obtain 7-methoxytropolones. As was 
outlined in previous synthetic endeavors, 7-methoxytropolones are a demethylation away from α-
hydroxytropolone. Banwell took commercially available 2,3-dimethoxyphenol (93) and subjected it to 
oxidation with Thallium (III) nitrate to produce the acetal, 94 (Scheme 1.12).60  
 
The acetal was cyclopropanated with dimethyloxosulfonium methylide to form 95 in 35% yield. Hydrolysis 
with hydrochloric acid (HCl) gave diketone 96 in 84% yield. This product expanded into the boron 
difluoride methoxytropolone 97 in 55% yield (with minor amounts of the hydroxylated version) with six 
equivalents of boron trifluoride etherate. 7-methoxytropolone 98 was generated in 83% yield with sulfuric 
acid under reflux.   
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Davies and Clark developed a rhodium catalyzed tandem cyclopropanation/Cope rearrangement 
to construct substituted tropolones.61 They were able to construct methoxytropones, as well as 
dimethoxytropolones using this technique. Utilizing a rhodium II catalyst  with an acetate, pivalate, or 
octanoate,  various vinyldiazomethanes were reacted with an electron rich diene 101 and the core 
cyclohexadiene rearrangement products were gained through cis selective divinylcyclopropane 
intermediate 102 (Scheme 1.13).  
 
They constructed various methoxytropolones by installing different substrates alpha to the 
carbonyl such as a methyl, phenyl, methyl ester, and benzene thiol. To construct a dimethoxytropone 
they needed to use a vinyldiazomethane with an electron donating methoxy group (100). Due to the 
decreased stability of this substrate attributed to the electron donating methoxy group, the chemistry was 
a bit more challenging than their previous attempts with electron withdrawing groups. Under the rhodium 
catalyzed reaction conditions that utilized the octanoate, they successfully obtained product 103 in 32% 
yield. Under a one pot hydrolysis/oxidation with p-toluenesulfonic acid and DDQ conditions 
dimethoxytropolone 104 was obtained in 58% yield. Davies and Clark offered a short route that allowed 
versatility on the seven membered ring. It could be imagined that a variety of substrates could be 








1.6 Conclusion to the Biology and Synthesis of α-Hydroxytropolones  
 It has been shown that α-hydroxytropolones have promising biological activity, but SAR studies 
are limited by the ability to easily access these molecules. Previous syntheses have shown that the α-
hydroxytropolone structure can have stability issues and unpredictable ring reactivity. Due to these 
issues, synthesis of these molecules was circumvented with mimics, but reduced medicinal activity of 
these mimics outlined the strength these powerful small molecule inhibitors have that cannot simply be 
exchanged. Syntheses of diversely substituted α-hydroxytropolones for medicinal chemistry shines 
through in the work of Banwell and Föhlisch who both introduced ways to insert functionality on the core 
α-hydroxytropolone core structure. Additionally, the manipulation of natural products such as manicol 
have shown promise, and cross coupling reactions reveal an efficient way to derivate the core such as in 
the work with the dihydroxytropolone SAR studies. The elements of a medicinal chemistry driven 
synthesis of α-hydroxytropolone are out there, but the pieces have yet come together for continuously 



















CHAPTER 2: Synthetic Route and Chemistry 
2.1 Introduction 
As discussed, α-hydroxytropolones are somewhat understudied therapeutically due to the lack of 
a general method to 
synthesize them. Although 
viable synthetic routes for 
medicinal chemistry studies 
have been shown in the work of Föhlisch and Banwell, they do have their limitations. For example, 
Föhlisch’s multi- step synthesis allowed for diverse functional groups, but relied on early stage 
introduction of those groups through a furan.45 On the other hand, Banwell was able to introduce late 
stage substitution on the α-hydroxytropolone core, but the synthesis only allowed access to one place on 
the α-hydroxytropolone ring.59 A process that allows for late stage introduction of poly-substitution on the 
α-hydroxytropolone would be an ideal synthetic route for medicinal chemistry studies as a library of 
substrates could easily be accessed. It was envisioned that this could be achieved through a late state 
intermolecular oxidopyrylium dipolar cycloaddition with various alkynes (step 105-106) which could yield 
an array of multi substituted 8-oxabicyclo-[3.2.1]octadienones (106) that could be induced to open under 
acidic conditions to yield poly-substituted α-hydroxytropolones (107) (Scheme 2.1). The goal of this 
research was to develop a synthetic route to obtain the generation of a diverse array of α-
hydroxytropolones through an intermolecular oxidopyrylium cycloaddition between a β-hydroxy-
γ-pyrone generated oxidopyrylium ylide and an external alkyne followed by a ring opening. 
Oxidopyrylium cycloadditions have proven to be powerful transformations for the formation of 8-
oxabicyclo-[3.2.1]octadienones.62 Chemistry on these 8-oxabicyclo-[3.2.1]octadienones such as ring 
openings of the epoxide ring have showed that through these simple one step addition processes, 
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2.1.1 β-Hydroxy-γ-Pyrone Derived Oxidopyrylium Reactions  
Volkmann and co-workers first identified the [5+2] cycloaddition reaction products of β-hydroxy-γ-
pyrones, kojic acid and α-deoxykojic acid, with acrylonitrile. In addition they postulated a mechanism that 
involved an oxidopyrylium intermediate.63 The reaction was first performed by Hurd and co-workers, but 
wrong assignment of structural products led to an unclear mechanism.64 Volkmann identified one of the 
reaction products as 113a, and proposed a mechanistic pathway (Scheme 2.2).  
 
He suggested that the base catalyzed reaction was initiated by an intermolecular [5+2] cycloaddition 
reaction (109a) between kojic acid 108a and acrylonitrile, which led to cycloadduct 110a. Nucleophilic 
addition of another molecule of kojic acid to the carbonyl yielded 111a. Nucleophilic attack of the hydroxyl 
group into the cyanide moiety yielded imidolactone 112a (which was one of the products isolated by Hurd 
and co-workers), and after acidic workup compound 113a was obtained. Similar structures were identified 
by the reaction of α-deoxykojic acid and acrylonitrile following a similar mechanistic reason, which yielded 
product 111b. Also 111d and 111c that were derived from pyromeconic acid (108d) and 





A few years after 
Volkmann’s discovery, Garst and 
co-workers demonstrated the 
utility of an intramolecular 
oxidopyrylium reactions 
generated from β-hydroxy-γ-
pyrone cycloadditions. 65 From the 
pyrone based comenic acid (114), 
they assembled cycloadducts 117 
in 55% yield and 118 in 42% yield by refluxing in benzene for 12 hours and acetonitrile for 60 hours 
respectively, followed by acetylation (Scheme 2.3). Next, they experimented with expanding the chain 
length of the tethers.  First they assembled compound 119a from kojic acid and they used that to achieve 
cycloadduct 120a in 70% yield after 12 hours of reflux in benzene followed by acetylation. Following this 
successful reaction they tried to incorporate a 
six membered carbon ring which they 
achieved through the generation of 120b in 
65% yield. They gained this substrate after 
heating at higher temperatures of 110°C for 
48 hours in benzene followed by acetylation 
(Scheme 2.3). Expansion by one carbon 
further in this substrate was not possible 
(119c-120c), and higher temperatures just 
led to decomposition. Alternatively, addition 
of a benzene ring into the tether (121) and heating in methanesulfonic acid in methanol for 12 hours 
provided ketal 122 in 87% yield (Scheme 2.3).  
Volkmann’s and Garst’s work led to a hypothesis of how these short-lived oxidopyrylium 
intermediates from pyrone starting materials were generated. Subsequent work done by Wender and 


























115 117 (55% )
116 118 (42%)













































Scheme 2.4. Kojic acid derived pyrones and their cycloaddition products.
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formation of the oxidopyrylium species 124 that reacts in an intramolecular fashion to generate 
cycloadducts such as 125 (Scheme 
2.5).66,67,68 Not only can protons transfer 
but groups such as benzoate (Bz), 
tertbutylsilane (TBS), acyl (Ac) are also 
known to undergo the tranfromation.62b, 
69 Theoretical studies done by Domingo and co-workers based on Wender and Mascareñas experimental 
data that used DFT (density functional theory) methods at a B3LYP/6-31G* level of theory supported this 
mechanism.70 They found a more favorable energetic profile if the R group transfer happened before the 
cycloaddition than after the cycloaddition took place, validating the above mechanism.  
As was shown there was a strong basis for oxidopyrylium cycloaddition generated from β-
hydroxy-γ-pyrone, but mainly this reaction proceeded through an intramolecular mechanism. 
Intermolecular β-hydroxy-γ-pyrone based oxidopyrylium cycloadditions are to a lesser extent known. In 
fact, there are only two reactions to date where this reaction was demonstrated with an alkyne. In one, it 
was demonstrated that α-deoxykojic acid (108a) could react through an oxidopyrylium cyclization with an 
in situ formed benzyne (126) to form 
cycloadduct 127 in 33% yield (Scheme 2.6).71 
Due to the reactive nature of benzyne, another 
equivalent added into the carbonyl. A more 
general route was developed by Wender and 
Mascarenás, who showed that a triflate salt 105a generated through the reaction of α-deoxykojic acid 
108a and methyl triflate could be converted, through deprotonation with N,N-dimethylaniline, to a reactive 
oxidopyrylium zwitterion (128), capable of cyclizing with a range of activated alkene dipolarophiles under 
mild conditions; In addition they demonstrated the reaction with a reactive alkyne dipolarophile Dimethyl 
































To overcome the limitation of the intermolecular scope of reactions, Mascareñas and co-workers 
developed temporary tethering strategies. Intramolecular pyrone based oxidopyrylium reactions are 
inherently more reactive due to the nature of the reactants which are in closer contact with one another 
than in the intermolecular sphere. Utilizing this reactivity, Mascareñas and co-workers envisioned that 
they could attach a heteroatom containing tether to the pyrone species that would react in a more 
favorable intramolecular fashion and 
then simply break apart the tether 
with a reaction that could remove the 
specific heteroatom (Scheme 2.8).72 
They accomplished this by 
assembling a sulfur or silicon linker. Under heating in a sealed tube in toluene they successfully 
completed the cycloaddition of 129a and 129b to cycloadducts 130a and 130b respectively (Scheme 2.8). 
Removal of the sulfur with Raney nickel revealed the product 131a in 70% yield. The silyl was removed 
with potassium fluoride (KF) in meta-chloroperbenzoic acid (mCPBA) to form the diol 131b. 
Intermolecular pyrone based oxidopyrylium cycloadditions are difficult to access as shown with their 
narrow scope, but the vibrant complexity of this simple reaction is an important synthetic tool and an 




























Scheme 2.8. Mascareñas's tethering approach in oxidopyrylium cycloadditions.
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2.1.2 Oxidopyrylium Cycloadditions followed by Ring Openings in the Synthesis of the 
Tropolone Moiety. 
Oxidopyrylium cycloadditions followed by ring openings are powerful processes that serve as 
synthetic stepping stones to important biological targets; one of those targets happen to be tropolones. 
Baldwin and co-workers used an oxidopyrylium cycloaddition followed by a ring opening reaction to 
construct a deoxy analogue of the tropolone containing natural product epolone B.73 Starting with a 
commercially available furan, 3-methyl-2-furoate they obtained pyranulose 132 in 63% overall yield 
(Scheme 2.9).  
 
The oxidopyrylium reaction was initiated by heating the molecule in a sealed tube at 120°C in the 
presence of the dienophile α-acetoxyacrylonitrile. The pyranulose served as the oxidopyrylium species 
(structure in red) whereas the alkene of α-acetoxyacrylonitrile served as the reactive portion of the 
dienophile (structure in blue). The reaction afforded a mixture of compounds 133 in 54% overall yield. 
They tried to install another ketone in-place of the cyanide and acetate, which did not give their desired 
product. Alternatively, they reduced the already present ketone and installed another ketone with sodium 
methoxide in methanol to yield 134 in 98% yield. They attempted to ring open the either bridge directly 
from ketone 134, but had no success. The alternative path involved opening the bridge via an iodide 
induced elimination. After four steps from ketone 134 that involved a reduction, protection, removal of the 
tertbutyl silyl  (TBS) protecting group and finally installation of an  iodide, compound 135 was obtained in 
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84% yield (over 4 steps). The iodide was eliminated via reduction with zinc in refluxing ethanol to produce 
an alkene moiety into the desired ring opened product 137 in 78% yield. From there they successfully 
reached their tropolone core structure (138) after 6 steps in 37% yield from 135. While working on 
tropolone based natural products, Baldwin employed another intramolecular oxidopyrylium 
cycloaddition/ring opening procedure. The group employed a rhodium catalyzed oxidopyrylium reaction. 
With starting compound 139 gained in 33% yield over two steps from commercially available phthalic 
acid, an internal alkyne was installed as well as a diazoketone  (Scheme 2.10.). 74  
 
The oxidopyrylium species (structure in red) in 140 was generated from  reaction of the diazoketone with 
rhodium catalyst. This species reacted with the tethered internal alkyne (structure in blue) which served 
as the dipolarophile. They successfully achieved the oxabicyclic species 141 in 74% yield and under 
simple acidic conditions with hydrochloric acid (HCl) the bridged oxygen underwent a ring opening to form 
tropolone 142 in 93% yield. 
Schmalz utilized a similar oxidopyrylium reaction/ring opening reaction in the synthesis toward the 
tropolone containing natural product colchicine.75 They employed a rhodium catalyzed oxidopyrylium 
cycloaddition as the key step. They synthesized compound 143 over 5 steps in 45% overall yield 
(Scheme 2.11). To 143 was added Rh2(OAc)4 in refluxing toluene. The reaction was commenced with the 
formation of a rhodium carbene which was then attacked by the oxygen of the carbonyl (144) to generate 
the ylide 145.76 The generated oxidopyrylium ylide (structure in red of 145) reacted with the tethered 
alkyne (structure in blue) in a dipolar cycloaddition to yield key intermediate oxabicyclo compound 146 in 






The use of diethylaluminum chloride did not yield the ring opened product but produced complete removal 
of the ether bridge oxygen and resulted in the formation of a tropone. They believed they were losing the 
bridged oxygen by dehydration which possibly took place before the ring opening. They exercised an 
alternative method that involved reduction of the carbonyl to a hydroxyl group with L-selectride to 
generate 147 in 82% yield. The ring opening was then completed with the Lewis acid trimethylsilyl 
trifluoromethanesulfonate (TMS) in triethylamine (NEt3). It was believed that the TMS attacked the ether 
bridge (intermediate 148) and activated the molecule; then the base deprotonated the ring and the 
molecule opened to yield product 149 in 63% yield, after removal of the silyl groups. After a simple 





A more recent synthesis in the laboratory of Tang and co-workers further emphasized the value 
of an oxidopyrylium cycloaddition followed by a ring opening.77 This was the key step in their synthesis of 
the natural tropolone harringtonolide. The essential molecule for the cycloaddition (151) was obtained as 
combination of four diastereoisomers in 18 steps with a 3% yield from the starting material (Scheme 
2.12).  
 
The intramolecular oxidopyrylium cycloaddition of 151 occurred in refluxing chloroform with the non 
nucleophilic base DBU (1,8-Diazabicycloundec-7-ene) to yield cycloadduct 152 in 85% yield. The 
oxidopyrylium species was formed in situ from the dihydropyran ring unit (highlighted in red) that reacted 
with the internal cyclohexene ring (highlighted in blue) in structure 151. The cycloadduct was then set up 
to undergo the ring opening, after three steps they formed tertiary alcohol 153 in 78% yield from the 
cycloadduct. They installed the ketone moiety under a PCC oxidation to obtain 154 in 10%-40% yields. 
They tried a reductive cleavage of the ether bridge of 154 with samarium iodide but that led to no reaction 
or a complex mixture; they were not able to obtain anticipated tropone 156. An alternative procedure to 
open the ether bridge involved a two step process. Starting again from 153, they installed a phenylthio 
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group and obtained 155 in 75% yield. The proton attached to the same carbon as the phenylthiol was 
selectively removed with lithium diisopropylamide (LDA) in the presence of hexamethylphosphoramide 
(HMPA). This reaction promoted the ring opening to yield 157 in 90% yield which after 7 steps was 
converted to harringtonolide (158) in 11% yield from 157. These reactions showed that oxidopyrylium 
species in conjunction with creative ring opening procedures of the cycloadduct can serve as key reaction 
in the synthesis towards naturally containing tropolones.  
2.2 Synthesis and optimization of an Intermolecular Oxidopyrylium Cycloaddition78 
2.2.1 Initial Findings in the Intermolecular Oxidopyrylium Cycloaddition 
To gain access to the oxidopyrylium species a short and efficient synthesis was undertaken. The 
first step was a simple chlorination of the commercially available kojic acid (108a) to obtain 108c in 90% 
yield (Scheme 2.13). This was then reduced with Zn/HCl to gain 108b in 69% yield, followed by a 
methylation to obtain the oxidopyrylium species, 105a, in 53+% yield following recrystallization.68,79 
 
With conditions as outlined in the work of Wender and Mascareñas, the cycloaddition product 
106a was attained in 74% yield.68 Quickly it was found that under similar conditions with various alkyne 
dipolarophiles the reaction suffered from low yields and longer reaction times or little to no product 
formation.   The oxidopyrylium cycloaddition was an important sequence in our proposed synthetic route 
towards α-hydroxytropolones. For future SAR studies, the process ideally needed to take less time and 
be better yielding than it currently was. To overcome these limitations, initial optimization experiments 
were performed using one of the less reactive dipolarophiles, phenyl acetylene. Under Wender’s and 
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Mascarañes’s conditions, 20 equivalents of alkyne and 2 equivalents of the base  N,N-dimethylaniline, the 
reaction took one week at room temperature with a yield of 35% of the oxabicyclic compound 106b 
(Scheme 2.13). Since cycloadditions are accelerated by heat, the first technique attempted was to simply 
heat up the reaction. A microwave reactor seemed to be a logical choice as it provided a sealed tube 
enclosed environment, concentrated heating, and allowed for shorter reaction times. After a series of 
temperature screens, it was found that after 10 minutes at 100°C, conversion to the cycloproduct was 
taking place, whereas at lower temperatures such as 70°C, no conversion was seen. It was found that 45 
minutes was necessary to complete the reaction with a yield improvement of the oxidopyrylium 
cycloaddition product to 46%.  During these studies, an impurity was evidenced in the nuclear magnetic 
resonance (NMR) data and seemed to be increased with lower yields of the cycloproduct. The reaction 
was thus run in the absence of the alkyne in deuterated chloroform (CDCl3), and it was quickly found that 
this impurity was the deoxykojic acid salt 161 that formed under a substitution reaction between N,N-
dimethylaniline 159 with the 
deprotonated oxidopyrylium 
salt 160 (Scheme 2.14).  
The salt 161 was evidenced 
on the 1H NMR by three singlet peaks at 6.30 ppm, 7.80 ppm, and 2.25 ppm, integrating to one, one, and 
three protons, respectively. Also there appeared to be a singlet peak at 3.75 ppm integrating to nine 
protons which was believed to correspond to the three methyl groups of the trimethylammonium species 
162; further supporting the evidence that the mechanism of demethylation was taking place. It was 
thought that perhaps over time the demethylated product 161 could react in such a way as the 
oxidopyrylium salt; but when 20 equivalents of the alkyne was added to the reaction mixture no 
cycloproduct was formed and 161 persisted;  it was concluded that this was not a reversible process.  
Additionally another important observation was made during these initial studies, It was 
previously suggested in the work of Wender and Mascareñas that the formation of dimer 163 was the 
major impurity (Scheme 2.15), and efforts to optimize the reaction had been geared toward reducing the 
formation of this compound.68   However, it was found that in fact the dimer was not a sinkhole, and either 

















Scheme 2.14. Proposed mechanism of the demethylation of the oxidopyrylium salt via dimethylaniline.
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productive intermediate. When a zero point 
sample of the reaction mixture (salt, base, alkyne, 
and deuterated solvent) at room temperature was 
taken, a 1H NMR consistent with the dimer was 
revealed. It was interesting to note that no peaks 
were observed by 1H NMR that was believed to be from the zwitterion. 1H NMR samples were taken after 
various time points over the course of the reaction. Gradually over time, the peaks corresponding to the 
dimer regressed, eventually disappearing completely, while the product peaks remained. Two vital 
discoveries were made in these initial optimization studies: one was the discovery of a major impurity, the 
deoxykojic acid salt. The second was the observation of a necessary intermediate, the oxidopyrylium 
dimer which served as a way to monitor the progression of the reaction as optimization studies continued. 
In addition, it was found that heating sped up the reaction significantly and slightly improved the yield.  
2.2.2  Optimization and Substrate Scope of the Oxidopyrylium Cycloaddition 
With these findings, the optimization was geared toward limiting the formation of the deoxykojic 
acid salt. Assuming that the excess amount of base was causing this substitution reaction to take place, 
the equivalents of N,N-dimethylaniline were lowered to one.  With this change, the starting material did 
not fully convert to product. In addition, the impurity still subsisted. A more sterically hindered base was 
instituted to prevent this substitution reaction from taking place. 2,6-Lutidine, a pyridine based bulky base, 
was tried in a series of reactions and there was  no conversion to deoxykojic acid. This was promising, 
but yields were inconsistent, and it was not clear where the mass loss was coming from.  Thus, a less 
dramatic change from N,N-dimethylaniline to N,N-diethylaniline, was pursued. With this change, the 
impurity was reduced and less equivalents of base (1.2) achieved full conversion, thus fending off any of 
the other unwanted potential side products. Applying this change to the substrates it was found that the 
phenyl acetylene gave 106b in improved yields from 35% with N,N-dimethylaniline to an upper yield of 
53% with N,N-diethylaniline, and the time of the reaction went from 1 week to 45 minutes (Table 2.1). If 



















ketone, 3-butyn-2-one, a yield improvement from 44% to 75% of 106d was seen; both reaction times 
went from days to minutes.  
 
With these results in hand, it was envisioned that an even bulkier aniline would diminish the 
impurity even further; it was found that using N,N-diisopropylaniline with microwave heating suppressed 
the byproduct almost completely and yields increased drastically. The initial substrates used in the 
optimization were tried with the new optimized conditions of microwave irradiation at 100oC, N,N-
diisopropylanaline, and 20 eq. of alkyne. With DMAD the yield increased from 74% to 90% of product 
106a and a 17 hour reaction went to 5 minutes (Table 2.1). Reaction of the ester, ethyl propiolate, and 
methyl ketone, 3-butyne-2-one with 105a showed an increase of products 106c and 106d from 44% to 
88% and 95% yields, respectively. Also reaction times decreased to only a few minutes from 21 hours 
and 70 hours, respectively. Further, with an internal alkyne, ethyl but-2-ynoate that was more 
electronically rich therefore a less reactive dipolarophile, no product formation was observed in the initial 
conditions A, but with the optimized conditions a yield of 32% was achieved of cycloproduct 106e after an 
hour. The alkyne used for optimization, phenyl acetylene, showed a yield of product 106b increased from 
35% to 57%, and reaction time decreased to 35 minutes from a week.  
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Further optimization was sought by reducing the amount of alkyne from 20 equivalents. This was 
a concern in cases if the alkyne target was expensive, if a specific alkyne needed to be synthesized, or if 
there were only small quantities of an alkyne available. In addition, solvent free conditions were tried 
because that would produce an even more efficient reaction. With these changes a yield of 42% of 106b 
was found, which showed that these parameters could be manipulated with yield not suffering too 
dramatically (Table 2.1). For example, for one of the more costly alkynes, 1-phenylprop-2-yn-1-one, it was 
necessary to utilize 5 equivalents which gave a respectable yield of 85% of 106f (Scheme 2.16). In 
addition, 70% of unreacted alkyne could be recovered during purification, and reused in subsequent 
reactions.   
 
Chloro and bromo halide appendages are quite desirable, because they allow for modification via 
cross coupling reactions. Due to positive results with phenyl acetylene and the phenyl containing product, 
4-nitrophenyl acetylene which gave a 64% yield of cycloproduct 106g, the alkyne, 1-bromo-4-
ethynylbenzene was used to generate a bromine appendage with product 106k in 61% yield (Scheme 
2.16). This phenyl derivative showed yields somewhere between the other two phenyl alkynes tried, 
which showed how the halides have an ambivalent electronic nature, both an electron withdrawing 
inductive effect, yet electron donating resonance effects during the cycloaddition reaction. Additionally, for 
the choro appendage a oxidopyrylium salt that contained a chloro (105b) was utilized. The more sluggish 
alkyne, phenyl acetylene, successfully produced 106l in 66% yield but with longer conversion times 
(Scheme 2.16). When coupled to DMAD, a highly reactive species, it took 45 minutes, but with phenyl 
acetylene it took 4 hours of microwave heating (Scheme 2.17).80  
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Alternative groups were incorporated at the R1 position of the oxidopyrylium species to further 
add diverse functionality. The methyl appendage was replaced with a choro 105b, methoxy group 105c, 
and proton 105d (Scheme 2.17). These oxidopyrylium species were reacted with DMAD to give the 
cycloproducts 106h in 76% yield, 106i in 58% yield, and 106j in 61% yield. The times and temperatures 
varied as compared to when the methyl oxidopyrylium species was used.  
 
For example, when the choro and methoxy oxidopyrylium species were used it involved longer reaction 
times; the thought was that the partial positive 
charge generated at the oxocarbenium carbon 
was destabilized by the introduction of these 
groups (Scheme 2.18). In the case of the 
pyromeconic acid, the charge was even further 
destabilized as a proton was the least stabilizing 
of the species tried. With the derived species 106j, the reaction was even more sluggish and needed 
higher temperatures (150°C) to convert; no conversion was seen at 100oC, even at longer reaction times.   
2.2.3 Conclusion: Limitations and Future Challenges 
The optimization studies of the oxidopyrylium cycloaddition not only produced the desired bicyclic 
compounds, but a few important key facts were learned about the reaction such as the formation and 
elimination of an important side reaction, and the role the dimer played in the reaction as an important 
intermediate. One of the drawbacks of these conditions was the inability to achieve the reaction with 
inactivated dipolarophiles such as alkynes with aliphatic side chains. In the synthetic goals of this project 








R1=CH2Cl, H, or CH2OMe
Scheme 2.18. Depiction of the partial positive charge generated
at the oxocarbenium carbon during the cycloaddition reaction.
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oxidopyrylium cycloaddition was the key step to achieve this diversity, the ability to incorporate a wide 
array of alkynes was a significant aim. Alkynes with aliphatic side chains were attempted in our current 
conditions but there was no conversion to the cycloproducts. Therefore activation of these alkynes was 
attempted with various organometallic reagents that are known to active alkynes such as copper 
catalyzed click chemistry, gold (III) and cationic gold (I) chemistry. These reactions did not produce the 
desired cycloproducts but some results that were evidenced was formation of the deoxykojic acid salt 
when water or alcohol was used as the solvent, nonpolar solvents yielded no products, and cationic gold 
(I) was converting to some other unidentified products.  This creates a significant challenge but our initial 
attempts were brief, so more chemistry and alternative synthetic routes have yet to be undertaken.   
2.3 Ring Opening Methods to Access α-Hydroxytropolones 
2.3.1 Formation of α-Hydroxytropolones and 7-Methoxytropolones from 8-Oxabicyclo-
[3.2.1] octadienones Employing Boron Trichloride (BCl3)78 
Once the key oxidopyrylium cycloaddition was optimized the next important step was to find 
suitable conditions for the ring opening. 
The thought was that Lewis acids like the 
boron trihalides, that are known to 
demethylate methyl ethers, could promote 
both ring opening and demethylation.81 
This could happen as the halide 
deprotonates the methyl ether of the bicyclic compound (106) and promotes the ether bridge to open due 
to its activation by being bound to boron (164) 
to form α-hydroxytropolones 107 (Scheme 
2.19).  As boron tribromide (BBr3) is one of the 
most widely used demethylating agents, it was 
first tried. When the 8-oxabicyclo-







































Scheme 2.20. Conversion to methoxytropolone via BBr3.
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the ring opened product, 7-methoxytropolone 165a was obtained in 33% yield (Scheme 2.20). Attempts at 
modifying these conditions were unable to 
improve yield. Next, the closely related 
reagent boron trichloride (BCl3) was 
evaluated. It was thought this would 
create a milder environment and lead to a 
cleaner 7-methoxytropolone. Surprisingly, 
7 equivalents of BCl3 at 0°C yielded the α-hydroxytropolone 107a in 77% yield (Scheme 2.21).  
Unfortunately, all the substrates did not exhibit this selectivity towards the α-hydroxytropolone 
product.  It was found that the electronic properties of substitution on the ring could dramatically affect the 
reaction, and a mixture of α-hydroxytropolone and 7-methoxytropolone resulted. Clean conversion to the 
α-hydroxytropolones 
107h and 107i, resulted 
in the alternate DMAD 
derived species from 
the chloro and methoxy 
cycloproducts in 87% 
and 85% respectively (Scheme 2.21). Also the cycloadduct that contained an ester, 106c, and methyl 
ketone, 106d, showed a preference towards the α-hydroxytropolones, 107c and 107d, in 39% and >95% 
yields respectively (Scheme 2.22).  Compound 107c resulted in a lower yield due to possible hydrolysis 
during the work up. The cycloproduct 106e with all three R groups fully substituted with electronically 

















































107a, R1= CH3 (77%)
107h, R1= CH2Cl (87%)*
107i, R1= CH2OCH3 (85%)




The phenyl ketone 106f resulted in a 1:1 mixture of α-hydroxytropolone 107f to 7-methoxytropolone 165f 
in >95% yield (2.23).  Further, the nitro phenyl 106g showed a 1:1 mixture (107g/165g) in 81% yield. The 
phenyl cycloproduct 106b, 
yielded an inseparable 
mixture of compounds as did 
the pyromeconic derived 106j 
(Scheme 2.23). The reaction 
with 106j could be resolved 
into the 7-methoxytropolone 165j and α-hydroxytropolone 107j via reversed phase column 
chromatography conditions in acetonitrile and water spiked with 0.05% trifluoroacetic acid (TFA).  
The product distribution between α-hydroxytropolone and 7-methoxytropolone was notable, so to 
understand the preference a few experiments were explored. It was imagined that the 7-
methoxytropolones were intermediates in the ring expansion, so 7-methoxytropolone 165a and BCl3 were 
allowed to react with one 
another. In addition, longer 
reaction times were tried, 
and neither of these 
solutions yielded a α-
hydroxytropolone. In 
addition, salts such as 
sodium chloride and 
potassium chloride were 
added to increase the 
chloride concentration of the reaction mixture to promote the demethylation, but this only showed variable 
and inconsistent results.  It was hypothesized that the nature of the electronics on the ring may dominate 
the reaction mechanism. It was deduced that if R3 was electron donating such as in 106e, the mechanism 
proceeded by formation of a stable allylic carbocation at R1, 168, which then re-aromatized to the 7-






















Scheme 2.24. a.) Mechanistic hypothesis for ring opening with BCl3 to generate α-hydroxytropolones.






































BCl3 (7 eq. )
10 min
106f, R1= CH3, R
2=COPh, R3=H
106g, R1= CH3, R
2=4-NO2Ph, R
3=H
106j, R1= H, R2=R3=CO2Me








107f/165f, (1:1), R1= CH3, R
2=COPh, R3=H (>95%)
107g/165g, (1:1) R1= CH3, R
2=4-NO2Ph, R
3=H (81%)
107j/165j, (Complex mixture) R1= H, R2=R3=CO2Me
107b/165b, (Complex mixture) R1= CH3, R
2=Ph, R3=H
Scheme 2.23. Substrates that produced mixtures in the BCl3 reaction.
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the carbocation was destabilized at the allylic position (168) and a mechanism may have existed where 
demethylation occurs before ring opening (164) (a, Scheme 2.24). When a proton was at the R3 position 
such as in compounds 106c, 106d, 106f, and 106g, results varied. With compounds that contained an 
ester or methyl group at R2, such as 106c and 106d, the inductive withdrawing effects of the R2 group 
may have destabilized the carbocation of intermediate 168 and lead to a demethylation type mechanism  
as in mechanism a in Scheme 2.24. If R2 contained a phenyl ketone (106f) or a 4-nitrophenyl (106g) a 1:1 
mixture of α-hydroxytropolone to 7-
methoxytropolone resulted which insinuated a 
dual mechanism (Scheme 2.25). The electron 
withdrawing (EW) effects of both of these 
groups could have lead to a demethylation 
followed by ring opening such as was seen in 
the case of methyl and ester moieties leading to intermediate 164 (Scheme 2.25). Alternatively, it may 
have been possible that the phenyl group at R2 of 106f and 106g added a layer of stabilization to  the 
carbocation at R1 of 168 through space pi-cation interactions allowing for the ring opening mechanism to 
also take place (Scheme 2.25). 82   
As mentioned earlier, reverse phase column chromatography was a means of purification. Some 
of the substrates displayed sensitivity as well as low yields after column purification. To receive exclusive 
α-hydroxytropolone products, the mixtures of α-hydroxytropolones and 7-methoxytropolones could be 
demethylated through a known demethylation process of methoxytropolones using hydrogen 
bromide/acetic acid (HBr/AcOH), and these conditions were necessary for such substrates as the 
nitrophenyl 165g (Scheme 2.26).45 
Under demethylation conditions 
α-hydroxytropolone 107g was 
produced in 80% yield without further 








































Scheme 2.25. Phenyl groups at the R2 position lead to a dual mechanism.
proposed pathway







access 107g which was not compatible with the column conditions but  solidified conditions to gain pure 
α-hydroxytropolones in high yields with only one step. Some substrate mixtures such that gained from the 
phenyl oxabicyclo 106b could not be separated into identifiable products 107b/165b by either method.   
 These studies showed the formation of α-hydroxytropolones through an acid catalyzed ring 
opening with BCl3, but the unpredictable nature of this reaction called for an alternative method with 
foreseeable results especially for the rapid production of α-hydroxytropolones for SAR studies.  
2.3.2 Formation of 7-Methoxytropolones and Furans from 8-Oxabicyclo-[3.2.1] 
octadienones via a Triflic Acid (TfOH) Mediated Process80 
 The inability to obtain a clean phenyl substituted 7-methoxytropolone and/or α- hydroxytropolone 
from 106b motivated the development of other ring opening strategies. During these studies Brønsted 
acids were explored such as trifluoroacetic acid, toluenesulfonic acid, hydrochloric acid, sulfuric acid, and 
triflic acid. Trifluoroacetic acid, toluenesulfonic acid, and hydrochloric acid failed to produce ring opened 
products, but sulfuric acid and triflic acid produced the 7-methoxytropolone 165b within a half an hour at 
room temperature. Working with 106b it was as found that 0.5 equivalents of triflic acid formed the clean 
7-methoxytropolone 165b in >95% yield (Scheme 2.27).  
 
This was a thrilling result as further purification was not needed and as it was displayed through previous 
purification procedures developed through the BCl3 reaction, a simple HBr/AcOH demethylation could 
lead to our desired α-hydroxytropolones for SAR studies. Next, the 4-nitrophenyl species 106g was tried 
under the new triflic acid conditions, but it was found that 0.5 equivalents did not yield the desired  
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7- methoxytropolone. Doing a quick screen we found that 4 equivalents of triflic acid were optimal and the 
4-nitrophenyl substituted methoxytropolone 165g was obtained in 95% yield (Scheme 2.27). Not only did 
this new method convert the complex mixture of the phenyl cycloproduct to a clean 7-methoxytropolone, it 
offered a clean conversion to single product in high yield. For example, the 4-nitrophenyl gave a 1:1 
mixture of 7-methoxytropolone to hydroxytropolone under the BCl3 conditions, but this triflic acid process 
allowed for the generation of a singular predictable product in 95% yield.   
With these results in hand substrates that were studied under the BCl3 conditions were subjected 
to the triflic acid conditions. As was initially found with the nitrophenyl, the other cycloadducts that gave 
mixtures in the BCl3 reaction such as 106c and 106f went cleanly to 7-methoxytropolones, 165c and 165f 
in 89% and >95% yields respectively (Scheme 2.28).  
 
Cycloadduct 106c mainly favored the α-hydroxytropolone 107c in the BCl3 conditions, but the yield was 
very low. This process offered access to the methoxytropolone and the yield was greatly increased from 
39% to 89% of recovered compound. The cycloproduct 106e produced 7-methoxytropolone 165e in 
>95% yield; although this substrate was achieved in the BCl3 reaction, it resulted in a lower yield at 77% 
(Scheme 2.28).   
Since α-hydroxytropolones tend to be sensitive to certain reaction conditions, especially due to 
their binding ability to metals, they could possibly interfere with the ability of the cross coupling catalysts. 
On the other hand, it has been shown through Banwell’s work that methoxytropolones can be 
manipulated through cross coupling reactions.57 The triflic acid sequence allowed for the formation of 
exclusive methoxytropolones. Gratifyingly, 7-methoxytropolones 165k and 165l were gained from 
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oxabicyclic compound 106k and 106l through the triflic mediated method in 92% and 95% yields 










































CH3CN, rt, 12 hr
Scheme 2.29. Use of halogenated methoxytropolones to incorporate ring diversity.
Ph
 
With these substrates in hand, cross coupling methods were attempted. It was found that a Stille coupling 
in the presence of tetrakis(triphenylphosphine) palladium (0) (Pd(PPh3)4) produced the coupled product 
165m in 44-55% yield. This product was converted to α- hydroxytropolone 107m via HBr/AcOH in 95% 
yield. The cross coupling was ineffective on chloro appended 7-methoxytropolone 165l. This substrate 
was able to react with nucleophiles such as sodium acetate and sodium azide. The azide was then 
converted to the triazole containing 165o in 50% yield after click conditions.83   
Though most substrates converted to 7-methoxytropolones, surprisingly, cycloadduct, 106a,  
which went cleanly to α-hydroxytropolones 107a  in the BCl3 reaction, was converted to furan 170a with 
the triflic acid conditions  (a, Scheme 2.30). The pyromeconic acid derived cycloproduct 106j that gave a 
complex mixture in the BCl3 reaction went to the furan 170j. It was hypothesized that that the mechanism 
in which these substrates converted to furans was a type of cycloreversion following a similar 
fragmentation path as the work done by Mann and co-workers who worked with similar oxabicyclic 




As in the BCl3 conditions, when the 7-methoxytropolone was favored, an intermediate carbocation at the 
carbon connected to R1 was formed. It was believed that possibly the two electron withdrawing methyl 
esters destabilize this allylic carbocation, allowing for an alternative carbocation to form at the methoxy 
group as shown in structure 169 (a, Scheme 2.30). Similar to Mann’s mechanism with intermediate 173, 
the carbocation formed at the methoxy group allowed for the fragmentation of the oxabicyclic compound 
into the furan 174 (b, Scheme 2.30). 
Finally, it is well known that the methoxytropolones exist in tautomeric forms, 3-methoxy and 7 
methoxy tropolone (Figure 2.1). In literature it is often expressed as the 3-methoxytropolone tautomeric 
form, but it was found through HMBC (Heteronuclear Multiple Bond Correlation)/HSQC (Heteronuclear 
Single Quantum Coherence) NMR data that in this research it exists in the 7-methoxytropolone form 
(Figure 4.2, Chapter 4.4, Section 4.4.3). The isolated 
bromophenyl methoxytropolone (165k) was used to 
identify the connections (Figure 2.1). HSQC measures 
the direct connections of a specific carbon to specific 
proton, and HMBC measures the connections of a 
carbon and proton separated by two or three bonds, 
and sometimes further depending on the sensitivity. The HSQC data showed that the proton (H6) was 
connected to the aryl carbon (C6) and it was identified in our studies that the chemical shift of this proton 





























proton H3, next to the methoxy group could be assigned a chemical shift upfiled at 7.14 ppm that was 
confirmed with HSQC data. This data suggested a 7-methoxytropolone structure.  
The HMBC data revealed further correlations which lead to the deduction of the 7-
methoxytropolone structure. For example proton H3 showed through space connections to C1 (carbon at 
the carbonyl) and C2 (carbon at the methoxy group) (see 7-methoxytropolone structure in figure 2.1). 
Additionally, proton H6 displayed through space connections to C1 and C7 (carbon attached to the 
hydroxyl group). These relationships revealed a structure such as that of 7-methoxytropolone. If the 3-
methoxytropolone was the product the carbonyl carbon (C1) would have only one through space 
relationship with a proton (H7) (see 3-methoxytropolone structure in figure 2.1). In addition proton (H4) 
would correlate through space to both the hydroxyl carbon (C2) and methoxy carbon (C3) (3-
methoxytropolone structure in figure 2.1).  
2.3.3. Conclusion, Limitations, and Future Challenges  
 In conclusion two acid catalyzed ring openings were discovered that could convert oxabicylic 
compounds achieved through an oxidopyrylium cycloaddition to α-hydroxytropolone and 7-
methoxytropolone products. Each method was a necessary invention as substrate diversity created 
product variability in both cases. For example mixtures of α-hydroxytropolones and 7-methoxytropolones 
were found under the BCl3 conditions for some substrates, yet the triflic acid sequence led to pure 7-
methoxytropolone products. However other substrates that cleanly converted to α-hydroxytropolones in 
the BCl3 conditions were transformed into furans under the triflic acid conditions. The ability to have 
alterative processes to obtain the desired α-hydroxytropolone products was a key achievement in this 
medicinal chemistry driven synthesis. While successful, problems with the purification methods resulted. 
The HBr/AcOH conditions were too harsh for some sensitive functionality that was introduced into the 
ring, while column conditions were incompatible in other cases. The discovery of alternative ring opening 





2.4: Alcohol Exchange: New Findings in the Oxidopyrylium Cycloaddition 
2.4.1 Initial Discoveries  
 While the ring opening procedures were successful for the completion of most of the targeted α-
hydroxytropolones, problems occurred during the incorporation of certain functionalities.  For example, 
after many futile synthetic attempts, a biotintilated moiety could not be functionalized on the 7-
methoxytropolone or α-hydroxytropolone structure. Through the triflic acid conditions the pure 7-
methoxytroponoe was achieved but the demethylation conditions cleaved the biotin functionality. In the 
BCl3 conditions a mixture of α-hydroxytropolone and 7-methoxytropolone was obtained but column 
purification only led to   
decomposition. Another effort 
was undertaken that involved 
assembling the substrate via 
our newly invented cross 
coupling conditions.  The first step was to create a substantial amount of the bromocycloproduct (106k) to 
complete these studies. Although this reaction was run multiple times previously, surprisingly, after 
scaling the reaction up, it was found that the oxidopyrylium cycloaddition yielded two compounds. One, 
which happened to be the desired product 106k, in addition to  another product which was identified as 
176k (Scheme 2.31).  It appeared that an ethyl group replaced the methyl group in the cycloproduct. No 
ethanol was used in the reaction, but it was suspected that possibly the reagent grade chloroform used in 
this reaction may have been stabilized with ethanol, and during the cycloaddition this ethanol got 
incorporated into the oxidopyrylium species. Our previous studies were done in deuterated chloroform, so 
the product was never identified. This serendipitous discovery not only uncovered new findings in the 
oxidopyrylium cycloaddition, but offered a possible new alternative for our α-hydroxytropolone synthesis 























Scheme 2.31. Initial discovery of ethyl incorporated cycloproducts.
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It was envisioned that other 
alcohols that also serve as 
protecting groups could be 
substituted in the place of 
ethanol, 177 (Scheme 2.32).  The bicyclic intermediates formed could then be submitted to protecting 
group removal conditions that would hopefully open the ring and form our desired α-hydroxytropolones 
(107) and lead to milder conditions to address sensitive functionality (Scheme 2.32).  
The research quickly turned to explore conditions that would favor the ethanol incorporated 
cycloproduct. Using the previous optimized conditions with the phenyl acetylene as the alkyne, the first 
experiment ran was the reaction in the presence of varying known amounts of ethanol. Deuterated 
chloroform was used because it helped in monitoring the reaction, and allowed for complete control over 
ethanol concentration. Testing 
of a typical concentration in 
ethanol stabilized chloroform of 
1% of ethanol in deuterated 
chloroform (0.33 equivalents) as 
well as increases of 1, 2.5, 5, 
and 10 molar equivalents of 
ethanol were explored (Table 
2.2).  A balance between yield 
and substantial ethanol 
incorporation was sought. As 
suspected, as the equivalents of ethanol increased, the formation of the ethanol cycloproduct 176b was 
favored; 10 equivalents showed a ratio of nearly 1.6 to 1 of ethyl to methyl product. Importantly, the yields 
stayed consistent within the mid 60% range for all the amounts tried which was promising in regards to 
the viability of the reaction. Since increased amounts of ethanol showed better conversion, ethanol was 

























Scheme 2.32. Proposed synthetic use of alcohol exchange for formation of α-hydroxytropolones.



























Table 2.2. Effect of varying equivalents of ethanol in exchange.
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2.4.2 Optimization and Substrate Scope 
After these initial findings, it was hypothesized that incorporation of the alcohol could be taking 
place before cycloaddition. To test this theory, the reaction was allowed to stir with the deuterated 
chloroform, the salt, base, and ethanol at room temperature which was termed “equilibrating” conditions 
(Table 2.3).  After one week, 
phenyl acetylene was added and 
the oxidopyrylium cycloaddition 
addition was subjected to 
microwave irradiation. The 
greatest incorporation was seen 
with the 5 and 10 equivalent 
reactions with a ratio of 4:1 of 
ethyl to methyl, by far exceeding 
the amounts when all the 
reactants were run together, and 
the yield did not decrease. This 
experiment clearly showed that a 
substantial amount of 
incorporation was taking place before the cycloaddition was initiated.  Although it seemed the reaction 
was optimized greatly, a one week reaction was too long for assembling molecules for medicinal 
chemistry studies. The next step was to convert a one week reaction into a day or few hours, and it was 
thought this could be done with heat. With the equilibrating conditions and equivalents of ethanol 
established a set of experiments that utilized heating to speed up the reaction was undertaken (Table 
2.3). The 5 equivalents of ethanol were chosen because it gave a similar ratio to the 10 equivalents and 
yield was preserved. It involved the use of lesser reagent and this could be important for scare or pricey 
alcohols. It was found that at lower temperatures (60°C) and longer reaction times, 4 hours, a 3:1 ratio of 
ethyl to methyl product was found and the yield was preserved. At higher temperatures, longer times led 
to a better ratio, but the yield decreased. For example at 80°C, at the 4 hour time point almost all the 
Eq. of EtOH time temp
0.65:161 2.5 1 week r.t.
0.26:164 5 1 week r.t.
0.25:155 10 1 week r.t.
0.85:164 5 12 hours r.t.
0.71:163 5 1 hour 60°C
0.48:163 5 2 hours 60°C
0.37:162 5 4 hours 60°C
0.46:158 5 1 hour 80°C
0.06:129 5 4 hours 80°C


























product was the ethyl incorporated 176b, but the yield was only 29%.  At shorter times but higher 
temperatures, 1 hour at 80°C, the ratio decreased to about 2:1, but the yield was increased to 58%. At a 
slightly higher temperature, 90°C at 1 hour, the ratio was in the same range as the one week reaction at 
about 4:1, but the yield again decreased. Finding a balance between a practical yield, and respectable 
ratio in partiality of the ethyl product was the challenge, but moving forward, the 60°C at 4 hours fulfilled 
that criterion.  
Additionally, a quick study was done to verify that the majority of the incorporation was indeed 
taking place before the cycloaddition reaction and if any further modification could be found. At the newly 
found 60°C temperature point the reaction between the salt and alcohol was monitored at various time 
points from zero to 8 hours, with aliquots taken every 2 hours and the reaction was analyzed by 1H NMR 
spectroscopy (Figure 2.2).  
 
As discussed in our earlier studies, we were actually monitoring the conversion to the dimer (substrates 
163 and 178). It was clearly seen that at time zero there was only one peak that represents a proton (A) 
and methyl group (B) on the methoxy dimer (163) (Figure 2.2). As time increased another peak emerged 
more upfield that represented the same proton (D) and methyl group (E) but on the ethyl dimer (178). 
Figure 2.2. 1H NMR data monitoring conversion of the methyl ether dimer to the ethyl ether dimer 
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Further validation was seen with the disappearance of the methoxy groups (C) at the zero time point 
replaced by a methanol peak at the 8 hour time point, which was the byproduct of the exchange. This 
data supported 
the theory, as 
suspected, that 
most of the 
incorporation was taking place at this “equilibrating” step. This could lead to a mechanism were the 
ethanol adds in at the carbon where the methoxy group is attached as in 179 (Scheme 2.33) redistributing 
electrons on the positively charged cyclic oxygen. Then the methoxy group extracts a proton (180) that 
then generates a positive charge on the oxygen allowing the cyclic oxygen to be positively by 
redistribution of electrons (181) and loss of methanol to form the oxidopyrylium species 182. 
The reaction was further adapted for medicinal chemistry studies. As discussed, the initial 
optimized conditions required an equilibration with the alcohol at 4 hours at 60°C. Due to the long reaction 
time, the microwave reactor became an impracticable source of heating. Since our 1H NMR experiments 
showed that in a sealed tube, the reaction could be achieved with the same results, conditions were 
adapted accordingly. For our medicinal chemistry studies this would provide the ability to synthesize 
multiple substrates at once, as well as provide a more universal oxidopyrylium cycloaddition especially for 
those who may want to perform it but have no access to a microwave reactor. With the reaction 
conditions, a two step sequence that involved an equilibation with the alcohol at 60°C then heating up to 
100°C for the cycloaddition was followed. Various time points were reviewed at the 60°C equilibration 
point of the ethanol sequence to compare results. At the 2 hour time point, the reaction gave the same 
ratio (2:1) as in the microwave conditions, and the yield was in a similar range (56% yield), the reaction 
was ran twice to verify (Table 2.4). At the 4 hour optimized time point, the ratio of ethyl (176b) to methyl 
product (106b) increased from 3:1 to 5:1, which was promising, but the yield decreased from the 60% 
range to 40% range. A suitable amount of ethyl product (34-41%) was gained at both time points. 
Pushing the reaction further, an overnight reaction was run and full conversion to the ethyl product was 





















Scheme 2.33. Mechanism of alcohol exchange reaction.
179 180 181 182
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Next, substrate scope studies 
were carried out with alternative 
alcohols (Table 2.4). First 
isopropyl alcohol was tried. Due 
to its more hindered nature less 
incorporation was seen as 
compared with ethanol. At the 2 
hour time point at 60°C the ratio 
of methyl (106b) to ethyl (183b) 
was 10:1 favoring the methyl; at 
4 hours the incorporation of the 
isopropyl was increased  with a 
4:1 ratio of methyl to ethyl, but 
yield declined from 48% to 39%. 
Again an overnight reaction 
produced full conversion to the 
isopropyl product. The benzyl 
and allyl alcohol series proved to have a different profile. After only 30 minutes at 60°C the conversion 
ratio of benzyl (184b) to methyl (106b) was 1.5:1 with a yield of 41%. As time increased to 2 hours, the 
ratio did not increase much (approximately 2:1) and the yield decreased from 41% to 16%. Milder 
conditions were then tried, 12 hours at room temperature, which gave similar results to the half hour 
reaction with a yield to 46%, and the same ratio of benzyl to methyl at about 1.5:1. In the case of the allyl 
alcohol, the 2 hr time point at 60°C showed a lower yield and increased ratio of the allyl cycloproduct 
(185b) at 2:1 to the methyl. At 30 minutes the methyl was favored at a ratio of about 1.5:1 with a decent 
overall yield of 56%. Overnight conditions at room temperature did not increase the allyl ratio. It was 
obvious that all alcohols may not follow the general optimized conditions as set by the ethanol series 
which may be due to the steric and electronic difference between the alcohols. For example, when 4-
methoxybenzyl alcohol and 2-(trimethylsilyl) alcohol were used there was no conversion to their 
% yield 106b
% yield 176b,
179-181b % total yield alcohol time
19 (15)* 37 (41)* 56 Ethyl 2 hours
7 34 41 Ethyl 4 hours
0 14 14 Ethyl 12 hours
44 4 48 Isopropyl 2 hours
31 8 39 Isopropyl 4 hours
0 10 10 Isopropyl 12 hours
16 25 41 Benzyl 30 minutes
5 11 16 Benzyl 2 hours
19 27 46 Benzyl 12 hours**
34 22 56 30 minutes
176b
Allyl
5 9 14 2 hoursAllyl

































100°C for 30 min
sealed tube
105a
Table 2.4. Exchange with different alcohols.
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respective alcohol products; the methyl cycloproduct was isolated from both in approximately 30% yield. 
This may have been due to the more polarizing electronic nature of these substrates as compared to the 
other alcohols used. The 2-trimethylsilyl may come on and off more easily due to its electronically 
deficient nature, and the electron donating nature of the paramethoxybenzyl may revert the substrate 
back to deoxykojic acid.  
Not only was variability seen with different alcohols, if the alkyne was exchanged there were also 
different results. For example, the alkyne ethyl propiolate was substituted in place of phenyl acetylene 
under the optimized conditions which entailed an equilibration at 60°C for 4 hours, then cycloaddition 
reaction at 100°C for 15 minutes. The total yield of the reaction was 77% and there appeared to be a 1:1 
ratio between the amounts of ethyl to methyl product. The yield stayed in the upper range, but the ratio of 
ethyl product decreased.  
2.4.3 Conclusion, Limitations, and Future Challenges 
This preliminary work enhanced our knowledge on the oxidopyrylium cycloaddition, as well as 
opened up the way for alternative ring opening procedures. This reaction and the ability to utilize 
protecting group removal techniques to yield α-hydroxytropolones will continue to be explored within the 
Murelli laboratory. Additionally, alternative alkynes need to be explored to fully understand the conversion 
issues, so this process can keep in line with our goal of introducing diversity through the alkyne 
counterpart. Also, varying conditions with different alcohols and the ability of some alcohols to exchange 













2.5 Conclusion to Synthetic Route and Chemistry 
 This research not only displayed a key intermolecular β-hydroxy-γ-pyrone oxidopyrylium 
cycloaddition reaction with a wide range of alkyne dipolarophiles, but additional important information was 
gained about this scarcely studied reaction. It was found that a dimer formed from the oxidopyrylium salt 
was a key intermediate, and that a side product, deoxykojic acid, was produced due to the use of less 
bulky bases. Additionally, the oxidopyrylium species displayed an exchange mechanism with various 
alcohols which outlined the reactive nature of various places on the ring of the oxidopyrylium species. 
These discoveries not only produced intermediates for two alternative acid catalyzed ring openings to 
yield α-hydroxytropolones and 7-methoxytropolones, but opened up the possibility of alternative ring 
opening procedures. With this research the immediate synthetic goal was met, a medicinal chemistry 
driven synthesis of α-hydroxytropolones, each with distinct functionality. Even though limitations do exist 
such as harsh or incompatible purification techniques, mixtures of products at the acid catalyzed ring 
opening stage, and the inability to incorporate aliphatic appendages, these initial synthetic endeavors 

















CHAPTER 3: Preliminary Structure-Function Studies of Synthetic α-Hydroxytropolones 
3.1 Introduction  
The chemistry developed in the Murelli laboratories and the basis of this thesis served as the 
platform for the synthesis of compounds for SAR studies. Our target molecule was the core scaffold of a 
α-hydroxytropolone, a potential small molecule therapeutic whose bioactivity was limited by its 
cytotoxicity. The goal of this research was to enhance selectivity of these molecules for their given 
therapeutic target, hopefully circumventing this cytotoxicity while also increasing potency. First a simple 
and easy pathway to synthesize the starting material, a triflate salt was achieved as the general starting 
material (105) (Scheme 3.1).  
 
Complexity was introduced through a key oxidopyrylium cycloaddition that was optimized to a quick, high 
yielding reaction. The efficiency of the reaction allowed for the attainment of an array of oxabicylic 
compounds (106) with diverse substitution patterns, and most could be generated in only a few hours.78 
Once selectivity was established the core scaffold was sought, and two acid derived sequences led to the 
ring opened 7-membered heptatriene ring (165/107).78,80 Further modification could be introduced at a 
late stage cross coupling reaction on the 7-methoxytropolone core.80 Finally purification methods allowed 
for discrete retrieval of the diverse α-hydroxytropolones under demethylation or reverse phase column 
chromatography conditions. The second goal of this research was to test the various synthetic α-
hydroxytropolones obtained through the oxidopyrylium/ring opening synthetic sequence and 
subject them to various medicinal chemistry studies to find how therapeutic activity was 




3.2 Aminoglycoside-2’’-O-nucleotidyltransferase-[ANT(2’’)-Ia]  
3.2.1 Overview of Aminoglycosides and Resistance 
 Aminoglycosides are a form of antibiotics isolated from bacterial fermentation; one of the first 
discovered was streptomycin in 1944, and it was found to have inhibitory activity against M. 
tuberculosis.85 After years of use for bacterial and tuberculosis infections, streptomycin displayed 
inactivity and was replaced by other antituberculosis drugs such as isoniazid, rifampicin, and 
ethambutol.86 These drugs too became resistant, so renewed interest in streptomycin for drug resistant 
M. tuberculosis strains became apparent. In addition to streptomycin other aminoglycoside based 
antibiotics were isolated from bacterial sources such as neomycin, gentamicin and tobramycin.87  
Aminoglycosides’ antibacterial properties work by disrupting gram negative bacterial protein synthesis, 
but bacteria have developed several mechanisms of resistance including enzymes that modify these 
aminoglycosides, reducing their antibiotic ability.88 The three important enzymes that impart this 
resistance are O-adenylyltransferases (adenyltransferase, nucleotidyltransferase, ANT), N-
acetyltransferases (AAC), and O-phosphotransferases (APH).27 In combination with resistance the clinical 
use of aminoglycosides have some issues including poor oral absorption and toxicity at higher 
concentrations and increased number of doses  where the molecules were found to collect in the renal 
tubule and cause nephrotoxicity in addition to ototoxicity.86,87  Combination therapies that combine cell 
wall disrupting β-lactam antibiotics with gentamicin have shown to increase potency of the 
aminoglycoside, while relieving the dosage requirements and circumventing some resistance.86 
Unfortunately, β-lactams have their own issues with resistance with modifying enzymes such as Ser-β-










3.2.2 Overview of ANT-(2”) and its Inhibitors   
 Aminoglycoside-O-nucleotidyltransferases are enzymes that catalyze adenylation. Adenylation is 
the process in which a protein or biological molecule (in this case an aminoglycoside antibiotic) containing 
a functional group such as amino, hydroxyl, or carboxylate group reacts with one phosphate group of ATP 
(adenosine triphosphate).90 In particular, a clinically prevalent ANT enzyme ANT(2’’)-Ia is one of the few 
aminocglycoside modifying enzymes to modify a hydroxyl group.91 The unique mechanism is catalyzed by 
two magnesium ions 
within the enzymatic 
pocket. For example 
aminoglycoside 
gentamicin’s exposed 
hydroxyl group at the 2’’ 
(2 double prime carbon) 
position is activated by an 
aspartic acid (Asp) 
residue in the enzyme and reacts with one of the phosphate groups in ATP (Figure 3.1).91 Once 
gentamicin is bound to ATP, the remaining two phosphate groups are induced to leave as a 
pyrophosphate. ATP becomes AMP (adenosine monophosphate) and takes the place of C2” alcohol on 





































































ANT(2’’)-Ia is particularly important because it is one the most clinically prevalent modifying enzymes.91,92 
Although inhibitors based on modifying or 
mimicking an aminoglycoside structure are 
known for the general class of aminoglycoside 
modifying enzymes, specific non-carbohydrate 
based inhibitors for the ANT(2”) enzyme are 
understudied.  One inhibitor class that was 
discovered was 1,3-diamines.93 They are 
based off the 2-deoxystreptamine (2-DOS) core 
structure (central hexane ring) of important 
gram negative bacterial aminoglycoside 
antibiotics such as gentamicin, kanamycin B, 
and tobramycin. The 2-DOS core structure contains a 1,3 diamine motif (outlined in red) which the 
synthesized non-carbohydrate molecules mimic (Figure 3.2).93 Serpersu and co-workers synthesized 45 
different 1,3-diamine based compounds and found compounds G,H and H, I to be the best inhibitors of 
ANT(2”) (Figure 3.2).93 Compound G,H had 22% inhibition at a 0.05 mM concentration and was 
competitive with the aminoglycoside with a Ki of 540 ± 32 µM. Compound H,I gave 42% inhibition at a 
0.05 mM concentration and was competitive with ATP with a Ki of 125 ± 24 µM. As previously discussed, 
α-hydroxytropolones are another important inhibitor of ANT(2’’) where β-thujaplicinol and α-
hydroxytropolone displayed inhibition in the upper 70% range of ANT(2’’) at 55 µM and 73 µM 
concentrations, respectively. In addition, α-hydroxytropolone displayed a competitive mechanism with 
ATP with a Ki value of 10 µM.  These two classes of compounds are the only known non-carbohydrate 








































Figure 3.2. 1,3-Diamine motif in gentamicin and
synthesized1,3-diamine containing ANT(2") inhibitors (outlined in
red).
2-DOS core
double prime ring single prime ring
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3.2.3 ANT(2”)-Ia Enzymatic Inhibition and Rescue of Aminoglycoside Antibiotics by 
Synthetic α-Hydroxytropolones14,94 
 In collaboration with the Wright group at McMaster University, new α-hydroxytropolones 
synthesized by the methods discussed were tested for their ability to inhibit the enzyme and rescue 
antibiotic activity. The bacterial strain Escherichia coli BL21 (λDE3) where the ANT(2”)-Ia enzyme is  over 
expressed was used. The enzyme was extracted and purified and applied to a 96 well system and its 
activity was monitored by the formation of the byproduct pyrophosphate. Serial dilutions of α-
hydroxytropolones were added to the system and their inhibitory activity for the enzyme was measured in 
IC50 values as shown in Table 3.1. The natural product β-thujaplicinol had the best inhibition activity at 6.6 
µM. Of the synthetic α-
hydroxytropolones most showed 
very low inhibition with values >200 
µM. The exceptions were the 
methyl ketone 107d with a value of 
50 µM, and the nitro phenyl 107g 
with a value of 20 µM. Deductions 
on the enzymatic pocket could 
possibly be made from these 
studies. One deduction that could 
possibly be made was that those 
substrates that were substituted at 
three places on the ring such as 
substrates 107a, 107h, and 107i, 
could be too sterically demanding. 
Additionally, even with the 
substrates that showed inhibition, 
the IC50 values were higher than β-

















































IC50=>200 µΜ IC50=>200 µΜ IC50=>200 µΜ
IC50=>200 µΜ IC50= 50 + 8 µΜ
IC50=>200 µΜ
Ki= 29 + 6 µΜ
IC50=20 + 6 µΜ
IC50=>200 µΜ IC50= 6.6 + 0.8 µΜ
Ki= 21 + 0.4 µΜ
Ki= 6.4 + 0.9 µΜ
Table 3.1. ANT(2'')-Ia Inhibition by α-hydroxytropolones.
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the fact that β-thujaplicinol was the only monosubstituted substrate, again bringing in the notion that less 
sterically demanding functionality may be better for this enzyme. Ki values were determined for those 
substrates that showed inhibition, and these Ki values indicated competitive inhibition with ATP and 
mixed inhibition with the aminoglycoside. This data proposed that the α-hydroxytropolones could usurp 
the place of ATP at the enzymatic site or bind near the binding pocket of ATP.   
 Furthermore, a study was run to gauge the ability of α-hydroxytropolones to rescue antibiotic 
activity in the bacteria cells. A gentamicin resistant strain of E. coli BW25113 which also contained the 
ANT(2’’)-Ia enzyme was produced. Gentamicin resistance was increased to MIC of 64 µg/mL vs. 0.25 
µg/mL in the wild type. For these studies, a negative control was constructed with the strain of an E.coli 
that contained  an enzyme that was resistant to aminoglycoside antibiotics and was not inhibited by α-
hydroxytropolones called aminoglycoside phosphotransferase termed APH[2’’]-Id.  The synergetic value 
of gentamicin working in concert with the α-hydroxytropolone was measured by calculating the FIC index 
(FICI) and graphically outlined in a checkerboard analysis (Figure 3.3). A FICI value less than 0.5 implied 
a synergetic relationship while values between 0.5 and 4 showed no synergetic relationship. Also for a 
qualitative assessment a triangular shape of checkerboard graphs indicated a synergetic relationship. 
The compounds that showed positive inhibition values were tested for their ability to rescue antibiotic 
activity in these cellular assays, so β-thujaplicinol, and compounds 107d and 107g were evaluated.  First, 
β-thujaplicinol showed a FICI value of 0.375 which indicates a synergic value. For the ANT(2”)-Ia deficient 
strain, APH(2’’)-Id, there was no synergetic relationship with a FICI value of 3. This evidence supported a 





Compound 107d showed a synergetic value of 0.187 and while 107g did not with a value of 0.5. Other 
data gained through this analysis showed that at concentrations of 12 µM of β-thujaplicinol and 107d, the 
MIC of gentamicin was 8 µg/mL and 32 µg/mL, respectively. This mimicked the inhibitory behavior of the 
two substrates, demonstrating that β-thujaplicinol was the more potent of the two. Surprisingly at 50 µM 
concentrations of both substrates no healthy bacteria cells remained with β-thujaplicinol but with 
compound 107d a nice amount of 80% of cells remained alive. At 50 µM concentrations of 107d, 
minimum amounts of gentamicin were needed (2 µg/mL) to inhibit bacterial cell growth. From these 
results it was inferred that the α-hydroxytropolone was not killing the cells, but that the cell death was 
caused by the aminoglycoside. It was found that at the same concentration β-thujaplicinol was toxic. 
These α-hydroxytropolones may not be useful therapeutically as of yet, but for the synthetic compound, 
107d there may be opportunity to use it in cellular assays to study the bacterial stain and ANT(2’’)-Ia 
activity were aminoglycoside activity is problematic. This study not only built on and supported the 
positive inhibition qualities of α-hydroxytropolones with respect to the ANT(2’’)-Ia enzyme, but offered a 
more in-depth analysis with a cellular assay that could reveal more about the reaction within the cells and 
guide future SAR studies.   
 




3.3 The RT RNase H Metalloenzyme Active Site 
  3.3.1 Background on RNase H  
Reverse transcriptase is an enzyme present in many viruses that include the Human 
Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), and the Xenotropic Murine Leukemia-Virus 
related virus (XMRV), and Herpes Simplex (HSV).17, 34, 35, 39, 41 The role of reverse transcriptase is that it 
converts single stranded RNA (Ribonucleic acid) into double stranded DNA (Deoxyribonucleic acid).  The 
enzymatic sites vary between the viruses: often the enzyme has two active sites that impart its activity 
called DNA polymerase and Ribonuclease H (RNase H) which can be fairly far apart. For example, in HIV 
the active sites are 40 Å distance apart and exist on alternative ends of the enzyme unit.95,96 Current HIV 
and HBV drugs target the polymerase site. No current drugs on the market target the RNase H site and 
therefore pharmacophores that target this site would be of great value. The RNase H active site includes 
amino acid residues that loosely bind to two metal centers, thought to be Mg2+ or Mn2+.96 Once the metal 
centers are anchored into the RNase H site, they stabilize the 5’-scissile phosphate of RNA which actives 
water for hydrolysis, cleaving the RNA primer to complete the DNA synthesis.96,97 Viruses without RNase 
H are non-infectious therefore it is essential for replication.98 Inhibitors work in one of two ways; as active 
site inhibitors whereby they usurp the position of the scissile phosphate at the dimetallic center, or 
























3.3.2 Active Site Inhibitors of RNase H  
 
There are six important pharmacophores of active site HIV RT RNase H inhibitors: diketo acids, 
N-hydroxy naphthyridinones, N-hydroxyimides pyrimidinol carboxylic acids, pyrido-pyrimidinones, and α-
hydroxytropolones (Figure 3.4).96 These structures all have similar components such as hydroxyl groups 































RNase H inhibition (IC50)= 3.3 M
Pharmacophore= N-hydroxyimide
RNase H inhibition (IC50)= 0.06 M
Pharmacophore= -hydroxytropolone
RNase H inhibition (IC50)= 0.2 M
Pharmacophore= pyrido-pyrimidinone
RNase H inhibition (IC50)= 0.032 M
Pharmacophore= pyrimidinol carboxylic acid
RNase H inhibition (IC50)= 0.17 M
186 187 6
190189188








 Initial work on the diketo acid functional group produced compound, 4-[5-(Benzoylamino)thien-2-yl]-2,4-
dioxobutanoic acid (BTDBA)  which was found to be an RNase H active site inhibitor in the presence of 
metal cations with an IC50 value of 3.2 µM, but showed no activity in a HIV cell based assay.100 More 
recently work done with the diketo complex found an inhibitor 186 with similar inhibition activity, but this 
compound showed viral replication inhibition at an EC50 value of 17 µM and a CC50 of >50 µM, which 
produced a Therapeutic Index (TI) (CC50/EC50) of >2.9.101 Further derivation found that with replacement 
of an ethyl group at the methyl ketone moiety and carboxylic acid proton of 186 produced a compound 
with lower inhibition at an IC50 value of 26 µM. Although inhibition activity of the enzyme was lowered, 
they found increased inhibition activity in the antiviral assay with an EC50 of 3.7 µM, CC50 of >50 µM, and 
a TI of >13.8. Modeling studies with diketo acids at the RNase H active site showed that the carbonyl 
groups interact at the Mg2+ metal centers and that there are possible lipophilic interactions between the 
para-fluoro benzyl and the piperazine moieties with residues in the enzymatic pocket.101 The N-hydroxy 
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naphthyridinones are another class of active site RNase H inhibitors. A crystal structure with a substrate 
from this class found that the hydroxyl group of the N-hydroxy naphthyridinone interacts with the metal 
cation centers of the active site.102 Compound 188 was developed as a mimic of a less substituted 
species. Due to the crystal structure data, the group believed substitution at the 4-position of the N-
hydroxy naphthyridinone could increase residue interactions.102b  The inclusion of the lipophilic side chain 
in compound 188 in place of an ethyl ester at the 4-position, increased potency from 0.11 µM to 0.045 
µM.102 Compound 188 even had good anti viral activity with an EC50 value of 0.2 µM, but it was found to 
be too cytotoxic (CC50=3.3 µM).102b, 96 The N-hydroxyimide pharmacophore found in molecule 187 
showed via a crystal structure to interact with the metal cations via the three contiguous oxygens found in 
the core N-hydroxyimide structure.103 Initial SAR studies with this pharmacophore showed little antiviral 
activity, cytotoxicity, and the need of the three contiguous oxygens for inhibition. Compound 187 was one 
of the more potent inhibitors discovered with an IC50 of 0.06 µM, and an EC50 of 13.4 µM.104 Another core 
active site moiety are pyrimidinol carboxylic acids. A crystal structure with this moiety in the active site 
found that the hydroxyl groups on the carboxylic acid and alcohols bind to the two metal centers of the 
enzyme through a three pronged approach such as N-hydroxyimides and α-hydroxytropolones.105  
Compound 190 was designed from this class and showed one of the best results with an IC50 of 0.17 µM 
for RNase H but no antiviral activity was established.106  In addition, 190 showed lower inhibition for 
Human RNase H with an IC50 value of 48 µM, and all substrates synthesized showed similar selectivity for 
RNase H. Researchers at GlaxoSmithKline discovered a new class of inhibitors termed pyrido-
pyrimidinones which have shown promise with a number of substrates synthesized from this class 
showing IC50 values for RNase H inhibitory activity ≤ 0.500 µM.107 One compound, 189, had an inhibition 
value (IC50) of 0.032 µM and antiviral activity (IC50) of 0.10 µM. It was found to be cytotoxic with a CC50 
value of 2.5 µM, which was probably due to its good cell permeability at 172 nm/s. They found that strong 
cell permeability correlated to a good ratio of antiviral activity to inhibitory activity, but compounds that fell 
under these criteria tended to be more cytotoxic.   The mechanism of action of these compounds is not 
yet known, yet the authors indicated that studies are forthcoming. Finally, as previously outlined,  
α-hydroxytropolones are a final class of RNase H active site inhibitors. Like some of the previous 
inhibitors, they were found via a crystal structure with the RNase H active site to inhibit the site at the two 
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metal cations through the three contiguous oxygens on the core α-hydroxytropolone manifold.28 The best 
known α-hydroxytropolone inhibitor to date is β-thujaplicinol (6) with an IC50 value of 0.2 µM, but this 
substrate showed no antiviral activity and was cytotoxic (CC50=2.3 µM).17 Active site inhibitors serve as 
important small molecule therapeutics for RNase H, and the ability to know how they bind via crystal 
structures help provide a link to how the powerful pharmacophore give their potency and can gear future 
activity studies of these important pharmacophores that have yet to be active drugs.  
 As HIV RNase H inhibitors are limited there are no known current RT RNase H inhibitors of HBV 
Current drugs on the market for chronically ill HBV patients that target the RT polymerase site are the 
inhibitors lamivudine, adefovir, entecavir, telbivudine.108  
 
 
 3.3.3 RNase H HIV and XMRV Data for Synthetic α-Hydroxytropolones 
Previous SAR studies on the HIV RNase H active site did not reveal a compound with greater 
inhibitory qualities than β-thujaplicinol or manicol, but did offer some promising leads on viral replication 
inhibition and lowering cytotoxicity which exemplified a further need for continuing these studies.18  With 
the synthetic strategies established in this research, and with multiple new synthetic α-hydroxytropolone, 
preliminary work on this enzymatic site as well as XMRV RNase H site have been under way. SAR work 
was established with the same group that did the manicol studies and led by Stuart Le Grice and John 
Beutler at NIH/NCI (National Institutes of Health/National Cancer Institute). The first series of synthetic 
substrates studies were those with the dimethyl ester moieties (Figure 3.5). While 107a had similar 
inhibitory activity for both enzymatic targets to β-thujaplicinol, it was still cytotoxic with a CC50 value of 1.4 
µM.  There seemed to be a trend in these substrates that the bulkier the appendage got at the methyl 
position, the lower the activity, but compound 107j that had no substitution at that position and showed 





The only difference was that 107j had the lowest cellular toxicity to all the substrates with a value of 21 
µM. The next set of compounds were those with two places of substitution, and one being a short chained 
ester or ketone (Figure 3.6). All these substrates showed similar inhibitory activity to β-thujaplicinol, but 
they all seemed to be 
slightly more toxic with 
CC50 values under 1 µM. 
Finally the nitrophenyl 
107g was slightly less 
potent than the ketone 
and esters, but the biphenyl 107m displayed the lowest activity profile with an IC50 value of 1.1 µM (Figure 
3.7). It appeared that very bulky lipophilic appendages such as in 107m were unfavorable for HIV RNase 
H. This compound tended to be less cytotoxic than the other substrates which could have something to 
do with cell permeability. For all the substrates none were able to suppress viral replication, except for the 
107d which produced an EC50 value of 0.13 µM. The XMRV RNase H site had similar inhibitory activity to 
the substrates’ RNase H 
profiles, which outlines a 
possibly similar enzymatic 
structure as was alluded to in 
previous crystallographic 
studies.34,35 There were two 
exceptions: Compound 107j 
was four times more potent against XMRV (IC50=0.26 µM) than HIV RNase H (IC50=1 µM). Additionally, 
compound 107g was five times more potent against XMRV (IC50=0.07 µM) as compared to HIV RNase H 
(IC50=0.36 µM).  Overall, these studies did not produce a stronger inhibitor, but exposed the usefulness of 
the newly established synthetic strategies, the ability to produce more diversely substituted substrates, 


















0.22 + 0.002 µM
0.15 + 0.004 µM
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HIV RNase H (IC50)
XMRV RNase H (IC50)
Cytotoxicity (CC50)
0.36 + 0.01 µM
0.07 + 0.03 µM
0.29 µM
1.1 + 0.04 µM
0.86 + 0.09 µM
2 µM




3.3.4 HBV RNase H Enzymatic Site Data for Synthetic α-Hydroxytropolones.109 
Tavis and co-workers at St. Louis University School of Medicine developed an assay for HBV 
RNase H inhibitors, and previously found that β-thujaplicinol had inhibitory activity against this enzyme.41 
α-Hydroxytropolones constructed in the Murelli laboratory as well as manicol derivates from the Le Grice 
group18 were tested in their assay. Recombinant HBV RNase H and Human RNase H1 were expressed 
and purified from E.coli. RNase H activity was measured using an oligonucleotide directed RNA cleavage 
assay and IC50 values were extracted. HBV replication and cell cytotoxicity were measured in EC50 and 
CC50 values respectively, using HepDES19 cells. From these values therapeutic index (TI) was extracted 
which was simply calculated from CC50/EC50. In this study 51 tropolone based compounds were 
screened, 36 were α-hydroxytropolones; α-hydroxytropolones made in relation to research discussed in 
this thesis and their results are listed in Table 3.2, and happened to be the most active compounds in the 
study. Synthesized α-hydroxytropolones 107f, with the phenyl ketone moiety, and 107m, with the 
biphenyl, are not listed in the table as they had no detectable inhibition in any of the assays even the 
qualitative study. Compounds 107i and 107c showed inhibition values around 60µM for HBV RnaseH, 
and 20 µM for human RNaseH in the qualitative study but failed to produce positive values in the more 
indepth screen. Initial qualitative screening results revealed that the α-hydroxytropolone moiety was 
needed for inhibition of RNase H. For example, α-hydroxytropolone, β-thujaplicinol (6) inhibited the 
enzyme yet its tropolone counterparts β-thujaplicin and γ-thujaplicin showed no activity toward the 
enzyme. In the initial qualitative screening all the synthetic α-hydroxytropolones had some activity toward 
both HBV genotype RNase H sites as well as Human RNase H, but only the ones that showed the best 
inhibition profiles were processed for further screening. Both genotypes had about the same qualitative 
inhibition values for each α-hydroxytropolone, which showed that there may not be a preference for a 










The only one that showed a slight difference between the two was for 107h, where genotype D 
was inhibited at about 40 µM and genotype C at 65 µM concentration. This data could insinuate some 
minor effect of the genotype, but these values are only specific to one substrate to constitute an overall 
effect. Also, the RNase H data revealed a possible correlation between substrate size and inhibition 
ability. For instance, the parent α-hydroxytropolone (3) with no substitution revealed no inhibition, β-
thujaplicinol with one short isopropyl appendage showed the best inhibition with IC50 values of 5.9 µM and 
2.3 µM, and long appendages such as the biphenyl and phenyl ketone showed no activity while the 
nitrophenyl, 107g, had very little activity. This was also further validated with synthetic compounds 107a 
and 107d which have short appendages such as the methyl esters and methyl ketone which displayed 
IC50 values of approximately 29 µM and 34.9 µM/22.9 µM respectively. As substitution length increased, 
as in the ethyl ester, 107c, by one methylene group, activity diminished. Also, manicol and its derivatives 
that were tested in the study demonstrated decreased activity, which further supports a size limitation 
effect. These trends may insinuate a smaller binding pocket for HBV RNase H as compared to HIV 
RNase H, as manicol and its derivatives did have some inhibition effects in HIV RNase H studies.18  
 Inhibition activity against Human RNase H1 was also tested, and substrates that had activity 
against HBV RNase H, tended to inhibit human RNase H1 too. Inhibition values differed between the two 
enzymatic targets, which imply selectivity. β-thujaplicinol was 10 to 20 times more active against HBV 
RNase H as compared to Human RNase H1 (5.9/2.3 µM vs. 58 µM), while synthetic substrates 107a was 
10 times more active against HBV RNase H (29 µM vs. 47.8 µM). Structures like the methyl ketone 
substituted 107d exhibited similar inhibition activity for both targets. On the other hand, nitrophenyl, 107g, 
displayed a slight preference for the Human RNase H1 enzyme. 
 The substrates that showed RNase H inhibition were tested for their ability to inhibit viral 
replication (accumulation of plus-polarity DNA strand) indicated as an EC50 value along with their 
cytotoxicity (loss of mitochondrial function) indicated with a CC50 value.  EC50 values tended to be lower 
than IC50 values; values were under 3 µM for the substrates referred to in the table. The greatest 
inhibition was seen with the methyl ketone, 107d with an EC50 value of 0.34 µM. Even though manicol 
had little to no inhibition against HBV RNase H and Human RNase H1, it had an EC50 value of 9 µM.  
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 Cytotoxicity values were similar to their substrates subsequent IC50 values, except β-thujaplicinol 
with a value of 25 µM compared with 5.9/2.3 µM RNase H inhibition profile. Due to the values, some 
cytotoxicity could be attributed to Human RNase H1 inhibition, but does not explain all routes of toxicity. 
For example, manicol had a CC50 value of 35 µM which was similar to both 107a and 107d cytotoxicity; 
whereas manicol had no inhibition activity against Human RNase H1, both 107a and 107d did.  
Therapeutic indexes were calculated from EC50 and CC50 values by dividing the CC50 by the EC50 
values. The best value of 94 was found with synthetic substrate 107d, and lowest value of 14 from 
substrate 107a. The natural compounds β-thujaplicinol and manicol tended to be lower with values of 25 
and 3.8 respectively. A difference between IC50 (enzymatic assay) to EC50 values (cellular assay) could 
reflect that the more complex cellular environment influences the inhibition of the compounds. Inhibition 
values were lower with EC50 values which insinuates possible other cellular interactions, greater cellular 
absorption of the compounds, and differences between the cellular and isolated RNase H enzyme (native 
vs. recombinant). In conclusion, this study offered the first in-depth SAR study to analyze the ability of α-
hydroxytropolones to inhibit HBV RNase H. Synthetic substrates such as 107d with a therapeutic index of 
















3. 4 Conclusion 
This research achieved a novel synthesis of poly-substituted α-hydroxytropolones. The goal of 
these synthetic studies was to accomplish a synthesis that could be applicable to medical chemistry 
studies, and it thus offered a simple synthesis, late stage introduction of substitution, and the ability to 
diversify that substitution to produce a robust library of unique α-hydroxytropolones for SAR studies. The 
synthetic process involved a key step that utilized an efficient intermolecular oxidopyrylium cycloaddition 
reaction that offered late stage incorporation of diverse substitution on the α-hydroxytropolone core 
structure and a simple one step acid catalyzed ring opening that attained the core scaffold in respectable 
yields. The medicinal chemistry side of the research came full circle, as the synthetic compounds were 
analyzed in various biological contexts for their ability to inhibit such enzymes as ANT(2”)-Ia, HBV RNase 
H, and HIV RNase H. Through this chemistry a new research program was established, and new 
discoveries were made, such as the exchange of alcohols in the oxidopyrylium cycloaddition. Hardships 
were overcome by discovery of alternate ring opening strategies. With any chemistry there still exists a 
need for new methods, such as a more predictable ring opening process, and the need to incorporate 
even more diverse groups such as aliphatic groups into the α-hydroxytropolone structure. This research 
paved the way for such discoveries and opened up the possibility for more medicinal chemistry studies on 














CHAPTER 4: Supporting Information  
4.1 General Information 
All starting materials and reagents were purchased from commercially available sources and 
used without further purification, with exception of dichloromethane (CH2Cl2) and benzene, which was 
purified on a solvent purification system prior to the reaction. 1H NMR shifts are measured using the 
solvent residual peak as the internal standard (CHCl3 δ 7.26, D2O δ 4.79), and reported as follows: 
chemical shift, multiplicity (s = singlet, bs = broad singlet, d = doublet, t = triplet, dd = doublet of doublet, q 
= quartet, m = multiplet), coupling constant (Hz), integration.13C NMR shifts are measured using the 
solvent residual peak as the internal standard (CDCl3 δ 77.20 or D2O), and reported as chemical shifts.  
Infrared (IR) spectral bands are characterized as broad (br), strong (s), medium (m), and weak (w). 
Microwave reactions were preformed via the Biotage Intiator 2.5. Purification via reverse phase column 
chromatography was performed on the Biotage Isolera Prime, with Biotage SNAP 12g cartridges, in a 
solvent system of acetonitrile (CH3CN) in water each solvent containing 0.05% trifluoroacetic acid (TFA). 
4.2: Data for the Oxidopyrylium Cycloaddition 



















Procedure: To a solution of 108b79 (1.31 g, 10.3 mmol) in CH2Cl2 (5.25 ml) was added 
methyl trifluoromethanesulfonate (MeOTf), (1.77 ml, 15.6 mmol).  Reaction stirred at reflux for 4 hours, 
cooled to room temperature, and then evaporated under reduced pressure to yield crude 105a as an 








(1.0g, 33% yield). 1H NMR (400 MHz, D2O) δ 8.78 (s, 1H), 7.65 (s, 1H), 4.33 (s, 3H), 2.79 (s, 3H). 13C 








































13C of 105a 





Procedure: To a solution of 108c2 (500 mg, 3.1 mmol) in benzene (1.6 ml) was added 
MeOTf, (1.03 ml, 9.3 mmol). The reaction was placed in the microwave reactor for 20 
minutes at 80°C, and then evaporated under reduced pressure to yield crude 105b as an off white solid 
(999 mg, >95% yield). Crystallization from Ethyl Acetate (EtOAc) yielded pure 105b as an off white solid 
(156 mg, 16% yield). Since the 105b salt does not dissolve in chloroform, and decomposes in other 
common deuterated solvents such as DMSO and D2O, verification of product was found by conversion 
and analysis of the dimer. To do this, an aliquot of the salt was placed in approximately 10-20% solution 
of Diethyl aniline (Et2NPh) in CDCl3. The presence of the dimer and disappearance of 105b was 
monitored by 1H NMR. 
 
Signature dimer peaks: 1H NMR (400 MHz, CDCl3) δ 5.95 (s, 1H), 5.13 (s, 1H), 4.98 (d, J = 2.6 Hz, 1H), 
4.63 (d, J = 2.6 Hz, 1H), 4.11 (s, 2H), 4.05 (d, J = 11.8 Hz, 1H), 3.80 (d, J = 11.1 Hz, 1H), 3.66 (s, 3H), 
3.50 (s, 3H). NMR cut to highlight the signature peaks, tend to be dwarfed on full NMR due to the strong 









































Procedure: To a solution of 108e1 (153 mg, 0.994 mmol) in CH2Cl2 (502 μL) was added 
MeOTf, (167 μL, 1.49 mmol).  Reaction stirred at reflux for 3.5 hours, cooled to room 
temperature, and then evaporated under reduced pressure to yield crude 105c as an 
orange to red tinted oil 2 (282 mg, 87%). The oil was taken up in hot chloroform, to which was added 
several drops of EtOAc while hot and solution became cloudy. Solution was placed on ice, and a white 
solid crystallized out 105c (20 mg, 6%). Decomposes at temperatures from 230-235 °C. IR (thin film, 
KBr) 3486 (br), 1634 (m), 1259 (s), 1174 (m), 1035 (s), 764 (w), 643 (w) cm-1.1H NMR (400 MHz, CDCl3) 
δ 8.99 (s, 1H), 7.53 (s, 1H), 4.72 (s, 2H), 4.42 (s, 3H), 3.60 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 174.37 
(s), 171.16 (s), 149.51 (s), 145.13 (s), 105.07 (s), 69.82 (s), 60.01 (s), 59.96 (s).  HRMS (ESI+) m/z calc’d 





                                                     
1 Prepared from a solution of 108b in a 0.2 M solution of methanol (MeOH) and 5eq of Na0 and stirred at 
room temperature over a 72 hour period.  
2 Oil decomposes when stored neat in the freezer. Storage in CHCl3 prevents this.  









 4.2.2 Formation and Isolation of the Dimer 
(1R,2S,6S,7R)-6,9-dimethoxy-4,7-dimethyl-3,11-
dioxatricyclo[5.3.1.12,6]dodeca-4,8-diene-10,12-dione (163). Procedure: To 
a solution of 105a (69.8 mg, 0.240 mmol) in CHCl3 (1.2 ml) was added 
triethylamine (29.1 mg, 0.288 mmol). After a short mixing time (~10 s) at room 
temperature, the reaction mixture was washed with NH4Claq (6 x 2mL) to yield 163 (24.4 mg, 73% yield) 
as a pale yellow solid. Decomposes at temperatures at 161°C.  Rf= 0.29 in 30% ethyl acetate (EtOAc) in 
hexanes. IR (thin film, KBr) 3078 (w), 2982 (w), 1744 (s), 1704 (s), 1663 (m), 1617 (m), 1454 (m) 1367 
(m) , 1289 (m), 1249 (m), 1186 (s),  1162 (m), 1133 (m), 1094 (m), 991 (m), 870 (s) cm-1. 1H NMR (400 
MHz, CDCl3) δ 5.94 (s, 1H), 4.79 (d, J = 2.7 Hz, 1H), 4.74 (s,1H), 4.47 (d, J = 2.7 Hz, 1H), 3.64 (s, 3H), 
3.45 (s, 3H), 2.00 (s, 3H), 1.47 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 199.67 (s), 186.12 (s), 158.15 (s), 
150.52 (s), 118.91 (s), 94.67 (s), 88.15 (s), 85.19 (s), 84.27 (s), 82.28 (s), 55.56 (s), 54.37 (s), 20.86 (s), 
19.58 (s). HRMS (ESI+) m/z calc’d for C14H16O6Na+: 303.08391 Found:  303.08455. 
 
 




















1H of 163 
13C of 163 
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 4.2.2 Oxidopyrylium Cycloaddition 
 
 
General Procedure A: To a solution of salt 105a and alkyne (20 equivalents) in CH2Cl2 (0.2 M) was 
added N,N-dimethylaniline (2 equivalents). The reaction stirred at room temperature and was monitored 
periodically by 1H NMR until dimer 163 was completely consumed. Reaction mixture was then loaded 
directly onto column for chromatography and purified. 
General Procedure B:  The procedure was optimized from that published by Wender and Mascarenas.1 
To a solution of salts 105a-105c and alkyne (5-20 equivalents) in CHCl3 (0.5 M) was added N,N-
diethylaniline. The reaction mixture was subjected to microwave irradiation at 100°C and was monitored 
periodically by 1H NMR until the dimer was completely consumed. Reaction mixture was then loaded 
directly onto column for chromatography and purified. 
General Procedure C: The procedure for the synthesis of 106a-106l was optimized from that published 
by Wender and Mascareñas.68 To a solution of salts 105a-105c and alkyne (5-20 equivalents) in CHCl3 
(0.5 M) was added N,N-diisopropylaniline (1.2 equivalents). The reaction mixture was subjected to 
microwave irradiation at 100°C and was monitored periodically by 1H NMR until the dimer was completely 
consumed. Reaction mixture was then loaded directly onto column for chromatography and purified. 
Dimethyl 3-methoxy-1-methyl-4-oxo-8-oxabicyclo[3.2.1]octa-2,6-diene-6,7-
dicarboxylate (106a).   
Procedure A: 105a (100 mg, 0.34 mmol) and dimethyl acetylenedicarboxylate 
(DMAD) (832 µL, 6.8 mmol) in CH2Cl2 (1.7 mL) was added N,N-dimethylaniline (86 µL, 0.68 mmol). After 
stirring at room temperature for 17 hours, reaction was purified by chromatography (silica gel, 18cm x 











in hexanes (200 mL)).  Product fractions were concentrated to yield 106a as an orange solid (71 mg, 73% 
yield). 
Procedure C: 105a (110.4 mg, 0.381 mmol) and DMAD (939 μL, 7.62 mmol) in CHCl3 (762 µL) was 
added N,N-diisopropylaniline (88 μL, 0.457 mmol). After microwave irradiation at 100°C for 5 minutes, 
reaction was purified by chromatography (silica gel, 18cm x 1.8cm,  solvent gradient: hexanes (50 mL); 
10% EtOAc in hexanes (100 mL); 15% EtOAc in hexanes (100 mL);  20% EtOAc in hexanes (100 mL); 
25% EtOAc in hexanes (200 mL)). Product fractions were concentrated to yield 106a as an orange solid 
(96.8 mg, 90% yield).  
Characterization of 106a: Melting Point (MP)= 94-97°C. Rf= 0.35 in 25%EtOAc in hexanes.  IR (thin film, 
KBr) 2956 (m), 1723 (s), 1653 (m), 1608 (s), 1437 (s), 1323 (s), 1286 (s), 1129 (s), 1073 (m), 1031 (m), 
980 (w), 866 (m) cm-1.  1H NMR (400 MHz, CDCl3) δ 6.03 (s, 1H), 5.26 (s, 1H), 3.91 (s, 3H), 3.80 (s, 3H), 
3.61 (s, 3H), 1.68 (s, 3H).  13C NMR (100 MHz, CDCl3) δ 186.86 (s), 163.72 (s), 161.38 (s), 153.46 (s), 
145.20 (s), 135.82 (s), 118.03 (s), 87.79 (s), 86.54 (s), 54.82 (s), 52.76 (s), 52.61 (s), 20.80 (s).  HRMS 









Procedure A: 105a (100 mg, 0.34 mmol) and phenylacetylene (745 μL, 6.8 mmol) in 
CH2Cl2 (1.7 mL) was added N,N-dimethylaniline (86 µL, 0.68 mmol). After stirring at room 
temperature for 1 week, reaction was purified by chromatography (silica gel, 18cm x 
1.8cm, solvent gradient: hexanes (50 mL); 10% EtOAc in hexanes (100 mL); 25% EtOAc in hexanes (100 
mL).  Product fractions were concentrated to yield 106b as an off white solid (29 mg, 35% yield). 
Procedure A with microwave heating: 105a (38.7 mg, 0.133 mmol) and phenylacetylene (292 μL, 2.6 
mmol) in CHCl3 (0.665 mL) was added N,N-dimethylaniline (34 µL, 0.26 mmol). After microwave 
irradiation at 100°C for 45 minutes reaction was purified by chromatography (silica gel, 18cm x 1.8cm, 
solvent gradient: hexanes (50 mL), 10% EtOAc in hexanes (100 mL); 20% EtOAc in hexanes (100 mL).  
Product fractions were concentrated to yield 106b as an off white solid (15 mg, 47% yield). 
Procedure B: 105a (15.8 mg, 0.053 mmol) and phenylacetylene (29 μL, 0.27 mmol) in CHCl3 (0.665 mL) 
was added N,N-diethylaniline (10.3 μL, 0.064 mmol). After microwave irradiation at 100°C for 45 minutes 
reaction was purified by chromatography (silica gel, 18cm x 1.8cm, solvent gradient: hexanes (50 mL), 
10% EtOAc in hexanes (50 mL); 20% EtOAc in hexanes (75 mL).  Product fractions were concentrated to 
yield 106b as an off white solid (7 mg, 53% yield). 
Procedure C3: 105a (102.8 mg, 0.354 mmol) and phenylacetylene (776 μL, 7.08 mmol) in CHCl3 (708 µl) 
was added N,N-diisopropylaniline (83 μL, 0.425 mmol). After microwave irradiation at 100°C for 30 
minutes, reaction was purified by chromatography (silica gel, 18cm x 1.8cm, solvent gradient): hexanes 
                                                     
3 5 eq of alkyne conditions were the same as stated but with the following amounts: 105a (97 mg, 0.334 
mmol), phenylacetylene (183 μL, 1.67 mmol), diisopropylaniline (78 μL. 0.400 mmol),  neat yielded 106b 
(34 mg, 42%).                                                                                                                                                                                                                                                           







(50 mL); 10% EtOAc in hexanes (75 mL); 15% EtOAc in hexanes (200 mL); Product fractions were 
concentrated to yield 106b as an off white solid (49 mg, 57% yield). 
Characterization of 106b:  MP= 76-84°C. Rf=0.56 in 26% EtOAc in hexanes. IR (thin film, KBr) 2977 (w), 
2934 (w), 2836 (w), 1711 (s), 1606 (m), 1491 (w), 1446 (w), 1130 (m), 1058 (w), 864 (m), 755 (m), 977 
(w), 697 (w), 661 (w) cm-1.1H NMR (400 MHz, CDCl3) δ 7.43 – 7.34 (m, 3H), 7.29 (dd, J = 5.1, 2.8 Hz, 
2H), 6.28 (d, J = 2.4 Hz, 1H), 6.19 (s, 1H), 4.99 (d, J = 2.5 Hz, 1H), 3.60 (s, 3H), 1.68 (s, 3H).  13C NMR 
(100 MHz, CDCl3) δ 189.89 (s), 158.72 (s), 145.91 (s), 133.02 (s), 128.73 (s), 128.70 (s), 125.97 (s), 
123.00 (s), 119.13 (s), 86.39 (s), 85.81 (s), 54.71 (s), 22.08 (s). HRMS (ESI+) m/z calc’d for 
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Procedure A: 105a (100 mg, 0.34 mmol) and ethyl propiolate (694 μL, 6.8 mmol) in CH2Cl2 (1.7 mL) was 
added N,N-dimethylaniline (86 µL, 0.68 mmol). After stirring at room temperature for 21 hours, reaction 
was purified by chromatography (silica gel, 18cm x 1.8cm, solvent gradient: hexanes (50 mL); 10% EtOAc 
in hexanes (100 mL); 25% EtOAc in hexanes (200 mL).  Product fractions were concentrated to yield 
106c as an off white solid (35.6 mg, 44% yield). 
Procedure B: 105a (18.7 mg, 0.065 mmol) and ethyl propiolate (131 μL, 1.29 mmol) in CH2Cl2 (362 µl) 
was added N,N-diethylaniline (12 μL, 0.077 mmol). After microwave irradiation at 100°C for 45 minutes, 
reaction was purified by chromatography (silica gel, 18cm x 1.8cm,  solvent gradient: hexanes (50 mL); 
10% EtOAc in hexanes (50 mL); 20% EtOAc in hexanes (75 mL); Product fractions were concentrated to 
yield 106c as an off white solid (11 mg, 72% yield). 
Procedure C: 105a (104 mg, 0.359 mmol) and ethyl propiolate (726 μL, 7.18 mmol) in CHCl3 (718 µl) 
was added N,N-diisopropylaniline (84 μL, 0.431 mmol). After microwave irradiation at 100°C for 15 
minutes, reaction was purified by chromatography (silica gel, 18cm x 1.8cm,  solvent gradient: hexanes 
(50 mL); 10% EtOAc in hexanes (100 mL); 15% EtOAc in hexanes (200 mL); Product fractions were 
concentrated to yield 106c as an off white solid (75.5 mg, 88% yield). 
Characterization of 106c:  MP= 52-55°C. Rf= 0.38 in 25% EtOAc in hexanes. IR (thin film, KBr) 2982 
(w), 2938 (w), 1711 (s), 1604 (m), 1452 (w), 1317 (m), 1128 (m), 1073 (m), 987 (w), 783 (w)  cm-1. 1H 
NMR (400 MHz, CDCl3) δ 7.08 (d, J = 2.5 Hz, 1H), 6.07 (s, 1H), 5.00 (d, J = 2.5 Hz, 1H), 4.24 (q, J = 7.2 
Hz, 2H), 3.54 (s, 3H), 1.76 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 189.41 (s), 
163.46 (s), 150.25 (s), 145.64 (s), 139.18 (s), 119.99 (s), 86.51 (s), 86.13 (s), 61.80 (s), 55.30 (s), 21.96 














6-Acetyl-3-methoxy-5-methyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (106d).  
Procedure A: 105a (50 mg, 0.172 mmol) and 3-butyn-2-one (270 µL, 3.4 mmol) in CH2Cl2 
(862 μL) was added N,N-dimethylaniline (44 µL, 0.34 mmol). After stirring at room temperature for 70 
hours, reaction was purified by chromatography (silica gel, 18cm x 1.8cm, solvent gradient: hexanes (50 
mL); 10% EtOAc in hexanes (100 mL); 15% EtOAc in hexanes (200 mL).  Product fractions were 
concentrated to yield 106d as a white solid (15.8 mg, 44% yield). 
13C of 106c 








Procedure B: 105a (17 mg, 0.057 mmol) and 3-butyn-2-one (92 μL, 1.17 mmol) in CH2Cl2 (293 µl) was 
added N,N-diethylaniline (11 μL, 0.070  mmol). After microwave irradiation at 100°C for 45 minutes, 
reaction was purified by chromatography (silica gel, 18cm x 1.8cm,  solvent gradient: hexanes (50 mL); 
10% EtOAc in hexanes (50 mL); 20% EtOAc in hexanes (75 mL+); Product fractions were concentrated 
to yield 106d as an off white solid (8 mg, 67% yield). 
Procedure C: 105a (102.4 mg, 0.353 mmol) and 3-butyn-2-one (540 μL, 7.06 mmol) in CHCl3 (706 µL) 
was added N,N-diisopropylaniline (82 μL, 0.424 mmol). After microwave irradiation at 100°C for 15 
minutes, reaction was purified by chromatography (silica gel, 18cm x 1.8cm, solvent gradient: hexanes 
(50 mL); 10% EtOAc in hexanes (100 mL); 15% EtOAc in hexanes (200 mL). Product fractions were 
concentrated to yield 106d as a white solid (71 mg, 97% yield). 
Characterization of 106d:  MP=146-150°C. Rf= 0.23 in 25% EtOAc in hexanes. IR (thin film, KBr) 3074 
(s), 2931 (w), 1708 (s), 1663 (s), 1608 (s), 1441 (w), 1228 (m). 1129 (m). 1063 (m), 990 (w), 881 (w), 660 
(w) cm-1.  1H NMR (400 MHz, CDCl3) δ 7.07 (d, J=1.4 Hz. 1H), 6.08 (s, 1H), 5.03 (d, J = 1.4 Hz, 1H), 3.52 
(s, 3H), 2.36 (s, 3H), 1.71 (s, 3H).  13C NMR (100 MHz, CDCl3) δ 194.63 (s), 189.16 (s), 156.78 (s), 
145.40 (s), 139.26 (s), 119.94 (s), 86.40 (s), 86.13 (s), 55.03 (s), 28.07 (s), 21.63 (s).  HRMS (ESI+) m/z 
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carboxylate (106e).  
Procedure A: 105a (50 mg, 0.17 mmol) and ethyl but-2-ynoate (402 µL, 3.4 mmol) in CH2Cl2 (862 μL) 
was added N,N-dimethylaniline (44 µL, 0.34 mmol). After stirring at room temperature for 70 hours, there 
was no conversion to product 106e. 
Procedure C: 106a (106.3 mg, 0.367 mmol) and ethyl but-2-ynoate (855 μL, 7.34 mmol) in CHCl3 (734 
µL) was added N,N-diisopropylaniline (78 μL, 0.440 mmol). After microwave irradiation at 100°C for 60 
minutes, reaction was purified by chromatography (silica gel, 18cm x 1.8cm,  solvent gradient: hexanes 
(50 mL); 2% EtOAc in hexanes (50 mL); 5% EtOAc in hexanes (200 mL);  10% EtOAc in hexanes (300 
mL). Product fractions were concentrated to yield 106e as a white solid (29.3 mg, 32% yield). 
Characterization of 106e:  MP=64-66°C.  Rf= 0.53 in 25% EtOAc in hexanes. IR (thin film, KBr) 2981 
(w), 2937 (w), 1706 (s), 1606 (m), 1446 (w), 1328 (m), 1132 (m), 1083 (m), 1048 (m), 871 (w), 785 (w) 
cm-1.  1H NMR (400 MHz, CDCl3) δ 6.13 (s, 1H), 4.80 (s, 1H), 4.36 – 4.15 (m, 2H), 3.54 (s, 3H), 2.12 (s, 
3H), 1.71 (s, 3H), 1.32 (t, J = 6.9 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 190.23 (s), 164.58 (s), 152.19 
(s), 145.66 (s), 141.22 (s), 121.66 (s), 91.06 (s), 87.45 (s), 61.36 (s), 55.25 (s), 22.45 (s), 14.86 (s), 13.33 
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   6-Benzoyl-3-methoxy-5-methyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (106f).  
Procedure C: 105a (100 mg, 0.340 mmol) and benzyl acetylene (225 mg, 1.72 mmol) 
in CHCl3 (706 µL) was added N,N-diisopropylaniline (80 μL, 0.408 mmol). After microwave irradiation at 
100°C for 10 minutes, reaction was purified by chromatography (silica gel, 26 cm x 2.6 cm, solvent 
gradient: hexanes (50 mL); 2% EtOAc in hexanes (100 mL), 5% EtOAc in hexanes (100mL), 10% EtOAc 
in hexanes (100 mL); 20%-25% EtOAc in hexanes (200 mL). Product fractions were concentrated to yield 
106f as a light yellow solid (78 mg, 85% yield). In addition, the benzyl acetylene was re-isolated (125 mg, 
70% yield (180 mg would be 100% theoretical yield of un-reacted product). 
Characterization of 106f: MP= 93-95°C. Rf=0.50 in 30% EtOAc in hexanes. IR (thin film, KBr) 3068 (w), 
2978 (w), 2936 (w), 1711 (s), 1643 (s), 1608 (s), 1448 (m), 1325 (s), 1227 (m), 1180 (m), 1126 (s), 1075 
(m), 988 (m), 819 (m), 843 (m), 701 (m), 667 (m) , 654 (m) cm-1.1H NMR (400 MHz, CDCl3) δ 7.82 (d, J = 
7.2 Hz, 2H), 7.59 (t, J = 7.4 Hz, 1H), 7.47 (dd, J =7.6, 7.6 Hz, 2H), 6.78 (d, J = 2.3 Hz, 1H), 6.26 (s, 1H), 
5.15 (d, J = 2.5 Hz, 1H), 3.56 (s, 3H), 1.74 (s, 3H).  13C NMR (100 MHz, CDCl3) δ 190.59 (s), 188.44 (s), 
155.01 (s), 145.05 (s), 138.84 (s), 136.82 (s), 133.61 (s), 129.01 (s), 128.73 (s), 120.31 (s), 87.04 (s), 
86.70 (s), 54.71 (s), 20.80 (s). HRMS (ESI+) m/z calc’d for C16H14O4H+: 271. 0965. Found: 271.0964. 
 
 













Procedure C: 105a (100 mg, 0.355 mmol) and 1-ethynyl-4-nitrobenzene (1.05 g, 7.10 
mmol) in CHCl3 (2.80 ml)4 was added N,N-diisopropylaniline (83 μL, 0.426 mmol). After microwave 
irradiation at 100°C for 30 minutes, reaction was purified by chromatography (silica gel, 26 cm x 2.6 cm 
solvent gradient, dry loaded5): hexanes (50 mL); 10% EtOAc in hexanes (100 mL); 15% EtOAc in 
hexanes (100 mL); 20% EtOAc in hexanes (100 mL); 25% EtOAc in hexanes (200 mL)). Product fractions 
were concentrated to yield 106g as a yellow solid (65 mg, 64% yield). 
Characterization of 106g: MP= 145-148°C. Rf=0.27 in 16% EtOAc in hexanes. IR (thin film, KBr) 3075 
(w), 2935 (w), 1712 (s), 1604 (m), 1516 (s), 1453 (w), 1341 (s), 1129 (m), 1108 (w), 987 (w), 865 (w), 851 
(m), 750 (m) cm-1.  1H NMR (400 MHz, CDCl3) δ 8.24 (d, J=8.7 Hz, 2H), 7.44 (d, J=8.7, 2H), 6.51 (d, J = 
2.5 Hz, 1H), 6.18 (s, 1H), 5.03 (d, J = 2.5 Hz, 1H), 3.61 (s, 3H), 1.67 (s, 3H).  13C NMR (100 MHz, CDCl3) 
                                                     
4 Increased solvent amount due to reduced solubility in lower amounts of chloroform.  
5 Took about ~500 mg of silica gel and placed into a round bottom with reaction mixture directly after 
microwave irradiation. Evaporated off any excess solvent and dried under vacuum for ~ 30 minutes. Then 
applied dried silica mixture directly onto column. 








δ 189.08 (s), 156.93 (s), 147.67 (s), 146.13 (s), 139.53 (s), 127.42 (s), 126.77 (s), 124.07 (s), 118.26 (s), 
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octa-2,6-diene-6,7-dicarboxylate (106h).  
 Procedure C: 105b (102.7 mg, 0.317 mmol) and DMAD (783 μL, 6.34 mmol) in 
CHCl3 (634 µL) was added N,N-diisopropylaniline (74 μL, 0.380 mmol). After microwave irradiation at 
100°C for 60 minutes, reaction was purified by chromatography (silica gel, 18cm x 1.8cm, solvent 
gradient: hexanes (50 mL); 10% EtOAc in hexanes (100 mL); 15% EtOAc in hexanes (100 mL);  20% 
EtOAc in hexanes (100 mL); 25% EtOAc in hexanes(100 mL)). Product fractions were concentrated to 
yield 106h as a light yellow solid (76 mg, 76% yield). MP= 127-130°C. Rf= 0.33 in 40% in EtOAc in 
hexanes. IR (thin film, KBr) 2956 (w), 1720 (s), 1649 (w), 1610 (s), 1437 (s), 1278 (s), 1219 (m), 1129 
(s), 1079 (m), 985 (m), 797 (w), 727 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 6.03 (s, 1H), 5.35 (s, 1H), 
3.99 (dd, J = 12.3, 12.3 Hz, 2H), 3.88 (s, 3H), 3.81 (s, 3H), 3.61 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 
185.98 (s), 162.87 (s), 161.01 (s), 148.90 (s), 146.05 (s), 138.27 (s), 113.71 (s), 90.08 (s), 86.92 (s), 



















Procedure C: 105c (114.6 mg, 0.358 mmol) and DMAD (870 μL, 7.16 mmol) in 
CHCl3 (716 µL) was added N,N-diisopropylaniline (84 μL, 0.430 mmol). After microwave irradiation at 
100°C for 15 minutes, reaction was purified by chromatography (silica gel, 18cm x 1.8cm,  solvent 
gradient: hexanes (50 mL); 10% EtOAc in hexanes (100 mL); 15% EtOAc in hexanes (100 mL);  20% 
EtOAc in hexanes (100 mL); 25% EtOAc in hexanes (200 mL). Product fractions were concentrated to 
yield 106i as a light yellow oil (68.3 mg, 58% yield). Rf= 0.22 in 26% EtOAc in hexanes.  IR (thin film, 
KBr) 2954 (w), 2841 (w), 1723 (s), 1610 (m), 1437 (m), 1263 (br/s), 1134 (m), 1110 (m), 1080 (w), 
1029(w), 977 (w), 809 (w) cm-1.  1H NMR (400 MHz, CDCl3) δ 6.03 (s, 1H), 5.31 (s, 1H), 3.87 (s, 3H), 3.81 
(dd, J = 3.1, 3.1 Hz, 2H), 3.78 (s, 3H), 3.60 (s, 3H), 3.42 (s, 3H).  13C NMR (100 MHz, CDCl3) δ 186.75 
(s), 163.54 (s), 161.11 (s), 151.49 (s), 146.19 (s), 136.16 (s), 114.06 (s), 90.51 (s), 86.73 (s), 71.94 (s), 
59.81 (s), 54.95 (s), 52.73 (s), 52.65 (s).  HRMS (ESI+) m/z calc’d for C14H16O8H+: 313.0918. Found: 
313.0922. 
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Procedure C: Triflate salt 105d6 (108 mg, 0.391 mmol), and dimethylacetylene 
dicarboxylate (1.11 mg, 7.82 mmol) were dissolved in CHCl3 (780 μL). N,N-diisopropylaniline (91 μL, 0.47 
mmol) was added to the reaction, the reaction vessel was sealed, and the reaction mixture was heated 
under microwave irradiation to 150ºC for 5 min.  The reaction mixture was then concentrated and purified 
by chromatography (silica gel, 18 x 1.8cm, 50 ml of Hexanes, 75 ml 10% EtOAc in Hexanes, 100 ml 20% 
EtOAc in Hexanes, 200 ml 30% EtOAc in Hexanes) to lead to 106j as a white solid (64 mg, 61% yield).  
Characterization of 106j:  MP = 113-116ºC.  Rf = 0.15 in 25% EtOAc/Hexanes.  IR (thin film, KBr) 688 
(m), 794 (w), 1000 (b), 1129 (s), 1611 (s), 1654 (m), 1716 (b), 2838 (m), 2956 (s), 3019 (w) cm-1; 1H NMR 
(400 MHz, CDCl3) δ 6.17 (d, J = 4.8 Hz, 1H), 5.46 (d, J = 4.8 Hz, 1H), 5.28 (s, 1H), 3.86 (s, 3H), 3.81 (s, 
3H), 3.60 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 186.8, 162.7, 161.9, 149.5, 146.9, 138.5, 114.2, 88.9, 





                                                     
6 Triflate salt 105d was prepared by mixing pyromeconic acid (500 mg, 4.46 mmol) and methyl triflate 
(759 μL, 6.69 mmol) in CH2Cl2 (2.25 ml, 1.98 M) and heating under reflux for 3 hours. After 3 hours, 
solvent was removed under reduced pressure, and recrystallized from CHCl3.  Unlike other salts however, 
105d decomposes over time (a few hours) as a solid, and thus it must be stored as a suspension in 
chloroform to prevent decomposition.  












Procedure C: Triflate salt 105a (100 mg, 0.34 mmol), and 1-ethynyl-4-bromobenzene 
(1.0 g, 6.9 mmol) were suspended in CHCl3 (2 mL). N,N-diisopropylaniline (81 μL, 0.41 
mmol) was added to the reaction, the reaction vessel was sealed, and the reaction mixture was heated 
under microwave irradiation to 100ºC for 30 min.  The reaction mixture was then concentrated and 
purified by chromatography (silica gel, 18 x 1.8cm, 50 ml Hexanes, 200 ml 2% EtOAc in Hexanes, 100 ml 
10% EtOAc in Hexanes, 200 ml 15% EtOAc in Hexanes) to lead to 106k as a light yellow solid (68 mg, 
61% yield).  
Characterization of 106k: MP = 192-200ºC.  Rf = 0.17 in 16% EtOAc/Hexanes.  IR (thin film, KBr) 525 
(m), 714 (m), 1057 (w), 1132(m), 1606(s), 1708(s), 1905 (w), 2978(m) cm-1.  1H NMR (400 MHz, CDCl3) δ 
7.49 (d, J = 8.5 Hz, 2H), 7.14 (d, J = 8.5 Hz, 2H), 6.29 (d, J = 2.5 Hz, 1H), 6.14 (s, 1H), 4.96 (d, J = 2.5 
Hz, 1H), 3.58 (s, 3H), 1.64 (s, J = 3H). 13C NMR (100 MHz, CDCl3) δ 105.6, 97.6, 94.7, 91.2, 90.0, 89.1, 















5-(Chloromethyl)-3-methoxy-6-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (106l).   
Procedure C: Triflate salt 105b (200 mg, 0.616 mmol), and phenylacetylene  (1.35 mL, 
12.3 mmol) were dissolved in CHCl3 (3.08 mL). N,N-diisopropylaniline (240 µL, 1.23 
mmol) was added to the reaction, the reaction vessel was sealed, and the reaction mixture was heated 
under microwave irradiation to 100ºC for 4 h.  The reaction mixture was then concentrated and purified by 
chromatography (silica gel, 18 x 1.8 cm, 50 ml Hexanes, 200 ml 2% EtOAc in Hexanes, 100 ml 10% 
EtOAc in Hexanes, 200 ml 15% EtOAc in Hexanes) to lead to 106l as a yellow solid (114 mg, 67% yield).  
Characterization of 106l:  MP = 41-65ºC.  Rf = 0.14 in 20% EtOAc in Hexanes.  IR (thin film, KBr) 
656(w), 798(s), 1078(m), 1261(s), 1607(b), 1709(b) 1960(w), 2254(w), 2838(w), 2962(s) cm-1. 1H NMR 
(400 MHz, CDCl3) δ 7.36 – 7.09 (m, 5H), 6.22 (d, J = 2.4 Hz, 1H), 6.11 (s, 1H), 4.98 (d, J = 2.4 Hz, 1H), 
13C of 106k 







3.94 (d, J = 12.4 Hz, 1H), 3.77 (d, J = 12.4 Hz, 1H), 3.52 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 189.2, 
156.3, 146.9, 132.7, 129.4, 129.2, 125.9, 124.9, 114.8, 88.7, 86.4, 55.2, 45.9. HRMS (ESI+): calc’d for 
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4.3 Data for the BCl3 Induced Ring Opening 
Dimethyl 7-hydroxy-5-methoxy-3-methyl-6-oxocyclohepta-2,4,7-triene-1,2-
dicarboxylate (165a).  
Procedure: To a solution of 106a (50 mg, 0.17 mmol) in CH2Cl2 (1.5 mL) at 0°C was 
added boron tribromide in CH2Cl2 (102 µL of 1.0 M solution, 0.1 mmol).  The reaction ran for 10 minutes, 
and a second portion of boron tribromide solution was added (102 µL, 0.1 mmol).  The reaction ran for an 
additional 10 minutes, at which time the reaction mixture was quenched with a saturated aqueous 
NaHCO3 solution (5 mL).  The aqueous layer was extracted with CH2Cl2 (3 x 5 mL), and then acidified to 
a pH of 7 by dropwise addition of a 2M HCl solution.  The acidified solution was then extracted with 
CH2Cl2 (5 x 5 mL), dried over Na2SO4, filtered and concentrated to yield 165a as a yellow oil (16 mg, 0.56 
mmol, 33% yield). MP=129-134. IR (thin film, KBr) 3225 (br), 2953 (w), 2852 (w), 1738 (s), 1571 (m), 
1437 (m), 1320 (w), 1263 (s), 1156 (m), 1068 (m), 939 (w), 763 (w) cm-1.  1H NMR (400 MHz, CDCl3) δ 
7.02 (s, 1H), 4.02 (s, 3H), 3.92 (s, 3H), 3.88 (s, 3H), 2.46 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 171.22 
(s), 168.52 (s), 167.26 (s), 158.96 (s), 156.35 (s), 134.72 (s), 131.45 (s), 122.78 (s), 121.71 (s), 56.81 (s), 
53.27 (s), 53.12 (s), 26.08 (s). HRMS (ESI+) m/z calc’d for C13H14O7Na+: 305.06317. Found:  305.06278. 
 
 












Procedure:  A solution of BCl3 (1.0 M in CH2Cl2) (588 μL, 0.588 mmol) was diluted 
with CH2Cl2 (6.0 mL) and cooled to 0°C.  In a separate round bottom flask, 106a (23.7 mg, 0.084 mmol) 
was dissolved in CH2Cl2 (6.0 mL), was cooled to 0°C and was added to the BCl3 solution.  After 10 
minutes of stirring at 0°C, the reaction mixture was quenched with H2O (12.0 mL), stirred for 2 minutes at 
0°C, and then warmed to room temperature where it continued to stir for 60 minutes. The organic layer 
was isolated and the aqueous layer was extracted with CH2Cl2, (5 x 10mL).  Combined organics were 
dried over Na2SO4, filtered, and concentrated under reduced pressure to yield 107a as a yellow solid 
(17.4 mg, 77%).7 MP= 159-161°C.  IR (thin film, KBr) 3260 (br), 2957 (w), 1738 (s), 1543 (m), 1436 (w), 
1256 (br/s), 1154 (m), 1065 (w), 1029 (w), 962 (w), 754 (w) cm-1.  1H NMR (400 MHz, CDCl3) δ 7.48 (s, 
1H), 3.94 (s, 3H), 3.89 (s, 3H), 2.46 (s, 3H).  13C NMR (100 MHz, CDCl3) δ 169.27 (s), 168.41 (s), 166.90 
                                                     
7 Compound can be further purified via reverse phase column chromatography (C-18) with a gradient of 
20-27% 16 column volumes (CV).  
 








(s), 158.40 (s), 154.56 (s), 138.42 (s), 132.18 (s), 125.28 (s), 124.48 (s), 53.40 (s), 53.20 (s), 25.74 (s).  
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Ethyl 4,6-dihydroxy-2-methyl-5-oxocyclohepta-1,3,6-trienecarboxylate (107c): 
Ethyl 6-hydroxy-4-methoxy-2-methyl-5-oxocyclohepta-1,3,6-trienecarboxylate 
(165c).  
Procedure:  A solution of BCl3 (1.0 M in CH2Cl2) (627 μL, 0.627 mmol) was diluted 
with CH2Cl2 (6.4 mL) and cooled to 0°C.  In a separate round bottom flask, 106c (21.3 mg, 0.089 mmol) 
was dissolved in CH2Cl2 (6.4 mL), was cooled to 0°C and was added to the BCl3 solution.  After 10 
minutes of stirring at 0°C, the reaction mixture was quenched with H2O (12.8 mL), stirred for 2 minutes at 
0°C, and then warmed to room temperature where it continued to stir for 30 minutes. The organic layer 
was isolated and the aqueous layer was extracted with CH2Cl2, (3 x 10 mL) and EtOAc (2 x 10 mL).  
Combined organics were dried over Na2SO4, filtered, and concentrated under reduced pressure. To the 
resulting solid was added CHCl3 where a white solid precipitated out. The organic layer was decanted off 
and concentrated under reduced pressure to yield a mixture of 107c:165c8 as a brownish green solid (7.9 






                                                     
8 Compound can be purified via reverse phase column chromatography (C-18) with a gradient of 20-27% 
for 1.9 CV (column volumes), 27-30% for 5 CV, 30-45% for 7 CV. 
 










Ethyl 4,6-dihydroxy-2-methyl-5-oxocyclohepta-1,3,6-trienecarboxylate (107c). 
Procedure: To the mixture of 107c:165c (7.9 mg, 0.033 mmol) was added acetic acid 
(192 μl) and 33% HBr in acetic acid (224 μl), and reaction was left to stir at 90°C for 3 
hours. After 3 hours, reaction mixture was let to cool to room temperature. The reaction was quenched 
with 7 pH phosphate buffer, and diluted with CH2Cl2. The organic layer was washed several times with 
the phosphate buffer. The organic layer was dried over Na2SO4, and evaporated under reduced pressure 
to yield a brown solid 107c (3.1 mg, 42% yield). Decomposes at temperatures above 80°C.  IR (thin film, 
KBr) 3260 (br), 2917 (w), 2849 (w), 1718 (s), 1500 (w), 1462 (w), 1217 (br/s), 1094 (m), 922 (w), 785 (w) 
cm-1.  1H NMR (400 MHz, CDCl3) 1δ 7.68 (s, 1H), 7.45 (s, 1H), 4.37 (q, J = 7.1 Hz, 2H), 2.53 (s, 3H), 1.38 
(t, J = 7.1 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 168.72 (s), 168.65 (s), 159.04 (s), 156.74 (s), 140.73 
(s), 132.94 (s), 124.35 (s), 120.54 (s), 62.28 (s), 25.67 (s), 14.33 (s).   HRMS (ESI+) m/z calc’d for 














Procedure:  A solution of BCl3 (1.0 M in CH2Cl2) (673 μL, 0.673 mmol) was diluted with 
CH2Cl2 (6.9 mL) and cooled to 0°C.  In a separate round bottom flask, 106d (20.0 mg, 
0.096 mmol) was dissolved in CH2Cl2 (6.9 mL), was cooled to 0°C and was added to the BCl3 solution.  
After 10 minutes of stirring at 0°C, the reaction mixture was quenched with H2O (13.7 mL), stirred for 2 
minutes at 0°C, and then warmed to room temperature where it continued to stir for 1 hour. The organic 
layer was isolated and the aqueous layer was extracted with CH2Cl2, (5 x 10 mL).  Combined organics 
were dried over Na2SO4, filtered, and concentrated under reduced pressure to yield 107d as an orange 
solid (19.6 mg, >95% yield).  MP= 106-110°C.  IR (thin film, KBr) 3240 (br), 2918 (w), 2852 (w), 1700 
(s), 1536 (s), 1446 (w), 1283 (m),  1203 (s), 1134 (m), 1031 (w), 893 (w), 785 (w) cm-1.  1H NMR (400 
MHz, CDCl3 δ 7.44 (s, 1H), 7.36 (s, 1H), 2.55 (s, 3H), 2.43 (s, 3H).  13C NMR (100 MHz, CDCl3 δ 204.08 
(s), 168.56 (s), 159.03 (s), 157.48 (s), 141.72 (s), 137.77 (s), 125.04 (s), 118.06 (s), 30.92 (s), 24.80 (s). 
HRMS (ESI+) m/z calc’d for C10H10O4H+: 195.06519. Found:  195.06531. 
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Procedure:  A solution of BCl3 (1.0 M in CH2Cl2) (486 μL, 0.486 mmol) was diluted with 
CH2Cl2 (5 mL) and cooled to 0°C.  In a separate round bottom flask, 106e (17.5 mg, 0.069 mmol) was 
dissolved in CH2Cl2 (5 mL), was cooled to 0°C and was added to the BCl3 solution.  After 10 minutes of 
stirring at 0°C, the reaction mixture was quenched with H2O (10 mL), stirred for 2 minutes at 0°C, and 
then warmed to room temperature where it continued to stir for 1 hour. The organic layer was isolated 
and the aqueous layer was extracted with CH2Cl2, (5 x 10 mL).  Combined organics were dried over 
Na2SO4, filtered, and concentrated under reduced pressure to yield 165e as a yellow solid (13.4 mg, 77% 
yield). MP= 64-70°C. IR (thin film, KBr) 3381 (w), 2917 (w), 2848 (w), 1727 (s), 1551 (w), 1454 (w), 1317 
(m),  1223 (s), 1146 (m), 1037 (m), 876 (w), 791 (w) cm-1.1H NMR (400 MHz, CDCll3) δ 6.95 (s, 1H), 4.40 
(q, J = 7.1 Hz, 2H), 3.97 (s, 3H), 2.40 (s, 3H), 2.37 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H).13C NMR (100 MHz, 
CDCl3) δ 169.70 (s), 168.91 (s), 160.01 (s), 158.30 (s), 137.98 (s), 131.45 (s), 126.86 (s), 120.88 (s), 
62.14 (s), 56.87 (s), 25.79 (s), 18.32 (s), 14.41 (s). HRMS (ESI+) m/z calc’d for C13H16O5Na+: 275.08899. 

















2-hydroxy-7-methoxy-5-methylcyclohepta-2,4,6-trienone (165f).  
Procedure:  A solution of BCl3 (1.0 M in CH2Cl2) (503 μL, 0.503 mmol) was diluted 
with CH2Cl2 (5.2 mL) and cooled to 0°C.  In a separate round bottom flask, 106f 
(19.4 mg, 0.072 mmol) was dissolved in CH2Cl2 (5.2 mL), was cooled to 0°C and was added to the BCl3 
solution.  After 10 minutes of stirring at 0°C, the reaction mixture was quenched with H2O (10.3 mL), 
stirred for 2 minutes at 0°C, and then warmed to room temperature where it continued to stir for 1 hour. 
The organic layer was isolated and the aqueous layer was extracted with CH2Cl2, (5 x 10 mL).  Combined 
organics were dried over Na2SO4, filtered, and concentrated under reduced pressure to yield 107f:165f 
as a yellow solid (19.6 mg, >95% yielded) in a 1:1 ratio. The mixture of compound 6i: 10i can be purified 
for characterization via reverse phase column chromatography (C-18) with a gradient of 27-35% for 5 
column volumes, and 35-65% for 8 column volumes, 165f collected on fractions 2-7; 107f was collected 
on fractions 10-13. 











4-Benzoyl-2,7-dihydroxy-5-methylcyclohepta-2,4,6-trienone (107f).  
Procedure: To the mixture of 107f:165f (16.9 mg, 0.062 mmol) was added acetic acid 
(364 μl) and 33% HBr in acetic acid (425 μl), and reaction was left to stir at 90°C for 3 
hours. After 3 hours, reaction mixture was let to cool to room temperature. The reaction was quenched 
with 7 pH phosphate buffer, and diluted with DCM. The organic layer was washed several times with the 
phosphate buffer. The organic layer was dried over Na2SO4, and evaporated under reduced pressure to 
yield a brown solid 6f (9.5 mg, 60% yield). Decomposed at temperatures from 45-50°C. IR (thin film, 
KBr) 3279 (br), 2918 (w), 2849 (w), 1674 (s), 1595 (w), 1536 (m), 1448 (m), 1284 (m), 1231 (s), 1084 (m), 
829 (w), 725 (w), 688 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.81 (d, J = 7.7 Hz, 2H), 7.64 (t, J = 7.3 Hz, 
1H), 7.52 (s, 1H), 7.49 (dd, J = 7.7, 7.7 Hz, 2H), 7.32 (s, 1H), 2.32 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 
197.09 (s), 168.38 (s), 158.69 (s), 156.94 (s), 139.71 (s), 138.08 (s), 135.58 (s), 134.36 (s), 130.10 (s), 
129.03 (s), 124.31 (s), 118.83 (s), 24.48 (s). HRMS (ESI+) m/z calc’d for C15H12O4H+: 257.0808. Found:  
257.0806. 














13C of 107f 




Characterization of 165f: MP= 143-145°C. IR (thin film, KBr) 3209 (br), 2918 (w), 2847 
(w), 1673 (s), 1560 (s), 1448 (w), 1262 (s),  1241 (s), 1145 (m), 1087 (m), 828 (w), 725 
(w), 688 (w) cm-1. 1H NMR (400 MHz, CDCll3)  δ 7.81 (d, J = 8.1 Hz, 2H), 7.64 (t, J = 7.3 Hz, 1H), 7.49 
(dd, J = 7.7, 7.7 Hz, 2H), 7.24 (s, 1H), 7.11 (s, 1H), 4.05 (s, 3H), 2.34 (s, 3H).13C NMR (100 MHz, CDCl3) 
δ 197.18 (s), 170.53 (s), 159.26 (s), 158.90 (s), 139.39 (s), 135.52 (s), 134.75 (s), 134.37 (s), 130.09 (s), 
129.03 (s), 122.00 (s), 116.76 (s), 56.54 (s), 24.83 (s). HRMS (ESI+) m/z calc’d for C16H14O4: 271.0965. 
Found:  271.0957. 
 
 
13C of 165f 











Procedure:  A solution of BCl3 (1.0 M in CH2Cl2) (728 μL, 0.728 mmol) was 
diluted with CH2Cl2 (7.4 mL) and cooled to 0°C.  In a separate round bottom flask, 
106g (29.8 mg, 0.104 mmol) was dissolved in CH2Cl2 (7.4 mL), was cooled to 0°C and was added to the 
BCl3 solution.  After 10 minutes of stirring at 0°C, the reaction mixture was quenched with H2O (15 mL), 
stirred for 2 minutes at 0°C, and then warmed to room temperature where it continued to stir for 1 hour. 
The organic layer was isolated and the aqueous layer was extracted with CH2Cl2, (5 x 10 mL).  Combined 
organics were dried over Na2SO4, filtered, and concentrated under reduced pressure to yield 107g:165g 
as a yellow solid (23.3 mg, 81%) in a 1:1 mixture. Compound mixture 107g:165g9 was purified for 
characterization via reverse phase column chromatography (C-18) with a gradient of 35-55% .Compound 

















                                                     
9 Compound 107g decomposes on reverse phase column. Mixture 107g:165g was dissolved in 
chloroform and applied to a dry load samplet, allow to dry under vacuum for an hour, then placed on 
column.  









2,7-Dihydroxy-4-methyl-5-(4-nitrophenyl)cyclohepta-2,4,6-trienone (107g).  
Procedure: To the mixture of 107g:165g (23.3 mg, 0.081 mmol) was added acetic acid 
(473 μl) and 33% HBr in acetic acid (552 μl), and reaction was left to stir at 90°C for 3 
hours. After 3 hours, reaction mixture was let to cool to room temperature. The reaction 
was quenched with 7 pH phosphate buffer, and diluted with DCM. The organic layer was washed several 
times with the phosphate buffer. The organic layer was dried over Na2SO4, and evaporated under 
reduced pressure to yield a brown solid 107g (17.8 mg, 80% yield). Decomposes at temperatures 
between 194-200°C.  IR (thin film, KBr) 3229 (br), 2917 (w), 1595 (m), 1518 (s), 1344 (s), 1279 (m), 
1260 (m), 1194 (m), 1092 (m), 855 (w), 702 (w) cm-1.1H NMR (400 MHz, CDCll3) δ 8.32 (d, J = 8.3 Hz, 
2H), 7.57 (s, 1H), 7.44 (d, J = 8.3 Hz, 2H), 7.38 (s, 1H), 2.24 (s, 3H).13C NMR (100 MHz, CDCl3) δ 167.65 
(s), 158.14 (s), 156.43 (s), 149.96 (s), 147.38 (s), 140.57 (s), 138.29 (s), 129.53 (s), 124.08 (s), 123.99 













2-Hydroxy-7-methoxy-5-methyl-4-(4-nitrophenyl)cyclohepta-2,4,6-trienone (165g).  
Characterization of 165g: MP= 210-214°C. IR (thin film, KBr) 3229 (br), 2917 (w), 
2848 (w), 1558 (s), 1514 (s), 1480 (m), 1344 (s), 1265 (s), 1229 (s), 1133 (s), 855 (w), 
725 (w) cm-1. 1H NMR (400 MHz, CDCll3) δ 8.32 (d, J = 8.3 Hz, 2H), 7.44 (d, J = 8.3 Hz, 
2H), 7.32 (s, 1H), 7.18 (s, 1H), 4.05 (s, 3H), 2.26 (s, 3H).13C NMR (100 MHz, CDCl3) δ 169.81 (s), 158.72 
(s), 158.57 (s), 149.86 (s), 147.38 (s), 140.37 (s), 135.05 (s), 129.51 (s), 124.00 (s), 122.04 (s), 121.03 
























13C of 165g 

























Figure 4.1. NOESY of 165g to confirm location of methoxy group. 
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 Dimethyl 3-(chloromethyl)-5,7-dihydroxy-6-oxocyclohepta-2,4,7-triene-1,2-dicarboxylate (107h).  
Procedure:  A solution of BCl3 (1.0 M in CH2Cl2) (1.26 mL, 1.26 mmol) was diluted with 
CH2Cl2 (6.0 mL) and cooled to 0°C.  In a separate round bottom flask, 106h (26.5 mg, 
0.084 mmol) was dissolved in CH2Cl2 (6.0 mL), was cooled to 0°C and was added to 
the BCl3 solution.  After 10 minutes of stirring at 0°C, the reaction mixture was quenched with H2O (12.0 
mL), stirred for 2 minutes at 0°C, and then warmed to room temperature where it continued to stir for 30 
minutes. The organic layer was isolated and the aqueous layer was extracted with CH2Cl2, (5 x 10 mL).  
Combined organics were dried over Na2SO4, filtered, and concentrated under reduced pressure to yield 
107h as a yellow solid (22 mg, 87%). Compound can be further purified via reverse phase column 
chromatography (C-18) with a gradient of 20-27% over 16 CV (7.7 mg after purification). Decomposes at 
temperatures 171-180°C.  IR (thin film, KBr) 3261 (br), 2956 (w), 1737 (s), 1557 (m), 1436 (m), 1260 
(br/s), 1153 (m), 989 (w), 668 (w) cm-1.  1H NMR (400 MHz, CDCl3)  δ 7.63 (s, 1H), 4.59 (s, 2H), 3.94 (s, 
3H), 3.92 (s, 3H).  13C NMR (100 MHz, CDCl3) δ 170.79 (s), 168.17 (s), 167.28 (s), 159.48 (s), 156.78 (s), 
137.55 (s), 133.51 (s), 125.94 (s), 124.11 (s), 54.40 (s), 54.27 (s), 48.03 (s).  HRMS (ESI+) m/z calc’d for 




                                                     
10 Molecular Formula minus Cl.  Believe Cl cleavage is taking place in Mass Spectrometer. Showed 
presence of Cl in 107b through positive Beilstein Test (presence of green flame) with control molecule 
108c (showed positive test), and negative control molecule 107a (which showed negative test). 



















dicarboxylate (107i).  
Procedure:  A solution of BCl3 (1.0 M in CH2Cl2) (459 μL, 459 mmol) was diluted 
with CH2Cl2 (4.7 mL) and cooled to 0°C.  In a separate round bottom flask, 106i (20.5 mg, 0.066 mmol) 
was dissolved in CH2Cl2 (4.7 mL), was cooled to 0°C and was added to the BCl3 solution.  After 10 
minutes of stirring at 0°C, the reaction mixture was quenched with H2O (9.4 mL), stirred for 2 minutes at 
0°C, and then warmed to room temperature where it continued to stir for 1 hour. The organic layer was 
isolated and the aqueous layer was extracted with CH2Cl2, (5 x 10 mL).  Combined organics were dried 
over Na2SO4, filtered, and concentrated under reduced pressure to yield 107i as a yellow oil (16.6 mg, 
85%). IR (thin film, KBr) 3261 (br), 2953 (w), 1738 (s), 1548 (m), 1436 (m), 1343 (m), 1259 (s), 1148 
(m), 1100 (m), 1061 (m), 890 (w), 734 (w), 668 (w) cm1.  1H NMR (400 MHz, CDCll3)  δ 7.73 (s, 1H), 4.48 
(s, 2H), 3.94 (s, 3H), 3.88 (s, 3H), 3.35 (s, 3H).  13C NMR (100 MHz, CDCl3) δ 169.26 (s), 167.57 (s), 
166.58 (s), 158.84 (s), 155.45 (s), 138.76 (s), 131.26 (s), 125.32 (s), 121.17 (s), 74.79 (s), 58.47 (s), 
53.25 (s), 53.13 (s).  HRMS (ESI+) m/z calc’d for C13H14O8H+: 299.0761. Found:  299.0757. 
 





















13C of 107i 




(165j); Dimethyl 5,7-dihydroxy-6-oxocyclohepta-2,4,7-triene-1,2-dicarboxylate 
(107j).  
Procedure:  A solution of BCl3 (1.0 M in CH2Cl2) (1.5 mL, 1.51 mmol) was diluted with CH2Cl2 (7.2 mL) 
and cooled to 0°C.  In a separate round bottom flask, 106j (27.3 mg, 0.101 mmol) was dissolved in 
CH2Cl2 (7.2 mL), was cooled to 0°C and was added to the BCl3 solution.  After 10 minutes of stirring at 
0°C, the reaction mixture was quenched with H2O (15 mL), stirred for 2 minutes at 0°C, and then warmed 
to room temperature where it continued to stir for 1 hour. The organic layer was isolated and the aqueous 
layer was extracted with CH2Cl2, (5 x 10 mL).  Combined organics were dried over Na2SO4, filtered, and 
concentrated under reduced pressure to yield a yellow solid (23.4 mg, 92%) in a complex mixture. 
Compound mixture was purified for characterization via reverse phase column chromatography (C-18) 
with a gradient of 27-35%, then 35%-55% .Compound 165j was collected in fractions 5, fraction 6 was a 
mixture, fraction 7,8 was 107j.  
 
Dimethyl 5,7-dihydroxy-6-oxocyclohepta-2,4,7-triene-1,2-dicarboxylate (107j). 
Characterization of 107j: MP 140-146°C.  IR (thin film, KBr) 3247 (br), 2961 (w), 
1595 (m), 1716 (s), 1543 (m), 1424 (m), 1259 (m), 1179 (w), 1015 (m), 805 (w), 724 
(w) cm-1. 1H NMR (400 MHz, CDCl3) δ 8.06 (d, J = 10.9 Hz, 1H), 7.50 (d, J = 11.0 Hz, 1H), 4.00 (s, J = 4.6 
Hz, 3H), 3.92 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 170.49 (s), 166.65 (s), 166.05 (s), 160.93 (s), 155.51 
(s), 132.16 (s), 128.13 (s), 126.56 (s), 118.66 (s), 53.50 (s), 53.09 (s). HRMS (ESI+) m/z calc’d for 




















13C of 107j 
1H of 107j 
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4.4 Data for the Triflic Acid Induced Ring Opening 
4.4.1 Formation and Substrate Scope of Methoxytropolones 
2-Hydroxy-7-methoxy-5-methyl-4-phenylcyclohepta-2,4,6-trienone (165b).  
Procedure: 8-Oxabicyclo[3.2.1]octene 106b (10 mg, 0.041 mmol) was dissolved in 
CHCl3 (410 µL) and trifluoromethanesulfonic acid (15 µL, 0.165 mmol) was added to the 
reaction.  The reaction stirred for 30 min and was quenched with pH 7 phosphate buffer 
(20 mL), extracted with CH2Cl2 (3 x 20 mL), dried over Na2SO4, filtered and concentrated to yield 165b as 
a yellow solid (9.5 mg, 95% yield). MP = 159-175ºC.  IR (thin film, KBr) 799 (s), 1095 (s), 1260 (s), 1451 
(w), 1726 (b), 2923 (w), 2962 (m) cm-1; 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.24 (m, 5H), 7.23 (s, 1H), 
7.18 (s, 1H), 4.04 (s, 3H), 2.27 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 169.9, 158.9, 158.4, 143.9, 143.6, 
135.4, 128.9, 128.6, 128.0, 122.7, 122.4, 56.8, 27.0. HRMS (ESI+): calc’d for C15H15O3 (M+H):  243.1016; 














Procedure: 8-Oxabicyclo[3.2.1]octene 106c  (40 mg, 0.168 mmol) was dissolved in 
CHCl3 (1.68 mL) and trifluoromethanesulfonic acid (59 µL, 0.672 mmol) was added to the reaction.  The 
reaction stirred for 30 min and was quenched with Phosphate buffer (1.6 M, pH = 7, 50 mL), extracted 
with CH2Cl2 (3 x 50 mL), dried over Na2SO4, filtered and concentrated to yield 165c as an orange solid 
(35.7 mg, 89% yield). MP = 99-106ºC.  IR (thin film, KBr) 750 (s), 1056 (w), 1457 (s), 1561 (s), 1717 (s), 
2927 (w), 3252 (b) cm-1; 1H NMR (400 MHz, CDCl3) δ 7.60 (s, 1H), 7.03 (s, 1H), 4.46 – 4.29 (q, J = 7.1 
Hz, 2H), 4.02 (s, 3H), 2.56 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 171.2, 168.9, 
159.8, 137.4, 132.4, 121.9, 117.8, 62.3, 56.8, 26.2, 14.5. HRMS (ESI+): calc’d for C12H15O5 (M+H):  
























1H of 165c 





Procedure: 8-Oxabicyclo[3.2.1]octene 106e (19 mg, 0.075 mmol) was dissolved in 
CHCl3 (750 µL) and trifluoromethanesulfonic acid (26 µL, 0.3 mmol) was added to the reaction.  The 
reaction stirred for 30 min and was quenches with Phosphate Buffer (1.6 M, pH = 7, 30 mL), extracted 
with CH2Cl2 (3 x 30 mL), dried over Na2SO4, filtered and concentrated to yield 165e as a red solid (18.5 
mg, >95% yield). 1H NMR matched previously reported data.78 1H NMR (400 MHz, CDCl3) δ 6.97 (s, 1H), 





Procedure: 8-Oxabicyclo[3.2.1]octene 106f (20 mg, 0.074 mmol) was dissolved in 
CDCl3 (0.74 mL) and trifluoromethanesulfonic acid (26.2 uL, 0.30 mmol) was added to 
the reaction.  The reaction stirred for 30 min and was quenched with Phosphate buffer (1.6 M, pH = 7, 25 
mL), extracted with CH2Cl2 (3 x 25 mL), dried over Na2SO4, filtered and concentrated to yield 165f as a 
dark yellow solid (19.7 mg, >95% yield). 1H NMR matched previously reported.78 1H NMR (400 MHz, 
CDCl3) δ 7.82 (d, J = 7.4 Hz, 2H), 7.63 (t, J = 7.0 Hz, 1H), 7.49 (t, J = 7.3 Hz, 2H), 7.19 (d, J = 29.1 Hz, 
1H), 7.10 (s, 1H), 4.30–3.69 (m, 3H), 2.33 (s, 3H). 
 















2-Hydroxy-7-methoxy-5-methyl-4-(4-nitrophenyl)cyclohepta-2,4,6-trienone (165g).  
Procedure: 8-Oxabicyclo[3.2.1]octene 106g  (29 mg, 0.10 mmol) was dissolved in 
CHCl3 (1.0 mL) and trifluoromethanesulfonic acid (61 µL, 0.41 mmol) was added to the 
reaction.  The reaction stirred for 30 min and was quenched with Phosphate Buffer (1.6 
M, pH = 7, 20 mL), extracted with CH2Cl2 (3 x 20 mL), dried over Na2SO4, filtered and concentrated to 
yield 165g as a fine, powdery yellow solid (30 mg, >95% yield).  1H NMR (400 MHz, CDCl3) δ 8.32 (d, J = 















Procedure: 8-Oxabicyclo[3.2.1]octene 106k (70.1 mg, 0.22 mmol) was dissolved in 
CDCl3 (2.2 mL) and trifluoromethanesulfonic acid (77 μL, 0.87 mmol) was added to the 
reaction.  The reaction stirred for 30 min and was quenched with Phosphate Buffer (1.6 M, pH = 7, 50 
mL), extracted with CH2Cl2 (3 x 50 mL), dried over Na2SO4, filtered and concentrated to yield 165k as a 
yellow solid (70 mg, >95% yield). MP = 110-115ºC. IR (thin film, KBr) 815.4 (w), 1211.4 (s), 1264.2 (s), 
1713.9 (w), 2939.4 (w), 3259.2 (b) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 8.3 Hz, 2H), 7.32 (s, 
1H), 7.14 (s, 1H), 7.12 (d, J = 8.3 Hz, 2H), 4.02 (s, 3H), 2.25 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 170.1, 
158.8, 158.5, 142.7, 141.8, 135.1, 132.1, 130.4, 122.4, 122.2, 121.7, 56.7, 26.9. HRMS (ESI+) calc’d for 
C15H14BrO3 (M+H):  321.0120; Found:  321.0128. 
 
  














4-(Chloromethyl)-7-hydroxy-2-methoxy-5-phenylcyclohepta-2,4,6-trienone (165l).  
Procedure:8-Oxabicyclo[3.2.1]octane 106l (37 mg, 0.13 mmol) was dissolved in CHCl3 
(1.34 mL) and trifluoromethanesulfonic acid (47 μL, 0.54 mmol) was added to the 
reaction.  The reaction stirred for 20 min and was quenches with Phosphate Buffer (1.6 
M, pH = 7, 5 mL), extracted with CH2Cl2 (3 x 5 mL), dried over Na2SO4, filtered and concentrated to yield 
165l as a brownish solid (34 mg, 92% yield). MP = 159-167ºC.  IR (thin film, KBr) 702 (s), 735 (m), 762 
1H of 165k 







(w), 1157 (w), 1261 (s), 1559 (b), 1713 (b), 2927 (b), 3247 (b) cm- 1. 1H NMR (400 MHz, CDCl3) δ 7.39 – 
7.14 (m, 8H), 4.31 (s, 2H), 3.99 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 170.49, 159.48, 158.96, 144.55, 
141.92, 134.06, 129.04, 128.72, 128.57, 122.05, 121.37, 56.97, 49.01. HRMS (ESI+): calc’d for 








1H of 165l 






one 165k (28 mg, 0.087 mmol) was suspended in toluene (1.75 mL) and 
trimethyl(phenyl)tin (47.6 uL) and tetrakis(triphenylphosphine)palladium(0) (10.02 mg, 0.26 mmol, 8.6 µM) 
were added.  The reaction was stirred vigorously for 4 days at reflux under argon.  The solution was 
cooled to room temperature and the solvent was removed under pressure. The resulting residue was 
dissolved in CH2Cl2 (2 mL). The solution was then treated with aqueous NaOH (1 M, 25 mL), aqueous 
NaF (Saturated, 25 mL) and stirred vigorously for 30 minutes. The solution was acidified with aqueous 
HCl (2M, 25 mL) to a pH of 3. The solution was extracted with CH2Cl2 (3 x 25 mL), dried over Na2SO4, 
filtered and concentrated to yield 165m as a light yellow solid (15 mg, 55% yield). MP = 190-200ºC.  IR 
(thin film, KBr) 1113 (s), 1132 (w), 1211 (s), 1554 (s), 1774 (w), 2933 (w), 2986 (w), 3018 (w), 3257 (s) 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.70 – 7.21 (m, 11H), 4.04 (s, 3H), 2.35 (s, 3H).  13C NMR (100 MHz, 
CDCl3) δ 169.79, 158.77, 158.24, 143.03, 142.66, 140.69, 140.57, 135.29, 129.06, 128.97, 127.77, 

















6-(p-Phenyl)phenyl-1,3-dihydroxy-5-methylcyclohepta-2,4,6-trien-1-one (107m).  
Procedure: 165m (16.5 mg, 0.052 mmol) was dissolved in 33%HBr/Acetic Acid (0.52 
mL). The reaction was heated to reflux for 3 h with constant stirring.  The solution was 
cooled to room temperature and extracted with CH2Cl2 (3 x 20 mL), dried over Na2SO4, 
filtered and concentrated to yield 107m as a light yellow solid (16.1 mg, >95% yield). MP = 170-175ºC.  IR 
(thin film, KBr) 1525 (s), 2923 (w), 3246 (br), cm-1; 1H NMR (400 MHz, CDCl3) 1H NMR (400 MHz, 
CDCl3) 1H NMR (400 MHz, CDCl3) δ 7.79 – 7.20 (m, 11H), 2.32 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 
167.35, 158.12, 156.87, 143.80, 142.84, 140.92, 140.70, 139.41, 129.24, 129.13, 127.96, 127.58, 127.44, 




1H of 107m 












Procedure: To a solution of chloromethoxytropolone 165l (62 mg, 0.22 mmol) in 
acetonitrile (22 ml), was added sodium azide (285 mg, 4.39 mmol). The reaction was 
stirred for 12 h at ambient temperature and atmosphere, and phosphate buffer (pH 6) was added. The 
aqueous layer was extracted with CH2Cl2 and the combined organic layers were dried over Na2SO4, 
filtered, and concentrated under reduced pressure to yield 165n as a brown solid (40mg, 64% yield). MP 
= 115-119ºC. (KBr, thin film) 3228(s), 2102(s), 1524(s), 1463(s), 1228(s), 1128(s), 703(s) cm-1. 1H NMR 
(400 MHz, CDCl3) δ 7.71 – 7.37 (m, 7H), 4.22 (s, 2H), 4.08 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 
170.57, 159.18, 158.56, 143.64, 141.67, 131.40, 128.81, 128.42, 128.30, 121.13, 119.56, 56.54, 56.16. 





















methyl)cyclohepta-2,4,6-trien-1-one (165o).  
Procedure: To a suspension of azidomethoxytropolone 165n (21 mg, 0.074 mmol) 
in water (800 mL) and tert-butanol (800 mL) was added phenylacetylene (20 mL, 
0.18 mmol), copper sulfate pentahydrate (2 mg, 0.008 mmol), and sodium ascorbate (3 mg, 0.015 mmol). 
The reaction mixture was heated under microwave irradiation at 110ºC (controlled temperature) for 30 
min. The t-BuOH/H2O was evaporated and the reaction was then re-suspended in NaCl (aq) (1 mL), 
extracted with CH2Cl2 (3 x 1 mL), dried over 
Na2SO4, filtered, and concentrated to yield 165o as a brown solid (14 mg, 50% yield). MP = 171-173ºC. 
(KBr, thin film) 3221(s), 2939(s), 1568(s), 1467(s), 1229(s), 1121(s) cm-1. 1H NMR (400 MHz, CDCl3) δ 
1H of 165n 









7.75 (d, J = 7.5 Hz, 2H), 7.63 – 7.29 (m, 10H), 7.23 (s, 1H), 5.42 (s, 2H), 3.91 (s, 3H). 13C NMR (100 
MHz, CDCl3/CD3OD) δ 170.33, 159.35, 158.48, 147.62, 143.59, 141.20, 130.17, 129.42, 128.56, 128.40, 
128.02, 128.00, 127.87, 125.16, 121.44, 120.40, 118.95, 55.62, 54.72. HRMS (ESI+) m/z calc’d for 





13C of 165o (CDCl3/CD3OD) 






Procedure: To a solution of chloromethoxytropolone 165l  (33 mg, 0.119 mmol) in 
acetonitrile (11.9 ml) was added sodium acetate (195 mg, 2.38 mmol). The reaction 
was stirred for 12 h ambient temperature and atmosphere, and phosphate buffer (pH 6) was added. The 
aqueous layer was extracted with CH2Cl2, and the combined organic layers were dried over Na2SO4, 
filtered, and concentrated under reduced pressure to yield 165p as a light yellow solid (20 mg, 56% yield). 
MP = 159-161ºC. IR (thin film, KBr) 3243(s), 1743(s),1579(s), 1478(s), 1264(s), 1103(s), 704(m) cm-1. 
1H NMR (200 MHz, CDCl3) δ 7.72 –6.96 (m, 7H), 4.88 (s, 2H), 4.04 (s, 3H), 2.08 (s, 3H). 13C NMR (50 
MHz, CDCl3) δ170.70, 159.53, 158.55, 144.72, 141.82, 131.75, 128.74, 128.57, 128.39, 121.45, 
120.33,67.72, 56.63, 21.16. 13C NMR (50 MHz, CDCl3/CD3CN) δ 169.82, 169.73, 158.64,157.85, 143.49, 
141.20, 131.33, 127.95, 127.86, 127.54, 120.40, 119.76, 66.76, 55.89,20.08. HRMS (ESI+) m/z calc’d for 












4.4.2 Formation and Substrate Scope of Furans 
Dimethyl 2-methylfuran-3,4-dicarboxylate (170a)  
Procedure: 8-Oxabicyclo[3.2.1]octene 106a (20 mg, 0.071 mmol) was dissolved in 
CHCl3 (0.71 mL) and trifluoromethanesulfonic acid (25 µL, 0.283 mmol) was added to 
the reaction.  The reaction stirred for 30 min and was quenched with triethylamine (50 µL), The reaction 
mixture was then concentrated and purified by chromatography (silica gel, 18 x 1.8 cm, 50 ml Hexanes, 
100 ml 5% EtOAc in Hexanes, 100 ml 10% EtOAc in Hexanes, 200 ml 20% EtOAc in Hexanes) to lead to 
170a as a light yellow solid (10.9 mg, 78% yield).  1H NMR matched previously reported data.110  1H NMR 




















Dimethyl furan-3,4-dicarboxylate (170j).  
Procedure: 106j (20 mg, 268.22 mmol) was dissolved in CHCl3 (0.746 mL) and 
trifluoromethanesulfonic acid (.0263 mL, 0.289 mmol) was added to the reaction.  
The reaction stirred for 30 min and was quenches with triethylamine (50 µL), The reaction mixture was 
then concentrated and purified by chromatography (silica gel, 18 x 1.8 cm, 50 ml Hexanes, 100 ml 2% 
EtOAc in Hexanes, 100 ml 5% EtOAc in Hexanes, 100 ml 8% EtOAc in Hexanes) to lead to 170j as a 
light yellow solid (8.6 mg, 63% yield). 1H NMR matched that previously reported.111 1H NMR (400 MHz, 

















1H of 170a 










  Ph(C-Br)-Ph(H both) 
 C5(tentative)-H3 
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Figure 4.2. HMBC and HSQC for 165k.  
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4.5 Data for the Alcohol Exchange Reaction 
3-Ethoxy-5-methyl-6-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (176b).  
Procedure: 105a (50 mg, 0.172 mmol), N,N-diisopropylaniline (41 μL, 0.208 mmol, 1.2 
eq), and CDCl3 (0.5 M, 344 μL) were added to a sealed tube reactor and stirred until no 
solid was observed. Ethanol (50 μL, 0.860 mmol, 5 eq) was then added and the reaction was heated to 
60ºC in silicon bath oil. After the appropriate times points, 2 hr, 4 hr, and 12 hr, the reaction was allowed 
to cool to room temperature. Phenyl acetylene (373 µL, 3.44 mmol, 20 eq) was added to the reaction and 
the seal tube was heated to 100ºC for 30 min. The reaction was then immediately purified by column 
chromatography (silica gel, 6 inch height of silica gel, 18cm x 1.8cm, solvent gradient: hexanes (50 mL); 
5% EtOAc in hexanes (100 mL); 10% EtOAc in hexanes (100 mL); 15% EtOAc in hexanes (150 mL)). 
Product fractions were concentrated to yield 176b as yellowish oil and 106b as yellowish solid after 2 hr 
(176b/106b = 17 mg: 8 mg, 56%), 4 hr (176b/106b = 15 mg: 3 mg, 41%), and 12 hr (176b only = 6 mg, 
14%) time points. 
 
Characterization of 176b: Rf = 0.21 in 15% EtOAc in hexanes. IR (thin film, KBr) 3057 (w), 2981 (w), 
2936 (w), 1713 (s), 1603 (m), 1493 (w), 1446 (w), 1381(w), 1339 (w), 1130 (m), 1058 (w), 898 (w), 864 
(w), 755 (m), 697 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.41 – 7.30 (m, 3H), 7.30 – 7.25 (m, 2H), 6.27 
(d, J = 2.5 Hz, 1H), 6.18 (s, 1H), 4.98 (d, J = 2.5 Hz, 1H), 3.85 – 3.67 (m, 2H), 1.66 (s, 3H), 1.36 (t, J = 7.0 
Hz, 3H). 13C NMR (50 MHz, CDCl3) δ 190.36, 158.98, 145.41, 133.37, 129.02, 128.97, 126.25, 123.40, 














 3-Isopropoxy-5-methyl-6-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (183b).  
Procedure: 105a (50 mg, 0.172 mmol), N,N-diisopropylaniline (41 μL, 0.208 mmol, 1.2 
eq), and CDCl3 (0.5 M, 344 μL) were added to a sealed tube reactor and stirred until no 
solid was observed. Isopropyl alcohol (66 μL, 0.860 mmol, 5 eq) was then added and the reaction was 
heated to 60ºC in silicon bath oil. After the appropriate times points, 2 hr, 4 hr, and 12 hr, the reaction was 
allowed to cool to room temperature. Phenyl acetylene (373 µL, 3.44 mmol, 20 eq) was added to the 
reaction and the seal tube was heated to 100ºC for 30 min. The reaction was then immediately purified by 
column chromatography ( silica gel, 6 inch height of silica gel, 18cm x 1.8cm, solvent gradient: hexanes 
(50 mL); 5% EtOAc in hexanes (100 mL); 8% EtOAc in hexanes (100 mL); 10% EtOAc in hexanes (100 
mL); 15% EtOAc in hexanes (100 mL)). Product fractions concentrated to yield 183b as yellowish oil and 
1H of 176b 
13C of 176b 
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106b as yellowish solid after 2 hr (183b/106b = 2 mg: 18 mg, 48%), 4 hr (183b/106b= 4 mg: 13 mg, 
39%), and 12 hr (183b only = 5 mg, 10%) time points. 
 
Characterization of 183b: Rf = 0.27 in 15% EtOAc in hexanes. IR (thin film, KBr) 3057 (w), 2979 (w), 
2935 (w) 1710 (s), 1600 (m), 1493 (w), 1447 (w), 1384 (w), 1375 (w), 1263 (w), 1125 (m), 1058 (w), 865 
(w), 754 (m), 697 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.31 (m, 3H), 7.30 – 7.25 (m, 2H), 6.28 
(d, J = 2.4 Hz, 1H), 6.19 (s, 1H), 4.98 (d, J = 2.5 Hz, 1H), 4.24 (hept, J = 6.1 Hz, 1H), 1.66 (s, 3H), 1.32 
(d, J = 6.1 Hz, 3H), 1.25 (d, J = 6.0 Hz, 3H). 13C NMR (50 MHz, CDCl3) δ 190.93, 159.00, 143.96, 133.49, 
129.05, 128.94, 126.27, 123.58, 121.33, 86.67, 86.33, 70.12, 22.40, 21.68. HRMS (ESI+) m/z calc’d for 
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3-(Benzyloxy)-5-methyl-6-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (184b).  
Procedure: 105a (50 mg, 0.172 mmol), N,N-diisopropylaniline (41 μL, 0.208 mmol, 
1.2 eq), and CDCl3 (0.5 M, 344 μL) were added to a sealed tube reactor and stirred 
until no solid was observed. Benzyl alcohol (89 μL, 0.860 mmol, 5 eq) was then added and the reaction 
was heated to 60ºC or left at room temperature in silicon bath oil. After the appropriate times points, 30 
min and 2 hr at 60ºC and 12 hr at room temperature, phenyl acetylene (373 µL, 3.44 mmol, 20 eq) was 
added to the reaction and the seal tube was heated to 100ºC for 30 min. The reaction was then 
immediately purified by column chromatography (silica gel, 6 inch height of silica gel, 18cm x 1.8cm, 
solvent gradient: hexanes (50 mL); 2% EtOAc in hexanes (100 mL); 5% EtOAc in hexanes (100 mL); 7% 
EtOAc in hexanes (200 mL); 10% EtOAc in hexanes (100 mL)). Product fractions concentrated to yield 
184b as white solid and 106b as yellowish solid after 30 min (184b/106b = 14 mg: 7 mg, 41%), 2 hr 
(184b/106b = 6 mg: 2 mg, 16%), and 12 hr (184b/106b= 8 mg: 15 mg, 46%) time points. 
 
Characterization of 184b: Melting Point (MP) = 112-114ºC. Rf = 0.24 in 15% EtOAc in hexanes. IR (thin 
film, KBr) 3061 (w), 3033 (w), 2979 (w), 2933 (w), 1709 (s), 1604 (m), 1491 (w), 1454 (w), 1339 (w), 
1263 (w), 1125 (m), 1058 (w), 866 (w), 754 (m), 697 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.27 
(m, 8H), 7.18 – 7.12 (m, 2H), 6.27 (d, J = 2.4 Hz, 1H), 6.24 (s, 1H), 5.01 (d, J = 2.5 Hz, 1H), 4.92 (d, J = 
12.0 Hz, 1H), 4.79 (d, J = 12.0 Hz, 1H), 1.62 (s, 3H). 13C NMR (50 MHz, CDCl3) δ 190.14, 159.06, 
144.85, 135.81, 133.33, 128.96, 128.91, 128.47, 127.73, 126.21, 123.37, 121.77, 86.70, 86.31, 69.86, 















Procedure: 105a (50 mg, 0.172 mmol), N,N-diisopropylaniline (41 μL, 0.208 mmol, 
1.2 eq), and CDCl3 (0.5 M, 344 μL) were added to a sealed tube reactor and stirred 
until no solid was observed. Allyl alcohol (59 μL, 0.860 mmol, 5 eq) was then added and the reaction was 
heated to 60ºC or left at room temperature in silicon bath oil. After the appropriate times points, 30 min 
and 2 hr at 60ºC and 12 hr at room temperature, phenyl acetylene (373 µL, 3.44 mmol, 20 eq) was added 
to the reaction and the seal tube was heated to 100ºC for 30 min. The reaction was then immediately 
purified by column chromatography (silica gel, 6 inch height of silica gel, 18cm x 1.8cm, solvent gradient: 
hexanes (50 mL); 2% EtOAc in hexanes (100 mL); 5% EtOAc in hexanes (100 mL); 7% EtOAc in 
hexanes (150 mL); 10% EtOAc in hexanes (50 mL); 15% EtOAc in hexanes (100 mL)). Product fractions 
1H of 184b 
13C of 184b 
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concentrated to yield 185b as yellowish oil and 106b as yellowish solid after 30 min (185b/106b = 10 mg: 
14 mg, 56%), 2 hr (185b/106b = 4 mg: 2 mg, 14%), and 12 hr (185b/106b = 4 mg: 13 mg, 40%) time 
points. 
 
Characterization of 185b: Rf = 0.24 in 15% EtOAc in hexanes. IR (thin film, KBr) 3081 (w), 3057 (w), 
2981 (w), 2935 (w), 1710(s), 1603 (m), 1491 (w), 1447 (w), 1338 (w), 1264 (w), 1125 (m), 1058 (w), 865 
(w), 755 (m), 697 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.41 – 7.32 (m, 3H), 7.29 – 7.24 (m, 2H), 6.28 
(d, J = 2.5 Hz, 1H), 6.21 (s, 1H), 5.96 (ddt, J = 17.2, 10.9, 5.5 Hz, 1H), 5.35 (dq, J = 17.3, 1.5 Hz, 1H), 
5.27 (dq, J = 10.5, 1.3 Hz, 1H), 4.99 (d, J = 2.5 Hz, 1H), 4.34 (ddt, J = 12.6, 5.4, 1.4 Hz, 1H), 4.26 (ddt, J 
= 12.7, 5.6, 1.3 Hz, 1H), 1.66 (s, 1H).13C NMR (100 MHz, CDCl3) δ 190.16, 159.02, 144.90, 133.40, 
132.33, 129.04, 129.00, 126.31, 123.46, 121.02, 118.93, 86.70, 86.27, 68.81, 22.35. HRMS (ESI+) m/z 














1H of 185b 







1.  See Review: Meck, C.; D’Erasmo, M.P.; Hirsch, D.R.; Murelli, R.P. The Biology and Synthesis of α-
Hydroxytropolones. Med. Chem. Commun. 2014, 5, 842-852. 
 
2.  For an overall review of natural tropone, tropolone, and hydroxytropolones see: Bentley, R. A. Fresh 
Look at Natural Tropolonoids. Nat. Prod. Rep. 2008, 25, 118–138. 
 
3.  Birkinshaw, J.H.; Raistrick, H.  LIII. Studies in the Biochemistry of Micro-Organisms. XXIII. Puberulic 
acid C8H606 and an acid C8H406, New Products of the Metabolism of Glucose by Penicillium Puberulum 
Bainer and Penicillium Aurantio-Virens Biourge with an Appendix on Certain 
Dihydroxybenzen.edicarboxylic Acids. Biochem. J. 1932, 26, 441–453. 
 
4.  Corbett, R.E.; Hassall, C.H.; Johnson, A.W.; and Todd, A.R. Puberulic and Puberulonic Acids. Part I. 
The Molecular Formula of Puberulonic Acid and Consideration of Possible Benzenoid Structures for the 
Acids. J. Chem. Soc. 1950, 1-6.  
 
5.  Corbett, R.E.; C.H.; Johnson, A.W., and Todd, A.R. Puberulic and Puberulonic Acids. Part II. 
Structure. J. Chem. Soc. 1950, 6-9. 
 
6.  Dewar, M.J.S. Structure of Stipitatic Acid. Nature. 1945, 155, 50-51.  
 
7.  Dewar, M.J.S. Tropolone. Nature. 1950, 166, 790-791. 
 
8.  Dauben, H.J., Jr.; Ringold, H.J. Synthesis of Tropone. J. Am. Chem. Soc. 1951, 73, 876. 
 
9.  Martin, S. F.; Follows, B. C.; Hergenrother, P. J.; Franklin, C. L. A Novel Class of Zinc-Binding 
Inhibitors for the Phosphatidylcholine-Preferring Phospholipase C from Bacillus cereus.  J. Org. Chem. 
2000, 65, 4509-4514. 
 
10.  Pauson, P.L. Tropones and Tropolones. Chem. Rev. 1955, 55, 9-136.  
 
11.  Bryant, B.E.; Fernelius, W.C.; Douglas, B.E. Formation Constants of Metal Complexes of Tropolone 
and its Derivatives. I. Tropolone. J. Am. Chem. Soc. 1953, 75, 3784-3786.  
 
12.  Didierjean, J.; Isel, C.; Querré, F.; Mouscadet, J.F.; Aubertin, A.M.; Valnot, J.V.; Piettre, S.R.; 
Marquet, R. Inhibition of Immunodeficiency Virus Type 1 Reverse Transcriptase, RNase H, and Integrase 
Activities by Hydroxytropolones. Antimicrob. Agents Chemother. 2005, 49, 4884-94. 
 
13.  Dismukes, G.C. Manganese Enzymes with Binuclear Active Sites. Chem. Rev. 1996, 96, 2909-2926. 
 
14.  Allen, N.E.; Alborn, W.E., Jr.; Hobbs, J.N., Jr.; Kirst, H.A. 7-Hydroxytropolone: an Inhibitor of 
Aminoglycoside-2”-O-Adenylyltransferase. Antimicrob. Agents Chemother. 1982, 22, 824-831. 
 
15.  Piettre, S.R.; Ganzhorn, A.; Hoflack, J.; Islam, K.; Hornsperger, J.M. α-Hydroxytropolones: A New 
Class of Potent Inhibitors of Inositol Monophosphatase and other Bimetallic Enzymes. J. Am. Chem. Soc. 
1997, 119, 3201-3204. 
 
16.  Iwatsuki, M.; Takada, S.; Mori, M.; Ishiyama, A.; Namatame, M.; Nishihara-Tsukashima, A.; Nonaka, 
K.; Masuma, R.; Otoguro, K.; Shiomi, K.; Omura, S. J. In Vitro and in Vivo Antimalarial Activity of 







17.  Budihas, S. R.; Gorshkova, I.; Gaidamakov, S.; Wamiru, A.; Bona, M. K.; Parniak, M. A.; Crouch, R. 
J.; McMahon, J. B.;  Beutler, J. A.; Le Grice, S. F. J. Selective Inhibition of HIV-1 Reverse Transcriptase-
Associated Ribonuclease H activity by Hydroxylated Tropolones. Nuc. Acids Res. 2005, 33, 1249-1256. 
 
18.  Chung, S.; Himmel, D. M.; Jiang, J.K.; Wojtak, K.; Bauman, J. D.; Rausch, J. W.; Wilson, J. A.; 
Beutler, J. A.; Thomas, C. J.; Arnold, E.; Le Grice, S. F. J. Synthesis, Activity, and Structural Analysis of 
Novel α-Hydroxytropolone Inhibitors of Human Immunodeficiency Virus Reverse Transcriptase-
Associated Ribonuclease H.  J. Med. Chem. 2011, 54, 4462-4473. 
 
19.  Gardner, J.A.F.; Barton, G.M.; MacLean, H. Occurance of 2,7-Dihydroxy-4-isopropyl-2,4,6-
cycloheptatrien-1-one (7-hydroxy-4-isopropyltropolone) in Western Red Cedar (thuja plicata donn.). Can. 
J. Chem. 1957, 35, 1039-1048.  
 
20.  (a) Morris, P.I.; Stirling,R. Western Red Cedar Extractives Associated with Durability in Ground 
Contact. Wood Sci. Technol. 2012, 46, 991–1002; (b) Chedgy, R.J.; Lim, Y.W.; Brueil, C. Effects of 
Leaching on Fungal Growth and Decay of Western Red Cedar. Can. J. Microbiol. 2009, 55, 578–586. 
 
21.  Roff, J.W.; Whittaker, E.I. Toxicity Tests of a New Tropolone, β-Thujaplicinol, Occurring in Western 
Red Cedar. Can. J. Bot. 1959, 37, 1132–1134. 
 
22.  Kousha, M.; Tadi, R.; Soubani, A.O. Pulmonary Aspergillosis: A Clinical Review. Eur. Respir. Rev. 
2011, 121, 156–174. 
 
23.  Sanders, H.D. Some Pharmacological and Microbiological Studies on Beta-hydroxy Thujaplicin, M.S. 
thesis, The University of British Columbia, Canada, 1961, https://circle.ubc.ca/handle/2429/39828. 
 
24.  Sugawara, K.; Ohbayashi, M.; Shimizu, K. Hatori, M.; Kamei, H.; Konishi, M.;Oki, T.; Kawaguchi, H. 
BMY-28438 (3,7-Dihydroxytropolone), A New Antitumor Antibiotic Active Against B16 Melanoma I. 
Production, Isolation, Structure and Biological Activity. J.  Antibiot. 1988, 41, 862–868. 
 
25.  Fauroux, C.M.; Freeman, S. Inhibitors of Inositol Monophosphatase. J. Enzyme Inhib. 1999, 97-108. 
26.  a.) Pollack, S.J.: Atack, J.R.; Knowles, M.R.; McAllister, G.; Ragan, C.I.; Baker, R.; Fletcher, S.R.; 
Iversen, L.L; Broughton, H.B. Mechanism of Inositol Monophosphatase, Putitive Target of Lithium 
Therapy. Proc. Natl. Acad. Sci. 1994, 91, 5766-5770. b.) Hullin, R.P. Minimum Serum Lithium Levels for 
Effective Prophylaxis. In Handbook of Lithium Therapy; Johnson, F.N., Ed.; Springer: 1980, pp 243-247 
 
27.  Wright, G.D. Aminoglycoside-Modifying Enzymes. Curr. Opin.  Microbiol. 1999, 2, 499-503. 
 
28.  Himmel, D. M.; Maegley, K A.; Pauly, T. A.; Bauman, J. D.; Das, K.; Dharia, C.; Clark, A. D., Jr.; 
Ryan, K.; Hickey, M. J.; Love, R. A.; Hughes, S. H.; Bergqvist, S.; Arnold, E. Structure of  HIV Reverse 
Transcriptase with the Inhibitor β-thujaplicinol Bound at the RNase H Active Site. Structure. 2009, 17, 
1625-1635.  
 
29.  Semenova, E. A.; Johnson, A. A.; Marchand, C.; Davis, D. A.; Yarchoan, R.; Pommier, Y. Preferential 
Inhibition of the Magnesium-Dependant Strand Transfer Reaction of HIV-1 Integrase by α-
Hydroxytropolones. Mol. Pharmacol. 2006, 69, 1454-1460. 
 
30.  Lombardi, V.C.; Ruscetti, F.W.; Gupta, J.D.; Pfost, M.A.; Hagen, K.S.; Peterson, D.L.; Ruscetti, S.K.; 
Bagni, R.K.; Petrow-Sadowski, C.; Gold, B.; Dean, M.; Silverman, R.H.; Mikovits, J.A. Detection of an 
Infectious Retrovirus XMRV in Blood Cells of Patients with Chronic Fatigue Syndrome. Science.  2011, 






31.  Urisman, A.; Molinaro, R.J.: Fischer, N.; Plummer, S.J.; Casey, G.; Klein, E.A.; Malathi, K.; Magi-
Galluzzi, C.; Tubbs, R.R.; Ganem, D.; Silverman, R.H.; DeRisi, J.L. dentification of a Novel 
Gammaretrovirus in Prostate Tumors of Patients Homozygous for R462Q RNASEL Variant. PLos Pathog. 
2012, 8, 10.1371/annotation/7e2efc01-2e9b-4e9b-aef0-87ab0e4e4732. (Retraction)  
 
32.  Switzer, W.M.; Jia, H.; Hohn, O.; Zheng, H.; Tang, S.; Shankar, A.; Bannert, N.; Simmons, G.; 
Hendry, R.M.; Falkenberg, V.R.; Reeves, W.C.; Heneine, W. Absence of Evidence of Xenotropic Murine 
Leukemia Virus-rRelated Virus Infection in Persons with Chronic Fatigue Syndrome and Healthy Controls 
in the United States. Retrovirology. 2010, 7, 1-13. 
 
33.  Paprotka, T.; Delviks-Frankenberry, K.A.; Cingoz, O.; Martinez, A.; Kung, H-J.; Tepper, C.G.; Hu, W-
S.; Fivash, M.J.; Coffin J.M.; Pathak, V.K. Recombinant Origin of the Retrovirus XMRV. Science. 2011, 
333, 97-101.  
 
34.  Kirby, K.A.; Marchand,B.; Ong, Y.T.; Ndongwe, T.P.; Hachiya, A.; Michailidis, E. Leslie, M.D.; 
Sietsema, D.V.; Fetterly, T.L.; Dorst, C.A.; Singh, K.; Wang, Z.; Parniakand, M.A. Sarafianos, S.G. 
Structural and Inhibition Studies of Rnase H Function of Xenotropic Murine Leukemia Virus Related Virus 
Reverse Transcriptase.  Antimicrob. Agents Chemother. 2012, 56, 2048–2061. 
 
35.  Zhou, D.; Chung, S.; Miller, M.; Le Grice, S.F.J.; Wlodawer, A. Crystal Structure of Reverse 
Transcriptase Associated Ribonuclease H Domain of Xenotropic Murine Leukemia Virus Related Virus. J. 
Struct. Biol. 2012, 177, 638–645. 
 
36.  Center for Disease Control. Genital Herpes Fact Sheet. http://www.cdc.gov/std/herpes/STDFact-
herpes.htm (accessed Mar 2, 2015). 
 
37.  World Health Organization. An Estimate of the Global Prevalence and Incidence of Herpes Simplex 
Virus Type 2 Infection. http://www.who.int/bulletin/volumes/86/10/07-046128/en/ (accessed Mar 2, 2015). 
 
38.  Bryant, K.F.; Yan, Z,; Dreyfus, D.H.; Knipe, D.M Identification of a Divalent Metal Cation Binding Site 
in Herpes Simplex Virus 1 (HSV-1) ICP8 Required for HSV Replication. J. Virol. 2012, 86, 6825–6834. 
 
39.  Tavis, J.E.; Wang, H.; Tollefson, A.E.; Ying, B.; Korom, M.; Cheng, X.; Cao, F.; Davis, K.L.; Wold, 
W.S.M.; Morrison, L.A. Inhibitors of Nucleotidyltransferase Superfamily Enzymes Suppress Herpes 
Simplex Virus Replication. Antimicrob. Agents and Chemother. 2014, 58, 7451-7461.  
 
40. World Health Organization. Hepatitis B Fact Sheet.http://www.who.int/mediacentre/ 
factsheets/fs204/en/ (accessed Feb 3,2015). 
 
41.  Hu, Y.; Cheng, X.; Cao, F.; Huang, A.; Tavis, J.E.  β-Thujaplicinol inhibits hepatitis B virus replication 
by blocking the viral ribonuclease H activity. Antiviral. Res. 2013, 99, 221-229. 
 
42.  Piettre, S.R.; Andre, C.; Chanal, M.C.; Ducep, J.B.; Lesur, B.; Piriou, F.; Raboisson, P.; Rondeau, 
J.M.; Schelcher, C.; Zimmermann, P.; Ganzhom, A.J. Monoaryl and Bisaryldihydroxytropolones as Potent 
Inhibitors of Inositol Monophosphatase. J. Med. Chem. 1997, 40, 4208-4221. 
 
43.  Nozoe, T.; Seto, S.; Itô, S.; Sato, M.; Katono, T. “On Hydroxyl Derivatives of Tropolone, α-Thujaplicin 
and Hinokitiol and the Attempted Preparation of the so-called Tropoquinone” Sci. Rep. Tohoku Univ. Ser. 
1. 1953, 37, 191-210. 
 
44.  Takeshita, H.; Mori, A. An Improved Synthesis of 2,7-Dihydroxytropolones (3-Hydroxytropolones). 






45.  Zinser, J.; Henkel, S.; Fӧhlisch, B. A Novel Synthesis of 2-Alkoxy-3-hydroxytropones and 2,7-
Dihydroxytropones from Dialkoxy-8-oxabicyclo[3.2.1]oct-6-en-3-ones. Eur. J. Org. Chem. 2004, 1344-
1356. 
 
46.  Dastan, A.; Saracuglu, N.; Balci, M. A New Method for the Synthesis of Stipitatic Acid Isomers: 
Photooxygenation of Ethyl 6H-Cyclohepta[d][1,3]dixole-6-carboxylate. Eur. J. Org. Chem. 2001, 3519–
3522.  
 
47.  Nozoe, T.; Doi, K.; Hashimoto, T. Synthesis of Puberulonic Acid. Bull. Chem. Soc. Jpn.  1960, 33, 
1071-4. 
 
48.  Crow, W.D.; Haworth, R.D.; Jefferies, P.R. Purpurogallin. Part X.* Further Studies on the Oxidation 
Products of Purpurogallin and Purpurogallin Carboxylic Acid. J. Chem. Soc. 1952, 3705-3713. 
 
49. Haworth, R.D.; Hobson, J.D. Purpurogallin. Part IV.  Some Properties of Tropolones. J. Chem. Soc. 
1951, 561-568. 
 
50.  Bartels-Keith, J.R.; Johnson, A.W.; Taylor, W.I. A Synthesis of Stipitatic Acid. J. Chem. Soc. 1951, 
2352-2356. 
 
51.  Johns, R. B.; Johnson, A. W.; Murray, J.  Synthetic Experiments in the Cycloheptatrienone Series. 
Part III. Syntheses of puberulic acid and Isostipitatic acid” J. Chem. Soc. 1954, 198-202. 
 
52.  Banwell, M. G.; Collis, M. P.; Mackay, M. F.; Richards, S. L. Cis-Dihydrocatechols as Precursors to 
Highly Oxygenated Troponoids. Part 2. Regiocontrolled Synthesis of Stipitatic and Puberulic Acid.  J. 
Chem. Soc. Perkin Trans. 1. 1993, 1913-1920. 
 
53.  Banwell. M.G. An Improved Synthesis of (1α,6α)-Dioxabicylco[4.3.0]nona-2,4-diene. Org. Prep. 
Proced. Int. 1989, 21, 255-266. 
 
54.  Banwell, M.G.; Corbett, M.; Mackay, M.F.; Richards, S.L. Cis-Dihydrocatechols as precursors to 
highly oxygenated troponoids: a fully regiocontrolled synthesis of 3,4-dimethoxy-α-tropolone. J. Chem. 
Soc. Perkin Trans. 1. 1992, 1329-1334. 
 
55.  Sennari, G.; Hirose, T.; Iwatsuki, M.; Omura, S.; Sunazuka, T. A Concise Total Synthesis of Puberulic 
Acid, A Potent Antimalarial Agent. Chem. Comm. 2014, 50, 8715-8718. 
 
56.  Banwell, M. G.; Halton, B. Studies in the Tricyclooctane Series. III. Dehydrobromination of Some Bis-
Bromocarbene Adducts of Cyclohexadienes. Aust. J. Chem. 1979, 32, 2689-2699. 
 
57.  Banwell, M.G.; Onrust, R. A Versatile New Strategy for the Synthesis of Tropolones. Tetrahedron 
Lett. 1985, 26, 4543-4546. 
 
58.  Amon, C.; Banwell, M.G.; Gravatt, G.L. Oxidation of Vicinal Diols to α-Dicarbonyl Compounds by 
Trifluoroacetic Anhydride "Activated" Dimethyl Sulfoxide J. Org. Chem. 1987, 52, 4851-4855. 
 
59.  Banwell, M. G.; Collis, M. P.; Crisp, G. T.; Lambert, J. N.; Reum, M. E.; Scoble, J. A. The Palladium-
Mediated Cross-Coupling of Bromotropolones with Organostannanes; Application to Concise Syntheses 
of β-Dolabrin, β-Thujaplicin, 7-Methoxy-4-isopropyItropolone, and β-Thujaplicinol J. Chem. Soc., Chem. 
Commun. 1989, 10, 616-617. 
 
60.  Banwell, M.G.; Collis, M.P. Lewis-acid Promoted Rearrangement of σ-Homo-o-benzoquinones to α-
Tropolone Derivatives: Application to Regiocontrolled Syntheses of MY3-469 and lsopygmaein. J. Chem. 






61.  Davies, H.U.W.; Clark, T.J. Synthesis of Highly Functionalized Tropolones by Rhodium (II)-Catalyzed 
Reactions of Vinyldiazomethanes with Oxygenated Dienes. Tetrahedron. 1994, 50, 9883-9892. 
 
62.  See Reviews:  a.) Singh, V.; Krishna, U.M.; Vikrant; Trivedi, G.K. Cycloadditions of Oxidopyrylium 
Species in Organic Synthesis. Tetrahedron, 2008, 64, 3405-3428. b.) Mascareñas, J.L. The [5+2] 
Cycloaddition Chemistry of β-alkoxy-γ-pyrone. In Advances in Cycloaddition; Harmata, M., Ed.; Jai Press: 
Stamford, CT, 1999; Vol. 6; pp 1-54. C.) Pellissier, H. Recent Developments in the [5+2} Cycloaddition. 
Adv. Synth. Catal. 2011, 353, 189-218. 
 
63.  Volkmann, RA.; Weeks, P.D.; Kuhla, D.E.; Whipple, E.B.; Chmurny G.N. Reaction of Kojic Acid and 
Its Derivaties with acrylonitrile: A new look at an old problem. J. Org. Chem. 1977, 42, 3976-3977. 
 
64.  Hurd, C.D.; Trofimenko, S. Behavior of Kojic Acid toward Acrylonitrile, Halo Acids, and Hydrogen 
Cyanide. J. Am. Chem. Soc. 1958, 80, 2526-2527. 
 
65.  Garst, M.E.; McBride, B.J.; Douglass, J.G. Intra molecular cycloadditions  with 2-alkenyl-5-Hydroxy-4-
pyrones. Tetrahedron Lett. 1983, 24, 2675-1678.  
 
66.  Wender, P.A.; McDonald, F.E. Study of Tumor Promoters. 9. A Second Generation Synthesis of 
Phorbol . J. Am. Chem. Soc. 1990, 112, 4956-4958. 
  
67.  Wender, P.A.; Mascareñas, J.L. Studies on Tumor Promoters. 11. A New [5+2] Cycloaddition Method 
and its Application to the Synthesis of BC Ring Precursors of Phoboids. J Org. Chem. 1991, 56, 6267-
6269. 
 
68.  Wender, P.A.; Mascareñas, J.L. Preparation and Cycloadditions of a 4-Methoxy-3-Oxidopyrylium 
Ylid:  A Reagent for the Synthesis of Highly Substituted Seven-Membered Rings and Tetrahydrofurans. 
Tetrahedron Lett. 1992, 33, 2115-2118. 
 
69.  McBride, B.J.; Garst, M.E. Cycloadditions of 4-Pyrones. An Approach to Colchicine. Tetrahedron. 
1993, 49, 2839-2854.  
 
70.  a.) Zaragoza, R.J.; Aurell, M.J.; Domingo, L.R. The Role of the Transfer Group in the Intramolecular 
[5+2] Cycloadditions of Substituted β-hydroxy-γ-pyrones: A DFT Analysis. J. Phys. Org. Chem. 2005, 18, 
610-615. b.) Domingo, L.R.; Zaragoza, R.J. Toward an Understanding of the Mechanisms of the 
Intramolecular [5 + 2] Cycloaddition Reaction of γ-Pyrones Bearing Tethered Alkenes. A Theoretical 
Study. J. Org. Chem. 2000, 65, 5480-5486.  
  
71.  Nogueira, E.; Guitian, E.; Castedo, L.; Castifiereras. Tandem Benzyne Cycloadditions Leading to 
Polycyclic Compounds.  A. Aust. J. Chem.,1997, 50, 751-754. 
 
72.  Rumbo, A.; Castedo, L.; Mourino, A.; Mascareñas, J.L. Temporary Tethering Strategies for [5+2] 
Pyrone Alkene Cycloadditions. J. Org. Chem. 1993, 58, 5585-5586. 
  
73.  Adlington, R.M.; Baldwin, J.E.; Mayweg, A.V.W.; Pritchard, G.J. Biomimetic Cycloaddition Approach 
to Tropolone containing Natural Products via a Tropolone Ortho-quinone Methide. Org. Lett. 2002, 4, 
3009-3011. 
 
74. Baldwin, J.E.; Mayweg, A.V.W.; Neumann, K.; Pritchard, G.J. Studies toward the Biomimetic 
Synthesis of Tropolone Natural Products via a Hetero Diels-Alder Reaction. Org. Lett., 1999, 1, 1933-
1935. 
 





Rh-Triggered Cycloaddition Cascade.Org. Lett. 2005, 7, 4317-4320. 
 
76.  Graening, T.; Schmalz, H.G. Total Syntheses of Colchicine in Comparison: A Journey 
through 50 Years of Synthetic Organic Chemistry Angew. Chem. Int. Ed. 2004, 43, 3230-3256.  
 
77.  Zhang, M.; Liu, N. ; Tang, W. Stereoselective Total Synthesis of Hainanolidol and Harringtonolide via 
Oxidopyrylium-Based [5 + 2] Cycloaddition. J. Am. Chem. Soc. 2013, 135, 12434-12438. 
 
78.  Meck, C.; Mohd, N.; Murelli, R.P. An Oxidopyrylium Cyclization/Ring Opening Route to 
Polysubstituted α-Hydroxytropolones. Org. Lett. 2012, 14, 5988-5991. 
 
79.  Fakih, S.; Podinovskaia, M.; Kong, X.; Collins, H.L.; Schaible, U.E.; Hider, R.C.Targeting the 
Lysosome: Fluorescent Iron (III) Chelators to Selectively Monitor Endosomal/lysosomal labile Iron Pools. 
J.Med. Chem. 2008, 51, 4539-4552. 
 
80.  Williams, Y.D.; Meck. C.; Mohd, N.; Murelli, R.P. Triflic acid mediated rearrangements of 3-methoxy-
[3.2.1]octa-3,6-dien-2-ones: Synthesis of methoxytropolones and furans. J. Org. Chem. 2013, 78, 11707-
11713. 
 
81.  McOmie, J.F.W.; Watts, M.L.; West, D.E. Demethylation of aryl methyl ethers by boron tribromide. 
Tetrahedron. 1967, 24, 2289-2292. 
 
82.  Dougherty, D. A. Cation-π Interactions in Chemistry and Biology: A New View of Benzene, Phe, Tyr, 
and Trp. Science. 1996, 271, 163-168. 
 
83.  Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. A Stepwise Huisgen Cycloaddition 
Process: Copper (I) Catalyzed Regioselective Ligation of Azides and Terminal Alkynes. Angew. Chem. 
Int. Ed. 2002, 41, 2596-2599. 
 
84.  Mann, J.; Wilde, P. D.; Finch, M. W. Synthesis and Reaction of 2-aryl-8-oxabicyclo[3.2.1]oct-6-en-3-
ones. Tetrahedron, 1987, 43, 5431-5441. 
 
85.  Schatz, A.; Bugle, E.; Waksman, S.A. Streptomycin, a substance exhibiting antibiotic activity against 
gram positive and gram negative bacteria. Proc. Soc. Exp. Biol. Med. 1944, 55, 66-69. 
 
86. Magnet, S.; Blanchard, J.S. Molecular insights into aminoglycoside action and resistance. Chem. Rev. 
2005, 105, 477-498. 
 
87. Gonzalez, L.S., III; Spencer, J.P. Aminoglycosides: A Practical Review. Am. Fam. Physician. 1998, 
58, 1811-1820. 
 
88. Davies, J.E. Amnioglycosides: Ancient and Modern. J. Antibiot. 2006, 59, 529-532. 
 
89.  Wright, G.D. Molecular Mechanisms  of antibiotic resistance. Chem. Comm. 2011, 47, 4055-4061. 
 
90.  Itzen, A.; Blankenfeldt, W.; Goody, R.S. Adenylylation: Renaissance of a Forgotten Post 
Translational Modification. Trends Biochem. Sci. 2011, 36, 221-228.  
 
91.  Cox, G.; Stogios, P.J.; Savchenko, A.; Wright, G.D. Structural and Molecular Basis for Resistance of 
Aminoglycoside Antibiotics by Adenyltransferases ANT (2’’)-Ia. mBio. 2014, 6, 1-9. 
 
92.  Miller, G.H.; Sabatelli, F.J.; Hare, R.S.; Glupxzynski, Y.; Mackey, P.; Shales, D.; Shimizu, K.; Shaw, 





a relection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups. Clin. Infect. 
Dis. 1997, 24, (Suppl 1): S46-S62. 
 
93.  Welch, K.T.; Virga, K.G.; Whittemore, N.A.; Ozen, C.; Wright, E.; Brown, C.L.; Lee, R.E.; Serpersu, 
E.H. Discovery of non-carbohydrate inhibitors of aminoglycoside-modifying enzymes. Biorg. Med. Chem. 
2005, 13, 6252-6263. 
 
94.  Hirsch, D.R.; Cox, G.C.; D’Erasmo, M.P.; Shakya, T.; Meck, C.; Mohd, N.; Wright, G.D.; Murelli, R.P. 
“Inhibition of ANT (2”)-Ia Resistance Enzyme and Rescue of Aminoglycoside Antibiotic Activity by 
Synthetic α-Hydroxytropolones.” Bioorg. Med. Chem. Lett. 2014, 24, 4943-4947. 
 
95.  Davies, J.F.,II; Hostomska, Z.; Hostomsky, Z.; Jordan, S.R; Matthews, D.A. Crystal Structure of the 
Ribonuclease H Domain of HIV-1 Reverse Transcriptase. Science. 1991, 252, 88–95. 
 
96.  Ilina, T.; La Barge, K.; Sarafianos, S.G.; Ishima, R.; Parniak, M.A. Inhibitors of HIV-1 Reverse 
Transcriptase Associated Ribonuclease H Activity. Biology.  2012, 1, 521-541. 
 
97.  Schultz, S.J.; Champoux, J.J. RNase H activity: Structure, specificity, and function in reverse 
transcription. Virus Res. 2008, 134, 86-103. 
 
98.  Sarafianos, S.G.; Marchand, B.; Das, K.; Himmel, D.H.; Parniak, M.A.; Hughes, S.H.; Arnold, E. 
Structure and Function of HIV-1 Reverse Transcriptase: Molecular Mechanism of Polymerization 
Inhibition. J. Mol. Biol. 2009, 385, 693-713. 
 
99.  Corona, A.; Masaoka, T.; Tocco, G.; Tramontano, E.; Le Grice, S.F.J. Active site and allosteric 
inhibitors of the ribonuclease H activity of HIV reverse transcriptase. Future Medicinal Chemistry. 2013, 5, 
2127-2139.  
 
100.  Shaw-Reid, C.A.; Munshi, V.; Graham, P.; Wolfe, A.; Witmer, M.; Danzeisen, R.; Olsen, D.B.; 
Carroll, S.S.; Embrey, M.; Wai, J.S.; Miller, M.D.; Cole, J.L.; Hazuda, D.J. Inhibition of HIV-1 
ribonuclease H by a novel diketo acid, 4-[5-benzoylamino)thien-2-yl]-2,4-dioxobutanoic Acid. J. 
Biol. Chem. 2003, 278, 2777-2780. 
 
101.  Costi, R.; Metifiot, M.; Chung, S.; Crutti, G.C.; Maddali, K.; Pescatori, L.; Messore, A.; Madia, V.N.; 
Pupo, G.; Scipione, L.; Tortorella, S.; Di Leva, F.S.; Cosconati, S.; Marinelli, L.; Novellino, E.; Le Grice, 
S.F.J.; Corona, A.; Pommier, Y.; Marchand, C.; Di Santo, R. Basic Quinolinonyl Diketo Acid Derivatives 
as Inhibitors of HIV Integrase and their Activity against RNase H Function of Reverse 
Transcriptase. J. Med. Chem. 2014, 57, 3223-3234. 
 
102.  a) Su, H.P.; Yan, Y.; Prasad, S.; Smith, R.F.; Daniels, C.L.; Abeywickrema, P.D.; Reid, J.C.; 
Loughran, H.M.; Kornienko, M.; Sharma, S.; Grobler, J.A.; Xu, B.; Sardana, V.; Allison, T.J.; 
Williams, P.D.; Darke, P.L.; Hazuda, D.J.; Munshi, S. Structural Basis for the Inhibition of RNase 
H Activity of HIV-1 Reverse Transcriptase by RNase H Active Site-Directed Inhibitors. J. Virol. 
2010, 84, 7625-7633. b) Williams, P.D.; Staas, D.D.; Venkatraman, S.; Loughran, H.M.; Ruzek, R.D.; 
Booth, T.M.;Lyle, T.A.; Wai, J.S.; Vacca, J.P.; Feuston, B.P.; Ecto, L.T.; Flynn, J.A.; DiStefano, D.J.; 
Hazuda, D.J.; Bahnck, C.M.; Himmelberger, A.L.; Dornadula, G.; Hrin, R.C.; Stillmock, K.A.; 
Witmer, M.V.; Miller, M.D.; Grobler, J.A. Potent and selective HIV-1 ribonuclease H inhibitors 
based on a 1-hydroxy-1,8-naphthyridin-2(1H)-one scaffold. Bioorganic. Med. Chem. Lett. 2010, 
20, 6754-6757. 
 
103.  a) Klumpp, K.; Hang, J.Q.; Rajendran, S.; Yang, Y.; Derosier, A.; Wong Kai In, P.; Overton, H.; 
Parkes, K.E.B.; Cammack, N.; Martin, J.A. Two-metal ion mechanism of RNA cleavage by HIV 





Research. 2003, 31, 6852-6859. b) Hang, J.Q.; Rajendran, S.; Yang, Y.; Li, Y.; Wong Kai In, P.; Overton, 
H.; Parkes, K.E.B.; Cammack, N.; Martin, J.A.; Klumpp, K. Activity of the isolated HIV RNase H domain 
and specific inhibition by N-hydroxyimides. Biochem. Biophys. Res. Comm. 2006, 317, 321-329. 
 
104.  Billamboz, M.; Bailly, F.; Lion, C.; Touati, N.; Vezin, H.; Calmels, C.; Androla, M.-L.; Christ, F.; 
Debyser, Z.; Cotelle, P. Magnesium chelating 2-hydroxyisoquinoline-1,3(2H,4H)-diones, as 
inhibitors of HIV-1 integrase and/or the HIV-1 reverse transcriptase ribonuclease H domain: Discovery of 
a novel selective inhibitor of the ribonuclease H function. J. Med. Chem. 2011, 54, 1812-1824. 
 
105.  Lansdon, E. B.; Liu, Q.; Leavitt, S. A.; Balakrishnan, M.; Perry, J.K.; Lancaster-Moyer, C.; Kutty, N.; 
Liu, X.; Squires, N. H.; Watkins,W. J.; Kirschberg, T. A. Structural and binding analysis of pyrimidinol 
carboxylic acid and N-hydroxyquinazolinedione HIV-1 RNase H Inhibitors. Antimicrob. Agents Chemother. 
2011, 55, 2905−2915. 
 
106.  Kirschberg, T.A.; Balakrishnan, M.; Squires, N.H.; Barnes, T.; Brendza, K.M.; Chen, X.; 
Eisenberg, E.J.; Jin, W.; Kutty, N.; Leavitt, S.; Liclican, A.; Liu, Q.; Liu X.; Mak, J.; Perry, J.K.; 
Wang, M.; Watkins, W.J.; Lansdon, E.B. RNase H active site inhibitors of human 
immunodeficiency virus type 1 reverse transcriptase: Design, biochemical activity, and structural 
information. J. Med. Chem. 2009, 52, 5781-5784. 
 
107.   Velthuisen, E.J.; Johns, B.A.; Gerondelis, P.; Chen, Y.; Li, M.; Mou, K.; Zhang, W.; Seal, J.W.; 
Hightower, K.E.; Miranda, S.R.; Brown, K.; Leenitzer, L. Pyridopyrimidinone inhibitors of HIV-1 RNase H. 
Eur. J. Med. Chem. 2014, 83, 609-616. 
 
108.  Grimm, D.; Thimme, R.; Blum, H.E. HBV life cycle and novel drug targets. Hepatol. Int. 2011, 5, 
644–653. 
 
109.  Lu, G.; Lomonosova, E.; Cheng, X.; Moran, E.A., Meyers, M.J.; Le Grice, S.F; Thomas, C.J.; Jiang, 
J.K..; Meck, C.; Hirsch, D.R.; D’Erasmo, M.P.; Suyabatmaz, D.M.; Murelli, R.P.; Tavis, J.E. Antimicrob. 
Agents and Chemother. 2015, 59, 1070-1079.  
 
110.  Padwa, A.; Zhi, L.; Fryxell, G. E.  Studies dealing with the excited-state behavior of substituted 8-
oxabicylco[3.2.1]oct-6-en-2-ones.J. Org. Chem. 1991, 56, 1077. 
 
111.  Song, Z. Z.; Ho, M. S.; Wong, H. N. C. Regiospecific  Synthesis of 3,4-Disubstitted furans. 7. 
Synthesis and reactions of 3,4-bis(trimethylsilyl) furan: Diels Alder cycloaddition, Friedel-Crafts acylation, 
and regiospecific conversion to 3,4-disubstituted furans.  J. Org. Chem. 1994, 59, 3917. 
